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ABSTRACT 
Human brain evolution has resulted in a cognitive superiority compared to all other animals. 
Unique cortical structures and expanding progenitor populations have been associated with the 
possibility for developing a highly folded neocortex and expanded surface area, which is linked 
to cognitive function. Alongside the development of the neuronal population there has been a 
remarkable evolution of a second population of brain cells called astrocytes. Astrocytes, which 
historically have been viewed as the glue of the brain, are now considered as a major regulator 
of brain homeostasis and neuron communication. Hypothesized to meet the increased 
complexity of neuronal sub-populations astrocytes have become highly diversified. Specific 
astrocytes can only be observed in higher primates and generally comprises a more advance 
form and structure enabling a single astrocyte to support a higher number of neurons. 
Additionally, it has been shown that human astrocytes can improve cognitive function in mice, 
an observation signifying the importance of astrocytes in human brain evolution. However, 
increased complexity is accompanied by biological errors resulting in human specific diseases. 
Disease mechanisms linked to human biological traits poses challenges when trying to uncover 
and develop treatments against its pathological conditions using animal models. With 
decreasing drug developmental programs in the pharmaceutical industry targeting neurological 
and psychiatric diseases there is a need to improve and accelerate drug discovery in this area.  
Studying cellular functions of the human brain is challenging partly due to limited accessibility 
of brain tissue. Historically, the main source of cells was derived from healthy tissue following 
surgical procedures as well as post-mortem and fetal tissue. However, since the discovery of 
induced pluripotent stem cells, having the potential to generate any cell type in the body, 
accessibility to neural like cells has changed dramatically. Common strategies for acquiring 
neurons and astrocytes from pluripotent stem cells are to try and mimic the naturally occurring 
embryonic development. However, this requires the establishment of defined and detailed 
protocols instructing the cells how to develop and becoming the cell type of interest. Neurons 
follow a step-wise development program which have been uncovered and in great parts 
mimicked in the lab. However, whether this step-wise developmental progression holds true 
for astrocytes is yet to be defined. 
The aim of this thesis was to develop a protocol to derive astrocytes from human induced 
pluripotent stem cells (hiPSC) and benchmark them against current models available for the 
pharmaceutical industry. Moreover, the project aimed to establish hiPSC derived neuronal and 
astrocyte models in a pharmaceutical setting to investigate their potential contribution in drug 
development.  
The characterization of four astrocytic models in comparison to a neural stem cell and non-
neural model showed expected astrocyte specific characteristics. However, large differences in 
gene expression and astrocyte associated functions indicated a large heterogeneity among 
models which was also demonstrated in drug response stimulations. This clearly implies that 
discovery of new chemical compounds for further drug development will be context dependent, 
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having identification bias towards the model of choice. Moreover, thorough characterization 
and diverse applications demonstrated a very robust and reproducible protocol for the 
generation of hiPSC derived astrocytes, a feature naturally critical if utilized in pharmaceutical 
assays. Finally, in addition to improved functionality compared to conventional models, hiPSC 
derived astrocytes show developmental traits linked to embryonic development increasing 
translability and model relevance. 
Furthermore, in a proof of principle study hiPSC derived neurons were shown to be able to 
predict unwanted side effect of a drug used to prevent excessive blood loss from major trauma 
or surgery. The drug is believed to affect specific neurons resulting in involuntary seizures. 
Besides demonstrating receptor activity of the drug, human iPSC derived neurons were shown 
to be applicable in the development of new drugs lacking this side effect. Finally, this was 
performed using a label-free and simple method which is highly applicable for drug screening. 
In conclusion this thesis presents a protocol for the derivation of an astrocytic model having 
translatability to the embryonic development and possesses several cellular functions observed 
by astrocytes in vivo. The application of hiPSC derived neurons and astrocytes in a 
pharmaceutical setting demonstrate that they can make a significant contribution in drug 
discovery. 
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1 Introduction 
Studying brain development and neural cellular function of human origin has traditionally been 
performed using isolated cells from human primary tissue of post-mortem samples, healthy 
tissue from surgical procedures and fetal tissue. However, primary isolation is always 
associated with limited accessibility which has been addressed by isolation, expansion and 
banking of stem cells or the generation of immortalized cell lines. Human embryos have 
historically been the only source for human pluripotent stem cells (hPSC) which due to ethical 
concerns and limited access have been applied sparsely. The emergence of the induced 
pluripotent stem cell (iPSC) technology (6) enabled the generation of human pluripotent stem 
cells from various sources such as skin, and consequently, the field has developed 
tremendously. In vitro development of specific somatic cells demonstrates impressive 
similarities to human embryonic development. When differentiated, hiPSC follow embryonic 
germline specification and regional patterning all along the neural tube and subsequent niche 
specific differentiation.  
Compared to astrocytic models hiPSC derived neuronal models have developed much faster 
with established protocols generating subspecific neurons and identities of specific cortical 
layers (7). The time for hiPSC to acquire neuronal cell fate is shorter for neurons than for 
astrocytes, a feature which correlates with human embryonic development. This highlights that 
culturing time is a possible factor for the observed differences in technical development of 
neuronal and astrocytic hiPSC models. During embryonic development astrocytes preced the 
development for oligodendrocytes, however, there are robust hiPSC-protocols established for 
the latter (8, 9). Neurons and oligodendrocytes follow a step-wise development where 
progenitors are restricted towards a specific lineage. The cells subsequently migrate from their 
regional centers and, upon arrival at the target region, exit the cell cycle and undergo terminal 
differentiation. Whether this step-wise developmental progression holds true for the 
heterogeneity of astrocytes has yet to be defined (10). Incomplete understanding of specific 
astrocytic developmental processes is in part due to the lack of reliable markers to characterize 
progenitors and astrocytes during development in contrast to what has been established for 
oligodendrocytes (11). Additionally, as a large fraction of astrocytes seemingly arise from 
progenitors from the sub-ventricular zone (SVZ) (12) the question is if the evolutionary change 
in cytoarchitectural structure of the cortex, more specifically the outer sub-ventricular zone 
(oSVZ) (13), has any influence on human astrocytic development and heterogeneity, thereby 
making animal model translation more difficult. The astrocyte specific marker in rodent, 
GFAP, is for example also expressed by various other cell types in humans of which also the 
GFAPδ isotype mark specific progenitors not observed in mice (14). Human astrocyte 
heterogeneity is partly due to regional identity which has been mimicked in vitro (15, 16), 
whereas functional diversity seemingly is dependent on neuronal input (17-19).  
Several current hiPSC derived astrocyte protocols (15, 20) assume that progenitor cells possess 
an intrinsic time course which transition differentiation potency. This means that sub-specific 
cells can be enriched from progenitor cells at specific temporal windows (4). If in vitro systems, 
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follow embryonic development it implies long and labor-intensive culturing. Alternatively, to 
shorten intrinsic developmental programs, and hence shorten model generation, one approach 
is to activate and drive developmental nodes to speed up the process, so called directed 
differentiation. However, a common problem of stem cell model generation is its immature 
phenotypes and fetal-like translatability. Despite this fact hiPSC derived models have 
demonstrated to be valuable in studying neural functionality (20) and disease mechanistic 
features (21) while also providing valuable information in phenotypic screening (22, 23). 
Human iPSC derived models show great potential to contribute to the development of new 
treatments for patients. Their possible application in the pharmaceutical industry are vast; 
providing large scale cultures, human genome origin, genomic diversity, functional evaluation, 
toxicity testing, ease of genomic editing for multiple downstream application as target 
identification, transcript overexpression, reporter systems, disease insertion and correction. 
Moreover, by utilizing established pharmaceutical infrastructure and previous results the 
information from hiPSC derived motor neuron models has shown to directly impact drug 
development by leading to the decision to launching a new clinical trial for treatment against 
amyotrophic lateral sclerosis (ALS) (24). Time will tell if the great potential of hiPSC derived 
models have a significant impact on drug discovery. 
  
  3 
1.1 The Human Brain 
The human brain contains approximately 100 billion neurons of which 20% reside in the 
neocortex, a structure associated with higher cognitive functions. To support the neuronal 
complexity, the human brain consists of the same amount or even higher number of glial cells. 
The neocortex is a hallmark in evolution existing as a unique structure observed among 
mammals. Its independent expansion along different evolutionary lineages highlight a positive 
selection for increasing neuronal numbers. A great enlargement is observed in primates, 
particularly humans, where the neocortex makes up 80% of the brain mass. In order to handle 
the great increase in neurons, without enlarging the skull, the neocortex expands its surface 
area by folding. Humans show a high level of gyrification as compared to the mouse which 
possess a smooth neocortex. Even though the layered structure of the neocortex is similar 
across mammals, its distribution is different, for example the human neuronal upper layers 
occupy a considerably larger part of the gray matter compared to rodents. This can be linked 
to the oSVZ populated by proliferative outer radial glia (oRG) which produce a high number 
of upper layer cortical neurons after gestation week (GW)17 (2, 25-27). Alongside the human 
cortical expansion follows the astroglia evolution which has undergone substantial changes. 
Astrocytes support and regulate the neuronal network. In addition to the development of 
primate specific astrocyte subtypes the cross-species astrocytes show diverse biology between 
mammals. Protoplasmic astrocytes, found in the gray matter, are 2.5 times larger in humans 
compared to rats. Additionally, human protoplasmic astrocytes occupy a 16.5 times larger 
volume, possess 10 times more primary processes and envelops approximately 2 million 
synapses compared to its rodent counterpart which envelope between 20 000-100 000 synapses 
(28). The intriguing question is if astrocytes contribute to increased cognitive function? 
Interestingly, when human glial progenitors were injected into the ventricle of newborn mice 
the progenitor population overtook the mouse brain outcompeting the host oligodendrocytes, 
protoplasmic and fibrous astrocytes. This resulted in improved performance on a variety of 
cognitive tests strongly indicating that human astrocytes improve cognitive ability in mice (29, 
30) 
Almost unthinkable, the structural complexity and neural diversity observed in the human brain 
all starts with lineage fate restriction of pluripotent stem cells which can generate any cell type 
in the body. 
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1.1.1 Neuroepithelial Stem Cells 
Pluripotent stem cells of the inner cell mass develop upon gastrulation into the three different 
germ layers; endoderm, mesoderm and ectoderm. Further development of the ectoderm 
restricts cellular potency to become the primitive neuroectoderm forming the neural plate, 
consisting of a central part forming the definitive neuroectoderm which is bordered by the 
neural crest. During this time the definitive neuroectoderm forming the central nervous system 
(CNS) is being regionalized along the anterior-posterior (AP) axis defining regions that later 
become the forebrain (prosencephalon), midbrain (mesencephalon), hindbrain 
(rhombencephalon) and the spinal cord. The neural plate subsequently closes establishing the 
neural tube which buds off from the surrounding tissue. The mesendodermal tissue and 
notochord underlines the neural tube at the ventricle side while the non-neural ectoderm asides 
the dorsal parts. The notochord and non-neural ectoderm will affect the patterning along the 
dorsal-ventral (DV) axis, equivalent to the earlier mediolateral axis in the neural plate. Along 
the AP axis there is a wingless (WNT) signaling gradient that become caudally stronger until 
the initiation of the spinal cord where retinoic acid (RA) and fibroblast growth factor (FGF) 
gradients become increasingly more dominant. The DV axis has opposing gradients of sonic 
hedgehog (SHH), which is strongest at the floor plate and decrease dorsally and bone 
morphogenetic protein (BMP)s/WNTs, which are strongest at the roof plate and decrease 
ventrally. In addition to the mesendodermal tissue, notochord and non-neural ectoderm there 
are three major local signaling centers (secondary organizers): anterior neural ridge (ANR) at 
the anterior pole of the secondary prosencephalon, zona limitans intrathalamica (ZLI) at the 
anterior diencephalon and the isthmic organizer (ISO), at mid-hindbrain junction which refine 
signaling gradients and local identities. The three-dimensional grid (Figure 1) which patterns 
the neuroepithelial cells before neurogenesis onset at GW6-7 will set the rough positional 
identity which is the foundation of region development of the brain and its neural specialization 
(3-5, 31). 
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1.1.2 Neurogenesis 
Around GW7 during cortical development in the telencephalon neuroepithelial cells transform 
into radial glia (RG) in the ventricle zone and start to divide asymmetrically generating 
intermediate progenitors in addition to their symmetrical division expanding the progenitor 
population. At this stage in development there is a marginal and ventricle zone. As 
neurogenesis is initiated the cortical plate divides into the subplate and marginal zone which 
later develops into layer I. Radial glia scaffold keeps generating intermediate progenitors which 
terminally differentiates into post-mitotic neurons or undergo further rounds of cellular division 
before final differentiation. Early projection pyramidal neurons originating from ventricular 
RG (vRG) migrate along the radial fiber scaffold accumulating between the marginal zone and 
the subplate initially generating layer VI while later born neurons make up more superficial 
layers finishing at layer II. At GW9-12 the subplate reaches its maximum thickness and there 
is a gradual thickening of the cortex. Below the subplate, the intermediate zone, which later 
becomes the white matter, and the SVZ start to be distinguishable. In humans the SVZ give 
rise to two distinct layers; the iSVZ and, adjacent to it, the oSVZ defined by the inner and outer 
fiber. Neurons generated at GW13-15 occupy the middle layers of the cortex which at GW18 
consists of six cortical layers. From this point to when neurogenesis ends there is an extensive 
production of neurons occupying the cortical layers in parallel with the increasing thickness of 
the SVZ. The ventricle zone is gradually reducing in size and by GW25-27 it has become one 
cell thick ependymal layer. Neuronal migration along the radial glia processes is complete at 
around GW28, at the same time, the deep and upper layers of the cortex have been generated. 
Nevertheless, tangential interneuron migration from the medial ganglionic eminence along the 
marginal and intermediate zone does not cease until the third trimester. By the end of the 
development, the cortical gray matter contains approximately 70-80% and 20-30% 
glutamatergic and GABAergic neurons respectively (2, 25-27). Notably, in human cortical 
development the ventricle radial glia scaffold, of which early newborn neurons migrate, is 
discontinued at GW17, losing its pial attachment and ending its processes in the oSVZ. This 
correlate to the change in progeny of oRG in the oSVZ which more frequently generates 
neurons in the upper layer of the cortex. Outer RG now make up the radial scaffold from the 
oSVZ to the pial surface. The time before and after GW17 is referred to as the continues and 
discontinuous scaffold stage, respectively (2) (Figure 2). 
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Development of different brain regions give rise to other major neuronal sub types. The 
mesencephalon divides along the DV axis to tectum and tegmentum containing the substantia 
nigra, an origin for dopaminergic neurons. Moreover, the DV axis of the rostral parts of the 
hindbrain, metencephalon, develop into the pons and cerebellum of which the raphe nuclei 
generating serotinergic neurons and locus coeruleus generating noradrenaline neurons originate 
from, respectively (31, 32) (Figure 3). 
 
Figure 3 – Patterning of neural stem cells (NSC) affect the cellular regional identity contributing to the formation of different 
brain regions. Subsequently, the specific niche concentration of morphogens at precise areas of the brain will potentiate 
neural stem cells working as developmental origins for sub-specific neurons. Human PSC derived glutamatergic neurons 
are often generated from a patterning identity associated with the dorsal parts of the telencephalon which ventral domain 
harbor progenitors for GABAergic and cholinergic neurons. Dopaminergic neuronal progenitors arise in the ventral 
midbrain whereas serotonergic neurons develop from progenitors in the ventral part of the rostral hindbrain. Progenitors 
associate with an identity of the ventral part of the spinal cord can in turn give rise to motor neurons. Adapted from (32) 
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1.1.3 Gliogenesis 
Gliogenesis is believed to be initiated around midgestation as neurogenic competence of 
progenitor cells switch into becoming gliogenic, which during development can be further 
divided into astrogenesis and oligodendrogenesis. As progenitors acquire an astrocytic fate 
they populate different regions of the brain. Two waves of astrocytic progenitors populate the 
pial surface of the cortex, at the time of the preplate formation and when the SVZ has formed. 
The SVZ and pial surface home progenitors which together migrate dorsally or descend into 
the cortical layers maturing as astrocytes. From the different progenitors in the SVZ another 
population of astrocyte occupy the white matter. Moreover, after neurogenesis is completed an 
additional source of transforming RG cells add to the astrocytic bulk of the brain which also 
expand in numbers by local proliferation. Regional identity and morphological characteristics 
are traditionally used to classify the heterogeneity of astrocytes. In relation to the evolutionary 
specific architectural structure of the human cortex and human astrocyte heterogeneity there is 
still a fundamental need to investigate the developmental programs of specific astrocytes (12, 
33-36). In the developing spinal cord distinct homeodomains are linked to astrocytic progeny 
generating ventral fibrous astrocyte populations while dorsal region give rise to both 
protoplasmic and fibrous astrocytes. Similar regional specificity is shown for oligodendrocyte 
of the spinal cord originating from the pMN domain where motor neurons also originate (10). 
From animal studies oligodendrogenesis is viewed to occur in three distinct waves, both in the 
forebrain and the spinal cord. Originating from the medial ganglionic eminence (MGE) region 
in the forebrain a first wave of oligodendrocyte progenitor cells (OPC) is generated which 
through dorsal-tangentially migration occupy the forebrain. Through dorsal migration a second 
wave of OPCs populate the cortex of the forebrain which originated predominantly from the 
lateral ganglionic eminence (LGE). Lastly, the corpus callosum and overlaying cortex is 
infiltrated by progenitor cells from the dorsal parts of the SVZ and oSVZ which home the 
finalizing third wave of populating OPCs. This developmental dynamic in the human brain is 
however uncertain (11)  
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2 Modeling Embryonic Development and Cellular Function 
A central problem of studying human neural cells is the limited access to human material. 
Isolation of primary cells is done primarily from fetal tissue, healthy tissue from surgical 
procedures and post-mortem samples. For post-mitotic cells, the limitation of material is 
pronounced since upscaling is not a possibility. Moreover, for mechanistic and functional 
studies, where genetic manipulation is desirable, transfection reagents often have a higher 
efficacy in proliferating cells. Purification of transfected post-mitotic cells without upscaling 
leave low number of successfully engineered cells. A solution is to use mitotic progenitors for 
which genetic manipulation, upscaling and banking is possible. However, extensive culturing 
of primary cells increases the risk of a phenotypic change thereby losing their high translational 
value. 
In 2006, Yamanaka and colleagues could generate pluripotent stem cells by overexpressing 
four transcription factors in somatic cells (6). This provided an alternative to primary cells, and 
since reprogramming could be performed on cells collected using non-invasive procedures 
such as skin fibroblasts it removed ethical concern apparent with the use of embryonic stem 
cells. Induce pluripotent stem cells can theoretically develop into any cell type and is especially 
valuable in scientific fields where access to human primary tissue is limited, such as 
neuroscience. Human PSC can be scaled and banked, genetically manipulated and possess 
disease specific background. However, to generate cell types of interest specific differentiation 
protocols are needed which can direct and restrict cell potency to acquire the correct cell state.  
Overexpression of OCT4, SOX2, MYC and KLF4 can reprogram mouse (6) and human 
fibroblast (37) into a pluripotent state. Reprogramming is also achieved with a different set of 
factors OCT4, SOX2, NANOG and LIN28 (38). To use hiPSC derived cells in clinical 
applications the use of non-integrating expression systems need to be applied to remove risks 
associated with genomic integration. There are several non-integrating reprogramming systems 
including RNA based sendai-virus (39), episomal DNA (40), RNA (41), protein (42) and small 
molecules, generating chemical induced pluripotent stem cells (43). Moreover, reprogramming 
(44) and hPSC cultures currently apply xeno-free systems (45, 46) removing previously 
necessary mouse feeder cells. Together this enabled development of good manufacturing 
practice (cGMP) compliant for pre-clinical and clinical applications (47). Moreover, it shows 
higher technical robustness and reproducibility. The strategy of overexpressing transcription 
factors for the acquisition of an alternative cell state also applies for the direct conversion of 
one somatic cell to another. This is for example achieved by converting fibroblast to neural 
progenitor cells (NPC) (48), neurons (49), and astrocytes (50).  
The combination of primary cells, differentiation of pluripotent stem cells and direct 
reprogramming to desired cell types are all used to model embryonic development and cellular 
functions of the human brain (Figure 4).  
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2.1.1 Neural Stem Cells 
Development of more defined medium compositions establishing the N2 (51) and B27 (52) 
supplements have enabled better culture conditions for the development of neural cultures. 
Isolation of neural stem cells (NSC) was done in 1999 by Vescovi et al. who showed that 
isolating and propagating human fetal tissue from GW 6-12 as neurospheres require culturing 
condition using the combination of FGF and EGF (53). Addition of LIF also support NSC 
cultures but was shown to be redundant in NSC propagation (54, 55). Isolation of human fetal 
neural epithelial stem cells from embryo at GW5-7 can be maintained in long term culture with 
sustained tri-potent differential capacity (56). Deriving progenitor cells at GW8 show increased 
identify with RG populations of early brain development (57, 58). 
Generation of human pluripotent derived NSC can be achieved by spontaneous differentiation. 
This occur during embryonic body (EB) formation in combination with FGF2 stimulation 
which upon plating generate rosette structures associated to neural tube formation (59). Even 
though propagation in culture conditions using FGF2 and EGF influence NSC to drift in 
cellular identity, Elkabetz et al. could maintain rosette NSC (R-NSC) phenotype for a few 
passages by isolating the inner cells of neural rosettes (60). The purity of long term human 
embryonic derived neural stem cells (lt-hESNSC) by mechanical isolation is crucial for long 
term cultures to avoid drifting in phenotypes (61). Establishment of hPSC derived long-term 
neuroepithelial like stem cells (ltNES) demonstrate that the cells can maintain tripotency and 
regional identity for over 100 passages (62). A directed approach using inhibitors of Activin/ 
transforming growth factor beta (TGFB)/ Nodal (63) or BMP pathway (64, 65) show to induce 
neuroectoderm formation from hPSC. Most efficient is the inhibition of both pathways 
simultaneously, called dual SMAD inhibition, applying Noggin and SB431542 to generate an 
enriched population of hPSC derived NSC (66). This can be further optimized with the use of 
small molecules like dorsomorphine (67, 68), DMH1 (69, 70) or LDN193189 (71). 
Additionally, isolation of NSC at an earlier state, primitive NSC (pNSC), is achieved by 
inducing WNT and janus kinases (JAK)/ signal transducer and activator of transcription 
proteins (STAT) signaling while maintaining dual SMAD inhibition. These cells lack 
polarization and they can generate rosette formations upon FGF2 stimulation (72). A common 
feature between R-NSC, ltNES, and pNSC is that they are restricted to CNS fate, limiting the 
derivation of motor neurons and neural crest cells. By using small molecules Reinhardt et al. 
managed to capture neuroepithelial cells, namely small molecule NPC (smNPC), which 
resemble cells of the neural plate borders having the potency to generate both motor and 
dopaminergic neurons (73). An alternative method is to directly reprogram fibroblasts 
generating induced NSC (iNSC) without a pluripotent intermediate state. Overexpression of 
SOX2 generates iNSC (48) which can be further improved by inhibiting Let-7 miRNAs 
resulting in upregulation of HMGA2 expression, affecting chromatin structure (74). 
2.1.2 Neurons 
Already in the 90’s were neuroblasts isolated from fetus used in intracerebral transplantations 
for cell therapy of Parkinson’s Disease (PD) (75). However, culturing and accessing sufficient 
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number of neuronal progenitors is challenging. This obstacle has been overcome by using 
hPSC derived dopaminergic progenitors supplying adequate cell numbers to treat primate PD 
models (76).  
Since the establishment of the iPS-technology the number of established protocols for the 
generation of neuronal subtypes has increased greatly, demonstrating neurons derived from 
progenitors with fore-, mid-, hindbrain and spinal cord identities (68, 70, 77). Sub-specification 
is based on regionalization of neural progenitors, also called patterning. Physiologically 
patterning affects the neural plate and the neural tube formation, which further develop into the 
brain and spinal cord. Temporal and spatial morphogenic gradients along the AP and DV axis 
govern cellular specification. Morphogens patterning cues are mimicked in vitro during NSC 
generation to result in downstream sub-specification of neurons. Enrichment of regional 
specific progenitors is not only achieved by target progenitor stimulation but also via the 
restriction of neighboring progenitors. The latter is achieved via the use of opposing 
morphogens concentration, which results in a specified narrow regional milieu that affects the 
downstream neuronal sub-population purity. 
2.1.2.1 Glutamatergic neurons 
Initial NSC are consider to have a default cerebral cortical identity, also known as the 
activation-transformation model (3, 78, 79). Activation of neural tissue by induction would 
then acquire forebrain identity and caudalizing factors lead to a transformation to posterior 
neuroectoderm. This approach is used in the formation of hiPSC derived dorsal forebrain 
glutamatergic neurons (68, 80), even though a recent publication suggests a revision of current 
patterning model demonstrating that regional identity is acquired before neural identity (81). 
Dorsal forebrain PAX6/OTX2/FOXG1 expressing progenitors are generated upon ectoderm 
induction without stimulation of morphogens. Upon terminal differentiation toward 
glutamatergic neuronal fate the cells express TBR1 and SLC17A7 [VGLUT1] whilst acquiring 
identities of deep and upper-cortical layers (68, 80). However, generation of dorsal 
glutamatergic neurons is often accompanied with the generation of ventral GABAergic neurons 
(7, 82). Circumventing this problem and enhancing the purity of glutamatergic neurons is  
achieved by antagonizing ventral patterning using SHH inhibitors while keeping an anterior 
identity (7, 82). 
2.1.2.2 GABAergic neurons 
GABAergic neurons can be developed from the MGE and LGE of the forebrain generating 
GABA interneurons and striatal spiny GABA neurons, respectively. A NKX2-1 MGE 
forebrain identity is achieved by WNT signaling inhibition in combination with strong 
ventralization cues using high SHH (83). Differentiation of NKX2-1/FOXG1 progenitors can 
generate GABAergic neurons, but also CHAT+ cholinergic neurons derived from the same 
region (84). Technical optimization by limiting medium support for survival of cholinergic 
neurons can increase purity of GABAergic neurons up to 90% (83). Human PSC NKX2-
1::GFP reporter lines also demonstrate a temporal effect of SHH stimulation on GABAergic  
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and cholinergic fractions. The temporal stimulation of SHH which generates the highest 
number of GABAergic neurons also display the most homogenous NKX2-
1/FOXG1/OLIG2/ASCL1+ progenitor population (85). The importance of progenitor 
homogeneity is concurrent with other protocols, but optimal temporal stimulation is 
inconsistent (86). Further differentiation of NKX2-1/FOXG1/OLIG2 progenitors initiates 
expression of GABAergic interneuronal lineage markers ASCL1, DLX2, LHX6 and CALB1 
(85, 86). Temporal discrepancies could be observed due to endogenous caudalizing effects as 
a result of the increased FGF19 expression. This phenomenon could be explained by early SHH 
treatment shifting regional identity towards caudal ganglionic eminence (CGE). Caudalizing 
effects can be counteracted with exogenous FGF8 stimulation maintaining anterior position or 
exaggerated with FGF19 resulting in calretinin (CALB2) interneuron subtypes of CGE (87). 
More mature interneuron markers somatostatin (SST), and parvalbumin (PVALB) can be 
detected in hPSC derived GABAergic neurons with MGE identity (85, 87). To generate a more 
dorsal identity of the LGE region, a balanced SHH stimulation is essential. Using an opposing 
morphogen to ventralization, activin A, can stimulate a LGE identity of GSX2, DLX2, 
BCL11B [CTIP2], and FOXP2 expression which differentiate to GABAergic neurons 
expressing striatal marker PPP1R1B [DARPP32]+ (88). 
2.1.2.3 Cholinergic neurons 
Many of the protocols generating GABAergic neurons from MGE progenitors also form a 
fraction of cholinergic neurons from the most ventrally patterned progenitors. Optimizing SHH 
temporal treatment can enrich cholinergic neuron derivation, resulting in a NKX2-1/FOXG1 
population barely expressing OLIG2 (85). Basal forebrain progenitors differentiating to 
cholinergic neurons commonly express NKX2-1/FOXG1/LHX8 (89) followed by ISL1, 
CHAT and SLC18A3 [VAChT]. Long term EB expansion enriched basal progenitor 
population resulting in 90% pure cholinergic neuron cultures upon terminal differentiation 
(90). 
2.1.2.4 Dopaminergic neurons 
Dopaminergic neurons develop from ventral-midbrain progenitors. Human iPSC derived NSC 
are patterned by activation of the WNT and SHH pathways to regulate identity along the AP 
and DV axis, respectively (69, 71, 91-94). Fine tuning WNT signaling concentration gradient 
specify NSC to forebrain, midbrain or hindbrain fate which can be maintained during 
simultaneous DV specification using SHH signaling modulators. This methodology 
successfully generates midbrain progenitors efficiently differentiating into TH+ neurons (91). 
However, common progenitor markers of ventral mesencephalon (VM) LMX1A, FOXA2 and 
OTX2 poorly predicted dopaminergic neuronal sub-specification upon engraftment. 
Bioinformatic analysis of successful engraftments aligned with more caudal progenitor identity 
(77). Temporal addition of FGF8b, after VM patterning, could generate caudal VM, expressing 
EN1, SPRY1, PAX8, CNPY1, and ETV5, markers demonstrating good prediction of high 
dopaminergic sub-specification outcome (77). Technical optimization including the use of 
human recombinant laminin 111 and switch in basal medium composition resulted in a protocol 
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generating 40 fold more FOXA2+/LMX1A/B+ progenitors expressing EN1/OTX2/LMX1A 
(77). 
2.1.2.5 Serotonergic neurons 
Ventral hindbrain progenitors give rise to serotonin neurons. Progenitors from the rostral and 
caudal hindbrain differentiate into median raphe serotonin neurons and spinal cord connecting 
serotonin neurons, respectively (32). Regulation of the AP WNT gradient can derive hindbrain 
progenitors expressing caudal and spinal cord identity markers (70). Specific CHIR99021 
concentration generate rostral hindbrain HOXA2+ progenitors acquiring a ventral NKX2-
2/NKX6-1 identity during simultaneous SHH stimulation (70). Serotonin specification, 
indicated by high homogeneity of GATA2, need temporal addition of FGF4 for the acquisition 
of FOXA2 serotonergic fate. Terminal differentiation can generate 60% serotonin neurons 
assessed by TPH2, GATA2 and SLC18A2 [VMAT2] expression and the functional release of 
serotonin upon depolarization (70). 
2.1.2.6 Motor neurons 
Spinal cord progenitors are able to generate motor neurons originating from ventral-dorsal 
OLIG2+ region. Using RA and SHH can direct the differentiation toward OLIG2+ progenitors 
which can develop into ISL1 and CHAT positive motor neurons (95, 96). High SHH 
concentration generate progenitors with NKX2-2 regionality. To achieve more dorsal 
regionality WNT activation can antagonize ventral induction generating almost pure OLIG2+ 
populations. Terminal differentiation generate MNX1, ISL1 and over 90% CHAT+ motor 
neurons (97). Furthermore, Qu et al. achieved higher viability of motor neurons by exchanging 
Matrigel to a defined mixture of laminin, fibronectin, collagen I and collagen IV (98). 
2.1.2.7 iNeurons 
Another approach to generate sub-specific neurons is the direct conversion without going via 
stem cell state. Direct reprogramming into human induce neurons (hiN) is possible by 
transduction ASCL1, POU3F2_v1 [Brn2a] and MYT1L (49). The application of small 
molecules including dual SMAD and WNT activation lead to a significantly increased efficacy. 
This method generates mostly GABAergic neurons, however, adding LMX1A, LMX1B, 
FOXA2 and OTX2 to the vector mix provide the possibility to generate dopaminergic neurons 
(99). Generation of dopaminergic iN from hiPSC is achieved by using ASCL1, NR4A2, and 
LMX1A (100). Direct conversion of human fibroblast into hiN is performed by using 
mircoRNAs miR-9-3/5p [miR9/9*] and miR-124 (101). Increased efficacy to produce iN with 
GABAergic striatal medium spiny nature can be obtained by transducing BCL11B [CTIP2], 
DLX1, DLX2, and MYT1L together with miR-9-3/5p and miR124 (102). Interestingly, 
regulating microRNA circuits by shRNA inhibition of the polypyrimidine-tract-binding (PTB) 
protein can drive neuronal transdifferentiation from rat (103) and human fibroblasts (104). 
Generation of other subtype specific neurons such as iMN from human fibroblast and hESC 
can be achieved using a 8 factor combination (ASCL1, POU3F2, MYT1L, LHX3, MNX1 
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[Hb9], ISL1 and NEUROG2) (105) and 3 factor combination (NEUROG2, ISL1, LHX3), 
respectively (106). 
With the combination of established ectoderm differentiation protocols and the modulation of 
morphogenic gradients hPSC serve as a model of early embryonic brain development by 
acquiring different regional identities. This, in turn can reflect cellular transition of fate 
restriction and differentiation potency as specific progenitors acquire sub-specific neuronal 
phenotypes. In addition, genetic techniques introducing inducible neurons provide an 
alternative and effective approach of generating sub-specific neurons (Figure 4). 
2.1.3 Astrocytes 
Astrocytes are important for both brain homeostasis and functions. Moreover, astrocytes in 
non-human primates and humans are highly diversified across evolution to plausibly match the 
needs of neuronal subtypes. However, human cellular models of astrocyte biology have not 
developed equally to neurogenic models. This might be due to the lack of consensus on how to 
define an astrocyte. The next section will review astrocyte biology and the development of 
human astrocytic in vitro models. 
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3 Astrocyte Biology 
The human brain consists of various specialized neural cell types (107), which during evolution 
co-developed to meet the needs of one another (108). Astrogenesis takes place after 
neurogenesis where the main astrocyte subtypes can be specified into gray and white matter 
astrocytes, also known as protoplasmic and fibrous astrocytes, respectively (36). Astrocytes at 
the pial surface, layer-1 astrocytes, show similar morphology and GFAP expression as fibrous 
astrocytes (36). Populations of astrocytes also exists in the spinal cord where progenitor 
homeodomain regulate spatial location of gray and white matter astrocytes (109, 110). Müller 
cells in the retina, Bergman glia and protoplasmic velate astrocytes in the cerebellum are yet 
another example of glia diversity (111). There are also astrocytes specific to primates and 
humans including interlaminar and varicose projection astrocytes (36, 112-114). In addition, 
characterized by their GFAP and glycogen granules, adult astrocytes in the SVZ, namely type-
B1 and -B2 cells, are a tripotent stem cell population having the potential to generate neurons, 
astrocytes and oligodendrocytes (115). The astrocytic functions are diverse, and the list of 
functions associated with astrocyte biology has been expanding over the last decades. 
Astrocytes provide structural and metabolic support together with blood brain barrier (BBB) 
functions, regulating cerebral blood flow, synaptic homeostasis, inflammatory response to 
injury, and neuronal circuit integration, an area which has gained more attention the recent 
years. Astrocytes influence synaptogenesis and the synaptic connectivity, most likely also 
being part of fine tuning neuronal circuits. There are several excellent reviews on astrocyte 
biology (10, 12, 113, 116-120) 
3.1 Astrocytes in Early Brain Development 
Regional and morphological differences display astrocyte heterogeneity in adult brain even 
though GFAP expression is common across sub-types (112, 121). Additionally, differential 
gene expressional along the DV and AP axis in adult mice (122) indicate regional specific 
developmental origins and contribution of intracellular programs to astrocyte heterogeneity. 
However, neuronal niche dependent effects on astrocyte heterogeneity is also observed (19, 
123). The relative contribution between intracellular developmental programs and extrinsic 
signals to astrocyte heterogeneity remains to be fully determined. 
The generation of astrocytes during early brain development are believed to arise from RG, 
progenitors of the SVZ, local cellular division, and CSPG4 [NG2] (from here on named NG2), 
progenitors (12). During early development of the human cortex as the formation of the 
preplate occur the first wave of layer-1 astrocytes derived from ventricular zone (VZ) 
progenitors move to the subpial glial limiting membrane. As neural progenitors transition from 
being neurogenic to gliogenic after the formation of the gray matter a second wave of astrocyte 
from the SVZ migrate and populate the pial surface (124, 125). In adult human cortex the pial 
surface and adjacent regions are occupied by three subtypes of astrocytes; pia/layer-1 fibrous, 
interlaminar and protoplasmic astrocytes (112). Notably, protoplasmic astrocyte predominantly 
does not express GFAP but glutamate transporter SLC1A2 [EAAT2, GLT1] and SLC1A3 
[EAAT1, GLAST] (126). The progenitor identity of pia/layer-1 and protoplasmic astrocytes 
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are shown in mice to distinctly differ from one another (33). Since the interlaminar astrocyte is 
not observed in rodents it is not known if this sub-type arises from a progenitor different from 
pia/layer1 and protoplasmic astrocytes. 
The astrocytic SVZ progenitors migrate and populate all six cortical layers but also remain in 
SVZ and white matter (12). For the generation of protoplasmic and fibrous astrocytes there are 
indications that the two sub-types are derived from different progenitors in the SVZ (33). 
Genetic deletion of OLIG2 affect the formation of fibrous but not protoplasmic mouse 
astrocytes (127). In contrast, overexpression of OLIG2 increases glia production of astrocytes 
and oligodendrocytes (128) indicating OLIG2 to be an important intrinsic fate determinant for 
SVZ progenitor derived astrocytes of the OLIG2 niche in the MGE region. Additionally, early 
studies from human fetus indicate that RG type II with only ventricle attachment (124), similar 
to tRG definitions (2), develop into fibrous astrocytes, while RG type I develop into 
protoplasmic astrocyte after gray matter formation (124). At the end of radial neuronal 
migration RG transform by retracting their ventricle attachment moving the soma from the VZ 
towards the intermediate zone (IZ) transitioning into an astrocytic fate (125). The development 
of protoplasmic astrocytes is suggested to progress via a dorsal migration to the pial membrane 
and later descending into the cortical layers acquiring a maturing phenotype (33, 125, 126). 
Astrocyte numbers are further increased by local division to expand the protoplasmic astrocytes 
population in the cortical gray area (129). NG2 glia population, commonly associated as OPCs, 
have the potential to generate astrocytes. Lineage tracing of NG2 cells indicate in contrast to 
the possible contribution to the ventral forebrain astrocyte population that NG2 progenitors do 
not substantially contribute to the astrocyte population in the dorsal cortex (130, 131). Isolation 
of human glial progenitor cells (GPC) identified by NG2 expression in transplanted mice do 
show astrocytic differentiation competence (29, 30). However, generation of astrocytes from 
NG2 cells in physiological and in vitro system is still controversial. 
Astrocyte associated cell types in the hindbrain originating cerebellar structure include 
Bergman glia and protoplasmic velate astrocytes (111). These two subtypes share a common 
developmental progenitor (111). Interestingly, the molecular diversity between these cell types 
is shown to be dependent on neuronal input of SHH signaling. Inducing SHH in velate astrocyte 
made them become more Bergman like astrocytes (17). 
Progenitor origin and astrocyte heterogeneity in the spinal cord follow a more strict DV 
regional patterning. In the spinal cord, progenitor domains p1, p2, and p3 generate ventral white 
matter astrocytes VA1/VA2/VA3, respectively, while the pMN OLIG2-domain in between p2 
and p3 generate oligodendrocytes (109). The p0 DBX1-domain generate both protoplasmic 
and fibrous astrocytes which can also be observed for the overlaying dP1-dP6 PAX3-domains 
which gives rise to all dorsal astrocytes (110). The dynamics in generating gray and white 
matter astrocytes in the spinal cord is linked to ASCL1 expression where KO of ASCL1 
increase the number of gray matter astrocytes in relation to a reduction in both white matter 
astrocytes and oligodendrocytes (132). Long-term studies indicate that the distribution of 
astrocytes in the spinal cord are determined during embryogenesis, and that regional specific 
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astrocytes tend to only support neurons associated to its own region compared to adjacent 
regions (110). The ventral and dorsal region-specific transcription have direct physiological 
impact where ventral expression of SEMA3A is critical for sensorimotor circuit integrity (133). 
Even though studies of astrocyte generation and developmental origin in non-primate models 
provide very valuable information, astrocyte biology of humans show clear differences 
compared to non-primate models. Beside pial layer 1 astrocytes and protoplasmic astrocytes 
there is an additional subtype exists at the pial surface of higher primates not observed in rodent, 
the so-called interlaminar astrocytes. Interlaminar GFAP/CD44+ astrocytes extend poorly 
branched processes into the subcortical layers ending on blood vessels (36). Additionally, there 
is a second primate-specific subtype mainly situated in layer 5-6 called varicose projection 
astrocyte which also show GFAP/CD44+ expression. (36, 112). The evolutionary expansion 
of the cortex in higher primates is highly associated with the expanding progenitor population 
of the oSVZ, which contribute to the formation of the upper layers of the cortex (2, 13). How 
the progenitors of the SVZ contribute to the astrocyte heterogeneity and if this evolutionary 
diverged zone harbor progenitors responsible for human astrocytic subtypes is still unclear 
(Figure 5). 
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3.2 Non-coding Transcripts in Neural Biology 
The rapid development of sequencing techniques and computational power have made 
transcriptomic profiling more accessible with increasing granularity. This has demonstrated 
that non-coding RNAs have a bigger role in genome regulation than previously anticipated, 
even though we are just in the beginning of understanding its full regulatory contribution. 
Non-coding RNAs are divided up in long and short RNAs based on if the transcript is longer 
or shorter than 200nt, respectively. Further classification is possible, but exclusive guidelines 
are lacking (134). Evolutionary trends point towards a correlation between increased 
developmental complexity and increased non-coding repertoires (135), some being exclusive 
for primates (136) and enriched in the CNS (137). Protein-coding genes have in general higher 
expression than long non-coding RNAs (lncRNAs) which, however, display higher tissue 
specificity (138). Long ncRNAs can regulate and maintain pluripotency in PSC (139, 140) as 
well as developmental potency in neural stem cells (140) subsequently affecting and defining 
differentiation outcome (141) and functional development (142). Another group of ncRNAs 
called microRNAs (miRNAs), observed as small RNAs of ~18-25nt in length regulate a vast 
variety of cellular processes (101, 144, 145). MicroRNAs can target and regulate translation or 
function of other RNAs in a spatiotemporal manner at either the cell level or specific subcellular 
locations, which is important in highly polarized cells (143). Neural differentiation is highly 
linked to miRNA expression which induce neuronal fate directly (101) and is an important 
player in the neurogenic-to-gliogenic switch in NSC (144). Additionally, neuronal 
communication via miR-124-3p can regulate translation of astrocyte specific glutamate 
transporters in distal processes (145), shown to possess subcellular protein synthesis (146), 
regulating functional state. The interaction between lncRNAs and miRNAs has a role in 
neurodevelopment and in a primate specific context (147). The lncRNA for neurodevelopment 
(lncND), specifically expressed in certain primates is targeted at 16 sites by miR-143-3p. 
Downregulation of lncND or overexpression of miR-143-3p results in decreased proliferation 
and increased neuronal differentiation, respectively (147). miR-143-3p regulates notch 
signaling, which plays an important part in regulating progenitor proliferation and it is 
associated to primate neocortex expansion (148). Gain of function of lncND can expand the 
RG population in the mouse cortex (147) demonstrating the interplay between lncRNA and 
miRNA in the governance of cellular state.  
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3.3 Astrocyte Characterization 
Distinguishing between different cell populations is most commonly performed by studying 
transcript and protein expression. However, so far this approach has been challenging when 
defining astrocyte population since there are no unique genes identified that are only expressed 
by astrocytes. Additionally, the highly associated astrocytic marker GFAP, predominantly 
expressed by astrocytes in rodents, stain RG cells and adult stem cells in humans, 
demonstrating species variations in marker expression. Furthermore, GFAP mRNA expression 
in glia cells is not always associated with protein expression (149). Protein and RNA expression 
can be complemented by morphological characterization when studying astrocytes in vivo, but 
is not often conclusive in vitro. Therefore, astrocyte characterization needs to include several 
features to better define its cell type and subpopulations including morphology, combination 
of gene and protein expressions together with functional properties. 
3.3.1 Astrocyte Morphology 
The morphological and regional identity can define the major subclasses of astrocytes. 
Proteoplasmic astrocytes located in the cortical regions have largely branched tertiary 
processes enwrapping blood vessels while fibrous astrocyte in the white matter display more 
long unbranched processes. Layer 1 pial astrocytes have a fibrous morphology lining the pial 
matter. In higher primates there are two additional astrocyte sub-types; interlaminar astrocytes 
located in layer 1 of the cortex branching down into cortical layers 2-4 terminating their endfeet 
on blood vessels, and varicose projection astrocytes located in layers 5-6, which given by its 
name extend long projections across brain layers (112). 
GFAP is one of the most commonly used markers for visualizing astrocytes. However, GFAP 
staining only partially displays the astrocytes morphology which has numerous fine peripheral 
astrocyte processes (PAPs) generating a more cloud looking morphology, rather than the 
classical star shape, giving astrocytes their name. These fine processes can be as thin as 30-
50nm (150). Diastolic labeled GFAP positive cells show that GFAP staining only display 
roughly 15% of the cell volume, (35, 151), where PAPs roughly define up to 80% of an 
astrocytes surface area (152). Astrocytes connects to smaller vessels and capillaries, which in 
contrast to connections to larger vessels, visualized by GFAP staining, can be identified with 
intense AQP4 staining (153). Additionally, by only staining for GFAP the major protoplasmic 
astrocyte population is not visualized since it does not express GFAP (36, 126). 
Besides the fact that humans display astrocyte subpopulation not present in mice there is a 
significant difference in astrocyte morphology between human and mouse. Human 
protoplasmic astrocytes display 2.6 times larger diameter and extend 10 times more primary 
processes than their mouse counterpart. A larger size can also be observed regarding human 
fibrous astrocytes compared to the mice (112). The increased territory of human astrocytes 
compared to mice astrocytes has also been shown in vitro (154). A single astrocyte domain 
covers up to 2 000 000 synapses compared to the mouse astrocytes which covers around 120 
000 synapses (112). Interestingly, even though protoplasmic astrocytes are connected there is 
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very low overlap between cellular domains. Notably, in contrast to neighboring protoplasmic 
astrocytes is the domain border of a protoplasmic astrocyte not respected by CD44+ branches 
from interlaminar and varicose projection astrocytes which can cross and intrude protoplasmic 
domains (36). 
The morphology of isolated primary astrocyte is affected by in vitro culturing, which been 
demonstrated to be dependent on the application of fetal bovine serum (FBS). Defined medium 
or FBS containing conditions show significant differences on morphology, maintaining 
profound stellate morphology while inducing polygonal morphology, respectively (154, 155). 
Protoplasmic astrocytes in vivo can lose their bushy morphology acquiring a reactive 
phenotype reducing SLC1A2 while increasing CD44 expression (121). Since in vitro culturing 
can induce naturally occurring transformation of protoplasmic astrocytes it is important that in 
vitro culture can sustain a non-reactive environment, especially when studying the stellate 
protoplasmic astrocyte biology which is linked to the generation of the tripartite synapse (156). 
3.3.2 Astrocyte Transcriptional Profiling 
Transcriptomic profiling has undergone a big technical development in recent years with 
increased granularity by single cell transcriptome profiling. This provided valuable information 
about the cellular architecture of the brain highlighting the variety of neural cell specifications 
(107). There are several transcriptomic databases classifying astrocyte associated transcripts in 
non-pathological (154, 157-159) and pathological conditions (160-162). In addition to bulk 
sequencing some single cell studies capture astrocyte characterization (163-165). However, 
interpreting transcriptomic profiles should be done in the light of the cellular background of 
the transcriptomic samples. Human astrocytes isolated under defined conditions show an 
inflammatory induced response upon FBS culturing and similarities to glioma cells (154). 
Using inflammatory categorization (166), Zhang et al. demonstrate that serum-free isolated 
astrocytes show low association to a reactive astrocytic profile in contrast to astrocytes exposed 
to serum (154). Several astrocytic transcriptome profiles are based on samples isolated with the 
presence of serum (157, 160-162, 167, 168). 
Rodent models are commonly used for studying astrocyte biology for which several astrocyte 
enriched transcripts overlap with human astrocytes; GFAP, ALDH1L1, AQP4, CLU, SLC1A2, 
SLC1A3, SLC4A4, ELOVL2, ACSBG1, TTYH1, ATP1B2, SOX9 (154). However, comparing 
human fetal (GW17-20), juvenile (8-18yrs) and adult astrocytes (21-63yrs) with mouse 
astrocytes identify human specific astrocyte enriched genes in addition to transcripts associated 
with adult mature astrocytes; FAM198B, RYR3, AMY2B, LRRC3B, GPR98, CPE (154). Single 
cell analysis of fetal and adult human brain tissue validated previously identified astrocyte 
associated genes, but neither study displayed any astrocyte sub-type specification (165). Since 
human brain expansion is associated to the expanding SVZ during embryonic development, 
several studies focus on characterizing progenitor populations between GW12-23 including 
RG, vRG, oRG (148, 165, 169-174). The question is if the heterogeneity of the SVZ progenitor 
population is associated with later developing sub-classes of astrocytes? Transcriptomic 
identity of oRG cells show overlap with astrocyte associated transcripts (148). The transition 
  27 
of transcriptomic profiles from vRG/fetal astrocytes, oRG to mature astrocyte is studied in 
HEPACAM isolated cells from cerebral cortical spheroid models (175), which indicate the 
possibility of cell identity development of RG to astrocytes. Further development of single cell 
RNA sequencing analysis offers a time derivative of gene expression, providing rate and 
direction of entire transcriptomes, which enables further stratification of cellular transition. The 
analysis methodology demonstrates a developmental node between RG and astrocytes in 
rodent hippocampus associated to HES1 expression followed by AQP4 cellular expression 
(176). 
Non-coding RNAs can be cell type specific where certain miRNAs are enriched in cerebral 
and cerebellar astrocytes (167), but also associate to anatomic location and age in human 
astrocytes (177). Long non-coding RNA show similar characteristics where certain lncRNAs 
define RG (165, 171) and astrocyte populations (164). 
3.3.3 Astrocytic Protein Expression 
Astrocyte protein expression together with morphological and anatomic location is the basis 
for classical astrocyte sub-type specification. Layer-1 pial and interlaminar astrocytes together 
with fibrous and varicose projection astrocytes all are positive for GFAP/CD44 staining, which 
is predominantly not expressed by protoplasmic astrocytes (36, 112, 126). Intracortical 
astrocytes with similar morphology as protoplasmic astrocyte have been identified to stain for 
GFAP/CD44. However, since the cell characteristics are not present during fetal development 
and show high variability in adult samples, it might be an acquired phenotype which the author 
hypothesises to be linked to pathological change (36) as increased GFAP expression is 
associated with age (178). Protoplasmic astrocytes in adult brain express SLC1A2 and 
SLC1A3 which are also observed for pial and interlaminar astrocytes during development 
(126), but GFAP/CD44+ astrocytes generally show low expression of SLC1A2/3 (36, 126). 
Staining for AQP4 visualizes smaller vessels and capillaries (153) as it is expressed in the 
astrocytic endfeet of protoplasmic astrocytes (36). However, for CD44+ interlaminar and 
fibrous astrocytes AQP4, is observed around the soma and along processes instead of 
concentrating around blood vessels (36). S100B expression is predominantly expressed by 
protoplasmic astrocytes in the cortex but is expressed by GFAP+ and additional cell types in 
other parts of the brain (18, 179). GFAP expression is detected around GW13 in humans, 
defining a RG population. GFAP expression is also detected in stem cell populations in specific 
regions of the adult human brain including rostral migratory stream (RMS), the olfactory bulb 
(OB) and expression along the ventricle in the SVZ (180, 181). 
Besides being important during glial developmental onset (16, 182, 183) SOX9 has been shown 
to be a reliable and exclusive marker for astrocytic identity in the adult brain, except for 
ependymal cells and neural progenitors in neurogenic regions (184). Other proteins related to 
astrocytic biological processes include key enzyme in the foliate metabolism, ALDH1L1 (185), 
connexins GJB6 [Cx30] and GJA1 [CX43] (186, 187), potassium homeostasis, KIR4.1 (188), 
vitamin A metabolism, ALDH1A1 (189), glutamine synthesis, GLUL [GS] (190, 191), and 
thyroid hormone receptors SLC16A2 [MCT7/8] and SLCO1C1 (192). 
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Besides detection of protein expression can the fluorescent dye sulforhodamine 101 (SR101) 
be used to stain astrocytes in vivo (193). However, SR101 labels both astrocytes and 
myelinating oligodendrocytes since the dye is transferred via existing gap junctions between 
astrocytes and oligodendrocyte (194). Recently it was demonstrated that SR101 is taken up via 
the thyroid hormone receptor SLCO1C1 (192), which together with SLC16A2 [MCT7/8], are 
the major transporters for T4 (195, 196). Via T4 conversion by DIO2 activity, astrocytes serves 
as a major source of neuronal T3 during fetal development, which in adults is accessible 
directly via circulation (196). 
3.3.4 Neuronal Effect on Astrocyte Heterogeneity 
Recent technical development of single cell RNA sequencing has revealed a large subset of 
neuronal transcriptional identities (107, 197). However, the same technique has not diversified 
the astrocyte population to the same extent. One part of the explanation could be that astrocytes 
require a spatial and temporal plasticity of cellular specification and function which is later 
regulated by the local milieu and neuronal input. Peripheral astrocyte processes contain both 
ribosomes and rough ER translating local mRNAs providing the possibility for local maturation 
of membrane proteins. This subcellular architecture enables functional polarization of 
astrocytes (146). Secretion of neuronal exosomes containing miR-124-3p can induce 
translation of glutamate transporter SLC1A2 in astrocytes (145). Furthermore, in vivo 
experiments show that neuronal expression of SHH in the cerebellum affects gene expression 
in both adult mice and during development of Bergmann glial (BG) and velate astrocytes (VA). 
Increased SHH signaling in VA induced transformation to become more BG-like. SHH 
regulation also changes the electrophysiological properties of BG (17).  
Astrocyte heterogeneity can be associated with its position in the upper or deep cortical layers 
(123), which cannot be explained by diversified progenitor populations since clonal analysis 
indicating a common progenitor (33). Interestingly, the cortical heterogeneity disappears in 
mice lacking laminar structure (123). This indicates that layer-specific properties of astrocytes 
are not due to intrinsic developmental programs, but as an effect of extrinsic factors associated 
to neuronal layered structures (123). Modeling RG development in neural columns can show 
that neuronal cortical placement is followed by protoplasmic astrogenesis, where astrocyte 
precursors migrate radially distributing across the cortical layers before final rounds of division 
(18). This enables the cortical layers to associate diversity and regional specification of 
astrocytes derived from the same RG precursor. Additionally, maturation of astroglia is 
influenced by local neuronal signaling. Astrocytic domain development and expression of the 
glutamate transporter, SLC1A2, is significantly reduced by silencing glutamatergic synaptic 
activity in SLC17A7 [VGLUT1] KO mice (19). Similar arborization of astrocytic process and 
lowered SLC1A2 expression is observed when silencing the metabotropic receptor GRM5 
[MGLUR5] which mediate glutamatergic signaling in astrocytes. This effect is not observed in 
hypothalamus, where glutamatergic SLC17A7 signaling is not dominant. Together this 
indicates that functional maturation of cortical astrocytes is regulated by glutamatergic 
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signaling from local neurons (19). Moreover, neuronal effect on astrocyte function is also 
observed in vitro, significantly impacting astrocytic glutamate uptake (198). 
3.3.5 Astrocyte Functionality 
Astrocyte functionality is heterogenous and even though the contribution to brain function is 
not fully understood numerous key features associates to astrocyte biology. There are several 
excellent reviews highlighting the diversity of astrocytic function including glutamine-
glutamate/GABA cycle (199, 200), gliotransmission (201), calcium signaling (202, 203), 
potassium homeostasis (204), energy storage and support (205, 206), astrogliosis (207-210), 
water homeostasis (211), astrocyte-neuron lactate shuttle (212), thyroid metabolism (196), 
synaptogenesis (213), regulation of synaptic behavior and neurotransmission (214-216) and 
BBB interactions (217). Evaluation of glutamate uptake, inflammatory responsiveness, and 
calcium signaling are commonly performed in hPSC derived astrocytic models and is used as 
a measurement of astrocytic identity. 
3.3.5.1 Astrocyte Association to Glutamate/GABA Cycle 
Glutamate and GABA are secreted from the presynapse by glutamatergic and GABAergic 
neurons mediating excitatory and inhibitory signals, respectively. The neurotransmitters are 
taken up by postsynaptic neurons to continue neurotransmission. Depolarization and release of 
glutamate increase the concentration of glutamate in the synaptic cleft to the magnitude of 
100µM-1mM. For repeated transmission the concentration of glutamate in the synaptic cleft 
needs to be lowered reaching resting concentrations around 1-10µM (218, 219). Lowering the 
glutamate concentration is a key function for astrocytes which express glutamate transporters 
SLC1A3 and SLC1A2 (126) being responsible for the majority of glutamate transport (220), 
appreciably by SLC1A2 (221). A decrease in synaptic concentration occurs within 1 
millisecond (218) via rapid transport of SLC1A2/3, a rate which increasing during development 
in concordance with increased SLC1A2 expression (221). Failure to remove excess glutamate 
in the synaptic cleft can lead to excitotoxic effects and damaging of neurons (222). Glutamate 
transporters SLC1A2/3 are sodium dependent internalizing 3 Na+ per glutamate molecule 
which needs to be exported out from the cell by Na+,K+-ATPase to restore ion balance. The 
Na+,K+-ATPase ATP1B2 and ATP1A2 are associated to astrocytes (154) and RG (148, 165), 
respectively. Glutamate uptake is an energy demanding process. This is balanced by oxidative 
metabolism of glutamate generating α-ketoglutarate entering the TCA cycle via transamination 
or energy producing reactions governed by BCAT2/ GPT [ALAT] and GLUD1 [GDH], 
respectively (223). Exogenous glutamate is suggested to be primarily metabolized by GLUD1 
(224), which is highly transcribed in astrocytes (225). By GLUL [GS] glutamate is also 
converted into glutamine, an important for amino acid for neurons. The proportion of glutamate 
converted to glutamine or oxidized in the TCA cycle seems to be dependent on glutamate 
concentration (226). 
GABA released from presynaptic GABAergic neurons is taken up by astrocytes predominantly 
via SLC6A1 [GAT1]/ SLC6A11 [GAT3]. GABA is metabolized in the TCA cycle forming 
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glutamate and later glutamine (227). Glutamine is the only precursor molecule for the 
generation of amino acid neurotransmitters glutamate and GABA. As GLUL is predominantly 
expressed in astrocytes (228, 229) they serve as a critical source for glutamine synthesize. 
Glutamine is released from astrocytes via SLC38A3 [SNAT3]/ SLC38A5 [SNAT5] 
transporters and subsequently taken up and processed into glutamate and GABA in 
glutamatergic and GABAergic neurons, respectively (227). 
Glutamate uptake assays are commonly performed for validating astrocytic functions of hPSC 
derived astrocytes (15, 16, 183, 230-234). However, model comparison and interpretation are 
difficult since experimental procedures vary substantially between publications in regards to 
glutamate levels in the culture media before the assay, washout time before assay initiation, 
normalization, control conditions, number of time points, assay read out, and transporter 
modulation. Multiple cell types can reduce extracellular glutamate levels such as HEK293 cells 
(15, 234). However, astrocytic glutamate uptake is often associated to SLC1A3 and SLC1A2 
of the solute carrier 1 family [excitatory amino acid transporter, EAAT], constituted of five 
transporters SLC1A1-5. Since SLC1 transporters are sodium dependent several astroglia 
models can show that SLC1 transporters contribute to glutamate uptake by using Na+ depleted 
control conditions (15, 230). Applying glutamate competitive inhibitors L-trans-pyrrolidine-
2,4-dicarboxylic acid (PDC) (15, 230) or DL-threo-hydroxyaspartic acid (β-THA) (233) also 
demonstrates SLC1 dependent uptake in astroglia. However, further research is needed to 
stratify the relative activity of SLC1A2 and SLC1A3 to glutamate uptake in astrocytic models 
since they seemingly contribute differently in vivo (221). This can be performed using targeted 
pharmacological inhibitors (235). Moreover, additional characterization of the glutamate 
transport system including ion homeostasis via Na+,K+-ATPase, plausibly ATP1B2 and 
ATP1A2 in astrocytes, will further increase translability and relevance. 
3.3.5.2 Reactive Response by Astrocytes 
Astrocyte reactivity is a cellular response to neuropathologies including acute focal insults 
caused by traumatic injury and ischemic stroke as well as infections, neurodegenerative 
diseases, tumors, and autoimmune disease (207). Reactivity is a process to limit tissue damage, 
cell stress and restoring normal tissue homeostasis. The reactive response is not a homogenous 
single sided event, but is gradual and circumstantial, which can be linked to the type of 
neuropathology, characterized by brain region, niche, severity, and delimiting features (166).  
Invasive focal insult activates astrocytes in its vicinity which start to proliferate forming a 
barrier around the injured site. The scar is often composed of high astrocyte density with 
elongated and intermingled morphology having cell bodies double the size of healthy 
astrocytes (236). The proliferative phenotypic response accompanied with a stem cell like 
potential is predominantly observed during invasive trauma and cerebral ischemia which is not 
observed in noninvasive injuries. Isolation of glia cells from the injury site form proliferative 
neurospheres in cultures having multipotency capacity. The proliferative phenotype of reactive 
astrocytes is partly linked to SHH signaling which can also induce similar effects on non-
reactive astrocytes of the gray matter (237). Of note, isolation of primary astrocytes from non-
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pathological conditions often select for proliferative population, which show multipotency if 
isolated from neurogenic niches in the adult brain (181). 
There are a core set of transcripts upregulated in reactive astrocyte (166). However, large 
transcriptomic differences between neuroinflammation or ischemic stroke demonstrate injury 
specific astrocytic response, categorized as A1 and A2 astrocytes, respectively (166). 
Inflammatory response is also triggered by a variety of intercellular signaling molecules 
including proinflammatory factors such as TNF and IL1B originating from microglia, 
leukocytes and astrocytes (210). IL1A and IL1B stimulation show association of activating A1 
and A2 reactive astrocyte, respectively. Additionally, activation of A1 reactive astrocytes is 
dependent on the presence of reactive microglia, releasing specific cytokines as TNF, IL1A 
and C1QA (208). One commonly used biomarker for reactivity is the upregulation of GFAP 
(191, 238), which has also been used on clinical samples where various GFAP isoforms where 
upregulated in Alzheimer’s disease (AD) patients (191). Astrocytes also respond by 
upregulation of cytokine signaling genes (166) and secretion of cytokines (239) and other 
unknown factors shown to be neurotoxic (208). 
Modeling astrocyte reactivity in vitro mimicking physical insult have been done using scratch 
tests (240). Modeling neuroinflammation response is performed by stimulation using various 
factors followed by measuring the secretion of cytokines indicating reactive activation (241). 
Pro-inflammatory response is used to validate model functionality of hPSC derived astrocytes. 
Increased IL6 and IL8 secretion in response to IL1B stimulation is observed for several hPSC 
derived astrocytic models (183, 242-245) as well as to TNF (242, 244, 245) and Ab42 (246) 
stimulation. This is in concordance with pro-inflammatory stimulation of human primary fetal 
astrocytes (244, 246). However, stimulation with lipopolysaccharides (LPS), trying to mimic 
bacterial infection, display contradictive results where stimulation of astrocyte models 
generates both non-inflammatory response (208, 245, 247) and an increase in IL6 secretion 
(246, 247). 
Several hPSC derived astrocytic models studying reactivity (242-244, 246) and culture system 
for primary astrocytes (168) use FBS based conditions. A problem with investigating 
reactiveness of astrocytes in vitro is the fact that culturing conditions by it self can create a 
reactive stem cell like phenotype (20, 181) lowered by using defined condition (154, 208). This 
would imply that control conditions are not reflecting a non-reactive phenotypic state. The 
usefulness of a reactivity model would in such cases be dependent on the level at which the 
astrocyte is reactive in non-stimulated conditions. For example, if the astrocyte is at maximum 
reactivity before stimulation the inflammatory induction will not be representative, meaning 
that the stimulation response will depend on the basal level of reactivity during non-stimulated 
conditions. Several factors are associated with astrocyte reactivity including isolation 
procedure (248), extracellular matrix components (171), and the use of FBS (154, 155). New 
isolation and culture protocols maintaining a non-reactive state of primary human and mouse 
astrocytes demonstrate the importance of xeno-free and supportive cultures (154, 208, 248). 
Additionally, by applying defined conditions hPSC derived astrocytes differentiating via a glia 
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restricted progenitor (GRP) state demonstrate strong transcriptional changes after FBS 
exposure (20), which is also observed for primary GRP (155). However, withdrawal of FBS 
induced changes indicating a conversion back towards a non-reactive state (20). In accordance 
with FGF1 induced quiescence of FBS derived hPSC derived astrocytes (242) there are 
indication that a reactive state can at some level be reversible, but to what extent still needs to 
be determined. 
3.3.5.3 Calcium Signaling in Astrocytes 
Calcium signaling in astrocytes has gained increasing attention as it has shown higher 
importance to the neural circuits than historically believed (249). Astrocytes express a plethora 
of receptors (250) responsive to neurotransmitters such as glutamate, GABA, ATP and 
acetylcholine (ACh) which can induce an astrocytic calcium response. The endoplasmic 
reticulum (ER) is the major source for intracellular calcium which is an important second 
messenger for signal transduction. RYR3 and ITPR1/2 are the major calcium release channels 
expressed on the ER in astrocytes. Stimulation of G-protein couple receptors (GPCRs) can 
activate a downstream cascade where PLC cleave PIP2 forming IP3, which activate IP3 
receptors in the ER releasing stored calcium into the cytosol (203, 251).  
Astrocyte calcium oscillations related to synaptic transmission are not an all or nothing 
response, but dependent on synaptic transmission patterns which regulates oscillation 
amplitude in astrocytes (252). Neuronal transmission causing repetitive and sustained 
stimulation induce global calcium changes in the whole astrocyte (253). Calcium responses 
taking place in the soma are slow, seemingly contradictive for astrocytic regulation of fast and 
localized synaptic transmission. However, astrocytic response is more rapid in the fine 
processes (253). Astrocyte processes contain functional compartments enabling modulation of 
basal transmission, the release of neurotransmitters at individual synapses to a single action 
potential (252). Glutamatergic neuronal signaling, activating astrocytic GRM5 induced 
calcium signaling, can result in astrocytic release of adenosine which stimulate presynaptic 
ADORA2A receptors, modulating basal synaptic transmission (252).  
Calcium signaling in astrocytes is associated with their functional maturation during 
development. Glutamatergic neuronal signaling via SLC17A7 [VGLUT1] induces GRM5 
astrocytic calcium response (19). GRM5 expression is highest during development and 
decreased in adulthood (254). However, ablation of GRM5 induced calcium signaling reduces 
functional maturation and SLC1A2 expression. Additionally, a reduction of astrocytic domain 
development with arborization of astrocytic processes and lower synaptic enshealthing can be 
observed (19). Developmental maturation of calcium signaling response via GRM5 can also 
be observed for isolated human primary astrocytes. Fetal (GW17-23) and adult human 
astrocytes display calcium responsiveness to ATP stimulation but only adult astrocytes respond 
to glutamate stimulation. Pre-treatment with GRM5 antagonist, 2-methyl-6-phenylethynyl-
pyridine (MPEP), abolishes glutamate calcium induction indicating a GRM5 driven calcium 
response in adult human astrocytes (154). Glutamate and ATP induce synchronous and 
asynchronous calcium response patterns, respectively. Moreover, addition of MPEP do not 
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affect ATP driven calcium signaling which together indicate different triggering mechanisms 
of calcium response (154). 
ATP induced astrocytic calcium response can be activated via metabotropic P2Y1 and 
ionotropic P2X7 purinoceptors, and plausibly P2X2 and P2X4. However, ATP breakdown to 
ADP shows increased potency compared to ATP to trigger astrocyte calcium signaling whereas 
ADP breakdown to adenosine only triggers small astrocytic responses (255). Astrocytes can in 
turn propagate intercellular calcium signals by secretion of ATP and further activation of 
purinergic receptors on surrounding astrocytes (255). Calcium wave propagation is also 
observed via connexins, predominantly via GJB6 [Cx30] and GJA1 [Cx43] in astrocytes (187, 
256). Interestingly, intracellular calcium waves working via gap junctions or purinergic 
receptors show compensatory mechanisms as ablation of GJA1 can induce a switch to function 
via purinergic receptors (257). Notably, studying physical dynamics of calcium wave 
propagation in relation to connexin transport and ATP release can be challenging in biological 
systems, but where mathematical modeling can provide interesting hypothesises (258). 
Astrocytic GJB6 can regulate excitatory synaptic transmission and the protrusion of astrocytic 
processes into the synaptic cleft (256). Intracellular astrocytic calcium signaling is linked to 
potassium homeostasis which is critical for neuronal activity and firing of action potentials 
(259). Astrocytes can sustain axonal activity by spatial buffering of potassium via potassium 
channel KCNJ10 [KIR4-1] (260). Moreover, by GCPR induced increase of cytosolic calcium, 
astrocytes can control Na+,K+,ATPase activity and dynamically regulate extracellular 
potassium levels resulting in decreased synaptic failure and increased synaptic fidelity (259).  
Evaluation of calcium signaling is performed to functionally validate and assess the astrocyte 
biology of hPSC derived astrocytic models. Functional calcium signaling is shown in several 
hPSC derived models in response to mechanical (15, 16, 230, 242, 244), electrical (245), ATP 
(20, 183, 230) and glutamate simulation (246). Spontaneous calcium waves are also observed 
in hPSC derived models (183) together with calcium leakage from the ER, identified by 
inhibiting the major ER release channels RYR, IP3R and SERCA (245). Mechanically induced 
calcium wave propagation demonstrates ITPR mediated signaling dependent on ATP 
propagation (15) or gap-junction coupling (244). ITPR mediated signaling is also responsible 
for ATP stimulated calcium signaling in hiPSC derived astroglia (230). Notably, in vitro 
astroglia models often lack the complex morphology observed in vivo. This hinder to study the 
rapid calcium communication with neurons believed to occur in the fine branched processes as 
compared to slow calcium transients in the somata. 
3.3.5.4 Investigation of Astrocyte Associated Functions using hESC Derived Astrocytes  
Astrocyte functionality is diverse and several astrocyte-associated functions besides glutamate 
uptake, inflammatory response and calcium signaling are studied using hPSC derived models 
including; potassium conductance (15, 261), perineural net formation (262), oxygen 
consumption rates (245), phagocytosis (246), gap junctions connectivity (183) and metabolism 
(234). Notably, the development of astrocyte buffering functions of different ions is likely to 
be affected by medium composition where an imbalance might hinder this process. This can 
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be observed in neuronal cultures where classical basic medium and FBS impair electrical 
activity and synaptic communication (263). Moreover, hPSC derived astrocytes are being used 
to study astrocytic effects on neuronal biology including; synaptogenesis (183), neurite 
outgrowth (16, 20) and neuronal electrophysiology (183). Additionally, assessment of human 
isolated and PSC derived astroglia biology is studied by engraftment in rodents (8, 16, 29, 30, 
183). 
Establishing translational models of astrocyte biology provides the possibility to study 
astrocytes involvement in pathological conditions and diseases. Human isolated and PSC 
derived astroglia models are being used to study astrocytes involvement in AD (245, 264, 265), 
ALS (97, 230), Huntington’s disease (HD) (266), Alexander disease (183, 267), Costello 
Syndrome (262) and Schizophrenia (268).  
3.4 Astrocyte models 
Establishment of in vitro models to study human astrocyte biology currently use primary tissue 
or hPSCs as source material. Isolation from primary tissue can either focus on the direct 
utilization to study fetal and mature astrocytes (154), glioma (269) and adult stem cells (270) 
or the isolation of progenitors for further astrocyte differentiation and maturation in vitro (155, 
271). Human PSC derived astrocytic models apply differentiation protocols to direct hPSC 
towards an astrocytic fate after neuralization by using signaling factors (15, 20) and in 
combination with protein overexpression systems (16, 183). 
3.4.1 Primary Glia 
Primary astrocyte isolation methods have different methodology depending on the cell 
population to be targeted. Basic protocols focus on the proliferative capacity and attachment 
capabilities of isolated cells selecting for a mitotic population which expand over time and can 
easily be cultured (272). Besides genetically engineered reporter systems in mice, isolation of 
specific cell population from adult and fetal brain is predominantly based on protein expression 
or lack of protein using immunoselection (273, 274). Additionally, to isolate various cell types, 
a multistep immunopanning procedure can be applied where different cells populations are 
removed as part of the selection of the targeted cell population (154, 208, 248).  
Supporting culture conditions are critical for cell survival and sustained phenotypes of primary 
cells. Growth factor FGF2 was used in early development of primary isolation methods of 
neural stem cells from mice which can drive NPC proliferation in vitro (53, 54). Combinations 
of FGF2 and EGF enable NPC isolation from both mouse and human primary tissue (58). 
Media using high FBS and glucose concentrations are used to increase survival and 
proliferation capacity after isolation. Purification of astrocytes from human fetal brain can be 
performed by continuous passaging to remove neurons and oligodendrocytes while free 
floating microglia are removed during medium changes (241). Isolation and selection between 
cell populations is also achieved by exploiting the cells potential to attach to different surfaces 
under static and shaking conditions (275). Focusing on proliferative properties enables the 
exclusion of FBS developing more defined conditions (155). More targeted isolation of human 
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glia restricted progenitors from fetal tissue is achieved by selection and counter-selection for a 
specific ganglioside ST8SIA1 detecting antibody A2B5 and for an epitope of a polysialic acid 
linked to NCAM1, respectively, which can also be recapitulated in vitro by hPSC 
differentiation (29, 30). Isolation from human adult tissue shows that tripotent stem cells reside 
in the adult brain (270, 276) which can also be utilized as a source for adult progenitor derived 
astrocytes (271). 
To support and sustain mature in vivo like astrocytic phenotypes fully defined isolation and 
culture conditions have been developed. By screening several factors hbEGF and/or Wnt7a in 
contrast to generally considered neurotrophic and gliotrophic factors, such as GDNF, are 
necessary for mouse primary astrocyte survival (248). The same culture conditions are proven 
to work for human primary astrocyte isolation from fetal and adult tissue (154). Combining 
immunopanning with defined supportive media composition can isolate human astrocytes 
displaying high morphological similarities with more mature astrocytes in vivo (154). This 
protocol has also been applied for purifying brain organoid derived astrocytes (175). Isolating 
cells with an astrocytic phenotype is currently performed using immunopanning with a last step 
purifying the cell population based on expression of HEPCAM (154) and ITGB5 (208).  
3.4.2 Human PSC Derived Astrocytes 
To regulate NSC differentiation potency to become gliogenic and generate astrocytes include 
the governance of signaling pathways associated to astrocyte development. Astrocyte 
differentiation can be observed as different stages; inhibition of astrogenesis, acquisition of 
gliogenic responsiveness, astrocyte differentiation, and astrocyte maturation. Commonly 
associated pathways include FGF, JAK/STAT, BMP/SMAD, TGFβ, EGF, and Notch signaling 
(277, 278), which are applied in various combination to differentiate hPSC to astroglia (Table 
1). 
During recent years several publications have provided methods to differentiate human PSC 
into astroglia lineages. Many of these protocols depend on long-term cultures spanning up to 
200 days (15, 264). Long-term protocols either use more defined conditions, culturing NPC in 
EGF and FGF2 (15), or in FBS (266), as well as with the combination of EGF, FGF and FBS 
(279). Expansion and generation of astroglia is done both in adherent (231, 266) and suspension 
cultures (15, 243). To improve differentiation purity and efficiency GFAP reporter cells lines 
have been established (243, 280) together with surface marker purification via FACS (Yuan, 
Martin 2013) and plastic attachment selection (264). 
Roybon, et al. apply a long-term protocol for the generation of astroglia relying on extensive 
culturing of neuronal cells in FBS. The differentiation into astroglia display characteristic 
markers including CD44, GJA1, VIM, NF1A, ALDOC, SLC1A2 and with a high efficiency 
of GFAP (70%) and S100B (~100%) expressing cells. These cells also show functional 
properties in the form of glutamate uptake, calcium waves and reactive response phenotype to 
TNF and IL1B stimulation. Applying FGF1/2 at the end of the differentiation process can 
change the astroglia phenotype, reducing GFAP and NF1A expression, but keeping a 
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functional glutamate transport, suggested by the author to be a quiescent phenotype (242). The 
long-term FBS culturing methodology is also applied by others to differentiate patient specific 
hiPSC cells into astroglia with an ALS genotype (280, 281). Via long term cultures using FGF2 
and EGF Krencik et al. generate astroglia displaying the characteristic marker profile S100B, 
GFAP, A2B5, CD44, NFIA. The astroglia demonstrate functional properties such as 
synaptogenesis promotion, glutamate uptake, and electrophysiological features including 
calcium wave propagation and decrease voltage dependent outward currents when co-cultured 
with neurons. At the end of the differentiation, after 180 days, addition of LIF or CNTF increase 
the percentage of GFAP/S100B positive cells, staining approximately 90% of the population 
(15). Defined conditions with an EGF and LIF intermediate step before CNTF maturation can 
shorten the protocol down to 80 days (20). Applying the maturation factor combination of 
BMP2/4 and LIF reduced time lines slightly further down to 70 days (231). Progenitor 
expansion in neurosphere format before astrocyte maturation also report shorter time lines 
(230, 282). Differentiation of NPC using FGF2 and EGF long term culture show cellular 
developmental stages associated to early (d14 E-RG) and midneurogenic radial glia (d35 M-
RG) followed by outer and gliogenic radial glia (d80 L-RG) which at day 220 associate to 
adult-like progenitor cells (283). Late RG display loss of epithelial integrity and increased 
association to SVZ and oRG progenitors. Transcripts OLIG1 and PDGFRA at day 80 associate 
to HES5+ cells, which substantially decrease during late development while SLC1A3, FABP7, 
EGFR, and S100B increase in both HES5+/- populations. Interestingly, differentiation potency 
to GFAP+ cells upon FBS stimulation was only observed from HES5+ L-RG. It demonstrates 
that astroglia expression profile of FABP7, SLC1A3 and S100B can develop via a GFAP 
negative progenitor state. This study provides insightful biological translation for astroglia 
differentiation protocols using long-term FGF2 and EGF expansion. Notably, astroglia 
protocols often include repetitive passaging which will purify mitotic populations where 
frequency of passaging will further select populations based on their proliferation rate. 
Shortening the laborsome long-term culturing protocols for the generation of astroglia would 
be most beneficial and is currently being developed by several groups. FGF2, used in the long-
term differentiation methods, is a common factor also in the majority of shorter astroglia 
differentiation protocols. However, the application of other signaling factors reduce the 
differentiation time lines down to 20-40 days from an initial NPC stage (233, 261). Notably, 
the definition of an astrocytic phenotype is variable between publications, making time lines 
context dependent. Majumder et al. modulate the epigenetic landscape by using chromatin 
modifiers including Aza-C and TSA together with BMP2 to achieve faster differentiation. 
Methylation arrays shows that astroglia related markers GFAP, S100B, AQP4 are 
hypermethylated in NSC. Combining Aza-C and TSA with BMP2 more efficiently 
differentiate NPCs into GFAP (20%) and S100B (80%) expressing cells within 15 days, which 
demonstrate decreased methylation pattern on astrocytic gene promoters. Additionally, 
markers such as ALDH1L1 and SLC1A3 could be detected, but no functional evaluation was 
performed on this population (284). Direct application of astrocytic factors CNTF, JAG1-Fc, 
and CT1 on isolated NPC rosette structure significantly increase the GFAP+ population within 
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35 days but still compose of a high number of βIII tubulin positive neurons (285). Shaltouki et 
al. can corroborate the generation of astroglia by CNTF and BMP2 stimulation, but the 
condition including a neuregulin splice variant, heregulin, show the highest differentiation 
efficacy. Differentiating NPC for 35 days, via a CD44 positive stage, results in 69-80% GFAP 
positive cells. These cells exhibit glutamate uptake functionality together with synaptogenesis 
promotion when directly co-cultured with hESC derived neurons. (233). After 28 days FGF2 
and BMP4 induction Lin et al. demonstrate by using immunoselection for SLC1A3 that a 
highly enriched S100B+ population can be achieved after 14 days of FBS exposure (286). Fully 
defined xeno-free system using FGF2 and BMP4 media on PLO-Fibronectin coating can also 
generate astroglia within 20-40 days (261) 
Goldman’s group has generated a protocol for hiPSC derived OPCs and oligodendrocytes, 
which can be applied to generate astroglia even though the differentiation process develops via 
an oligodendrocyte associated marker expression profile, including OLIG2, NKX2.2, SOX10, 
A2B5, PDGFRA. The protocol is around 120-200 days, which can generate astrocytes and 
oligodendrocytes, both in vitro and in vivo upon transplantation in mice (8). Similar approach 
differentiating via a glia restricted progenitor state expressing A2B5 is performed by several 
hPSC derived astrocytic protocols (244, 261). 
Screening the differentiation efficacy of several of the previously mentioned astrocyte 
differentiation mediums was performed by TCW et al. across 42 NPC lines (246). Quality was 
assessed by GFAP, S100B, morphology, survival, proliferation, reproducibility and cell lines 
variation. A non-defined commercial media in combination with 2% FBS met the desired 
criteria. The protocol generated highly proliferative astrocytes with astrocytic morphology 
expressing GFAP, S100B, SLC1A3, ALDH1L1, and APOE (246). The authors emphasized 
that the protocol efficacy depended on the quality of the NPCs (246), preferably having a 
PROM1 [CD133]+/ CXCR4 [CD184]+/ NGFR [CD271]- expression profile as previously 
described (287), in addition to strict single cell culturing during the first 30 days of the 
differentiation (246). 
Shortening and simplifying the generation of astrocyte models is also achieved by genetic 
techniques overexpressing SOX9, NFIA and NFIB in hPSC generating iAstrocytes (16, 183). 
Overexpression is combined with standard expansion conditions of FGF2 (16, 183), EGF (16) 
and FBS (183) followed by maturation factors including BMP4, CNTF (16, 183), dbcAMP 
and hbEGF (183). Using stable integration in the AAVS1 locus of doxycycline inducible 
construct (16) compared to lenti-viral infection (183) iAstrocytes can be regionalized before 
astrocyte specification by differentiating hPSC to NSC using standard dual SMAD inhibition 
under patterning condition (16). Using genomic techniques to drive glial differentiation 
shortened the hPSC derived astrocyte protocol from 6 months (15) to 52 days (16). However, 
using lenti-viral expression with antibiotic selection generate homogenous iAstrocytes culture 
within 28 days from an hPSC state (183). 
Generating regional specific astrocyte can be performed in similar fashion as for hiPSC derived 
neurons by patterning NSC before neural differentiation. Anterior-posterior patterning 
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generating OTX2-HOXB4 NPCs, respectively, persisted upon astroglia differentiation. 
Differences in calcium wave propagation distances can be observed between anterior-posterior 
astrocytes which otherwise show similar phenotypes (15). Lack of phenotypic differences 
between midbrain and spinal cord astrocytes is also observed in other protocols (243), which 
in general show small differences in GFAP and S100B expression. A recent study shows that 
the exposure or non-exposure to FBS is more discriminating than cellular origin (20), indicating 
plausible difficulties studying regional variances using FBS based differentiation protocols. 
This is indicated in the generation of Olig2-Astro which show large similarities with non-
directed patterning NPC-Astro. However, an intermediate A2B5+ stage define a 
developmental difference between the two models together with functional oxidative 
protection capabilities. Exposure to FBS instead of BMP4 and FGF2 for 20 days ablate the 
A2B5 intermediate stage (261). The use of FBS during derivation of astrocytes is commonly 
applied, but recently there is a debate concerning the effects of FBS and in vivo representation. 
Application of FBS to non-exposed cells have shown phenotypical changes (20, 154, 155, 288). 
However, FBS induced effects has also been shown to be reversible (242), but to want extent 
and if FBS causes permanent changes is still unclear. 
In vitro culturing conditions for astrocytes needs to be strictly defined to create reproducible 
and biological relevant astrocytic models since astrocyte biology has been shown, besides 
differentiation factors, to be affected by FBS addition (154, 155, 288), glucose levels (289) 
glutamate levels (290), basal medium composition (263), matrix proteins (171), and oxygen 
tension (291, 292). 
3.4.3 Human PSC Derived Organoids in the Generation of Astrocytes 
Recent technical development provides the possibility to generate brain organoids from PSCs 
which recapitulate brain structure, regionalization and cell diversity observed in vivo. This 
complex modeling system enables researchers to study unique features of human brain 
development, not fully captured in mice and non-human primate models (293). Organoids 
capture developing astrocyte around day 60 in culture (294), which over a longer time course 
of 180 days increase in abundancy (288). Isolated under defined serum-free conditions 
organoid derived GFAP+ astrocytes show stellate mature morphology (288). Stellate 
morphological cells transform into a polygonal shaped cells upon FBS stimulation while 
increasing markers of astrogliosis, demonstrating reactive responsiveness at this time point 
(288). Extending culture time of organoids to 590 days in vitro shows development and 
maturation of astrocytes resembling human primary mature adult astrocytes (154, 175). 
Immunopanning isolation of HEPACAM+ astrocytes from organoids spanning from 100 days 
to 495 days show increasing transcriptional identity with adult astrocytes in parallel to 
decreasing association with fetal stages. Mature organoid derived astrocytes show reduced 
proliferation and increased morphological complexity accompanied with acquisition of 
astrocyte associates functionality including SLC1 dependent glutamate uptake, phagocytose 
synaptosomes, induction of synaptogenesis, and effect on neuronal calcium signaling (175). 
Single cell analysis of 590-day organoid glial cells reveals population of cells at different 
  39 
developmental stages. Transcriptional transition can identify vRG, oRG, fetal and adult 
astrocyte over the culture period. These share a considerable overlap making it interesting from 
a lineage tracing perspective to try and identify the origin and developmental pathway of human 
astrocytes (148, 154, 175). Common approaches to generate organoids start with culturing of 
PSC or NSC. However, with the focus to study the dynamics of astrocyte networks and neurons 
Krenick et al. developed organoid spheres of pre-differentiated hPSC derived astrocytes called 
asteroids. Combining asteroids and iNeurons triggers the development of a more complex 
astrocyte morphology and increasing synaptic density. This model might enable the study of 
the tripartite synapse with higher translability (34).  
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4 Human iPSC derived Neural In vitro Models in 
Pharmaceutical Development 
Since the discovery of the iPSC technology the number of human iPSC derived neural models 
used in pharmaceutical screening settings has increased dramatically. Not to be neglected, 
circumventing the ethical aspects of using embryonic stem cells by applying iPSC has enable 
new possibilities. As the differentiation protocols improve the generation of more specific and 
functional models the application and investigation of specific biological traits using stem cell 
derived models increase. Screening settings can thereby look at disease mechanism linked to 
specific cellular subtypes such as dopaminergic neurons in PD. Another key factor in the 
utilization of stem cell derived neural models is the accessibility of the cell. Large compound 
screens require large number of cells. This has previously been circumvented using 
immortalized cell lines or applying primary cells later in drug development when validating 
desired properties of a reduce number of candidate compounds. By using hiPSC derived neural 
models the number of cells is not a problem. Additionally, genetic modifications are more 
easily performed in PSCs compared to primary cells which often have a limited number of 
division and are harder to transfect. This enables the generation and correction of genetic 
disease backgrounds in addition to the availability of genetic cohorts using hiPSC. The use of 
stem cell models could potentially improve drug target identification and optimize stratification 
of candidate compounds in the hope of achieving higher translability making clinical trials 
more efficient. Even though PSCs derived models present new challenges such as fetal like 
phenotypes, differentiational variability between lines and that there are not protocols for all 
cell types, yet they have shown their usefulness as models, particularly in neural systems where 
the supply of primary human cells is very limited. However, there is always a concern if the 
mechanism of disease and therapeutic candidate have any in vivo relevance, a translational gap 
that might be reduced with the utilization of stem cell derived complex physiological systems. 
The drug discovery process is commonly initiated by applying a diversified or selected 
compound library in a primary screen utilizing a model with a desirable read-out. Hit 
identification is followed by lead series generation which optimize compound target efficacy. 
Additionally, chemical optimization tries to remove undesired activity identified in a 
secondary/counter screen, for example minimizing off target effects. This is critically important 
when progressing with lead series compound minimizing late stage failures in more costly 
experimental set ups, or clinical development. 
4.1 Human iPSC Derived Neuronal Models in Screening 
Human iPSC derived neurons have been used to study disease (297) such as AD (21), PD (73, 
298), and HD (299). Additionally, as derivation protocols become more robust providing 
culture homogeneity and large-scale production hiPSC derived neurons are being utilized in 
compound screening of increasing size (22, 23). Safety issue is one of the major causes of drug 
projects closure, both in preclinical and clinical stages (300) signifying the need to selectively 
remove compounds displaying unwanted effects early in drug discovery programs. Human 
iPSC derived neurons are being applied in neurotoxicity screening (23) and used to study 
  45 
compounds affecting neurite out growth (22) contributing to safety selectivity in compound 
development progression. Applying hiPSC derived neurons for studying disease, function and 
safety could play a part in improving the decreasing number of CNS programs in drug 
development (301). 
4.1.1 Removing Unwanted Effect of Plasminogen Binding Inhibitors 
Upon damage to blood vessels, platelets form a plug at the site of injury in parallel to depositing 
mature fibrin by the conversion fibrinogen minimizing blood loss in the formation of a fibrin 
clot. Restoration of tissue function involves fibrinolysis, degradation of the fibrin clot. This is 
performed by plasma circulating plasminogen which anchor to fibrin by kringle 1 binding to 
plasminogen. Plasminogen unfolds once bound to fibrin and is converted into active plasmin 
by tissue-plasminogen activator. Plasmin then cleaves fibrin generating fibrin degradation 
products and subsequent removal of the fibrin clot (302).  
However, in the clinic, major surgeries requiring blood transfusion are associated to 
hyperfibrinolysis initiating unwanted bleeding which can causing severe effects. Thereby, 
antifibrinolytic drugs are used to reduce mortality following major trauma as well as reduce the 
need for blood transfusion and minimizing the risk of reoperation due to bleeding (303-305). 
Fibrinolysis can be reduced by plasminogen binding inhibitors (PBIs) which act to prevent 
kringle binding to plasminogen inhibiting its anchoring to fibrin and subsequent maturation to 
plasmin (306). PBIs are currently used and administrated in the clinic (303-305). However, 
commonly used plasminogen binding inhibitor TXA is associated with an increased risk of 
seizures (305, 307). This has been associated to an unwanted selectivity towards inhibitory 
neuronal receptors GABAA and glycine (307-309) which is also observed for more potent 
inhibitors as 4-PIOL (310). To identify PBIs which do not show GABAA receptor activity 
potent inhibitors are counter screened for this effect (311). 
Receptor functionality in neurons is of major interest in the pharmaceutical industry. Studying 
receptor functionality in hiPSC derived neurons is performed by using various techniques such 
as patch clamping (312), calcium imaging (313), MEA, used to study neuronal circuit-
connectivity (314). One of the previous techniques in the pharmaceutical industry to measure 
binding activity to neuronal derived receptors is based on isolation of neuronal rat membrane 
(310, 311). This requires animal and is both time consuming and does not show compound 
mode of action, if it behaves as an agonist or antagonist. Human iPSC derived neurons having 
a transcriptomic profile associated to fetal prefrontal cortex showed functional ionotropic 
glutamate receptors observed by dose dependent response to AMPA and NMDA 
administrations (313). In addition, the hiPSC derived neuronal model shows immature GABAA 
receptor functionality by calcium response to GABA and gabazine administration (313). Patch 
clamping techniques show similar GABAA receptor functionality in response to GABA and 
inhibition by bicuculine (312). Patch-clamping also demonstrate functional glycine receptors 
in hiPSC neuronal cells partially inhibited by picrotoxin indicating heteromeric receptor 
composition (315). A common problem with previous techniques is the low-throughput relative 
to compound screening. To increase throughput in functional studies automated patch-
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clamping can be used, this technique shows a 40% success rate of measured cells, providing 
comparable concentration response curves (312, 316). Optical biosensors that detects refractive 
index alterations due to dynamic mass redistribution is another potential high-throughput 
technique to study receptor functionality (317, 318), which together with an additional label 
free technology is commonly used to study GPCRs (319). By activating the GABAA receptor 
of a neuroblastoma cell model, live cellular responses are measured by translocation of cellular 
mass demonstrating corroborating concentration response curves to GABA stimulation (320).  
Besides studying development and disease mechanistic pathways hiPSC derived neural models 
have a great potential and applicability in pharmaceutical development to identify and avoid 
unwanted functional effects of lead compounds. This can lead to more efficient lead series 
optimization and effective generation of candidate drugs with the goal of minimizing the risk 
of patient health. 
4.2 Human Astrocytic Models in Screening 
Astrocytes are implicated to contribute to various diseases and pathophysiological conditions 
(321) making them a reasonable target for therapeutic intervention. Drug induced effects have 
been studied in various human astrocytic models including CCF-SSTG1 (269, 322), primary 
fetal (269, 322, 323) and human PSC derived astrocytes (23, 264, 324). Screening using glial 
models has commonly focused on treatment against glial tumors, either by using cells expanded 
from the primary tumor (325), reprogrammed cancer cells (326) or by genetic modifications of 
hiPSC derived glia inducing cancerous phenotypes (327). Combining glioblastoma like cells 
with normal stem cells, a counter-selection of compounds can be made identifying hits 
affecting glioblastoma like cells but not healthy stem cells (327, 328). Moreover, for drug 
induced effects of astrocytic models, several studies have focused on phenotypic readouts of 
reduced oxidative stress (323), neurotoxicity (23), APOE secretion, (269, 322), and AD (264). 
A larger number of evaluated compounds is observed in a few studies using hiPSC derived or 
human primary astrocytes (23, 269, 322, 324). 
4.2.1 APOE Biology in Relation to Alzheimer’s Disease 
Lipid and cholesterol transfer between cells is facilitated by APOE serving as a ligand to 
endocytic mediated uptake via LRP1 and LDL receptor family expressed on neurons, microglia 
and astrocytes (329, 330). APOE is predominately expressed by astrocytes (331) therefore 
having an important role in regulating cholesterol homeostasis. There are three APOE isotypes 
(APOE2/3/4) of which APOE4 is a strong genetic risk factor for developing sporadic AD (332) 
contributing to the majority of AD cases compared to familial AD which is linked to specific 
mutation in the APP and PSEN1/2 genes (333). Molecular associations of AD are increased 
load of Amyloid-β (Aβ) peptide composition and aggregation in combination with Tau 
accumulation (334). APOE3 compared to APOE4 code for cysteine and arginine at the amino 
acid position 112, respectively. Arginine affects protein structure affecting APOE4 function, 
reducing binding of cholesterol and lipids (335) and susceptibility to proteolytic cleavage 
(336). The different APOE isotypes are associated to increased Aβ accumulation in increasing 
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order APOE2<APOE3<APOE4 (337) while lipidated APOE-Aβ binding correlates inversely 
(338) indicative of APOE association to Aβ clearance. APOE affects Aβ clearance by cellular 
uptake (339) degradation (340) and receptor-mediated transport across the BBB (341). 
Decreased deposition is linked to increased APOE lipidation regulated by ABCA1 function 
which mediate cholesterol efflux (342). APOE4 and ABCA1 loss of function mutation have a 
hazard ration for AD of 7.70 and 4.13, respectively, indicating its relevance in AD development 
(332). On this line AD mouse models show that LXR and RXR agonist stimulation regulate 
APOE and ABCA1 expression levels influencing AD pathology (343). Genetically modified 
AD rodent models provide insight in AD biology and regulation but since large number of 
drugs have failed to reach the clinic (344) discussions on how to interpret the outcomes from 
these rodent AD models (345) and the role of APOE in disease and as therapeutic target (333) 
are ongoing.  
4.2.2 Screening for Increased Secretion of Astrocytic APOE  
Biological features associated to AD are observed in hiPSC derived astrocytes (264, 265, 346) 
displaying both oligomeric Aβ accumulation in relation to AD genotypes (264) and functional 
ability to secrete Aβ and soluble APPα (346). Additionally, hiPSC derived astrocytes generated 
from an APOE4 genotype display phenotypic association with PSEN1 genotype compared to 
healthy control (265). Moreover, APOE4 and an isogenic control APOE3 display distinct 
differential APOE protein expression, cholesterol binding and secretion, Aβ uptake and 
lysosomal degradation in hiPSC derived astrocytes together with increased Aβ association to 
synaptic puncta in organoid models (286). 
Mice AD models show reduced Aβ levels and improved memory in association with increased 
APOE expression during agonist treatment of LXR and RXR (343). Additionally, Aβ 
degradation is dependent of APOE lipidation (340) which can be regulated by ABCA1, 
increased by LXR/RXR agonists. The strategy to increase APOE and/or lipidation levels might 
be a therapeutic possibility. Screening for APOE enhancing agents using human astrocytoma 
cell line CCF-STTG1 and human fetal astrocytes confirm upregulated expression of APOE 
during treatment with LXR agonists GW3965 and T0901317 (Tularik) (269, 322). However, 
as these agonists cause unwanted effects such as hypertriglyceridemia (347) Fan et al. could 
identify a LXR transactivating compound with lower SREBP-1c induction but still increased 
ABCA1 and APOE expression, thereby likely reducing hepatotoxic effects observed with 
traditional LXR/RXR agonists (322). Further development identified APOE and ABCA1 
enhancing P2X7 annotated compounds with low SREBP-1c induction through an indirect LXR 
mechanism (348). Using a reverse approach Finan et al. applied human fetal astrocytes in the 
primary screen which demonstrated a mechanism of increased APOE secretion without 
ABCA1 induction (269). These compounds affect enzymes in the cholesterol biosynthesis 
pathway DHCR7 and DHCR24 (269) which show decreased levels in neurons of affected AD 
brain regions (349). DHCR24 mediates lipid raft formation and is a target gene of LXRα (350). 
Interestingly, these compounds increased APOE levels in primary astrocytes but not in the 
astrocytoma cell lines (269). This demonstrates that cellular context affects hit finding, 
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highlighting the risk and complexity of excluding compounds based on the primary screen. If 
the astrocytoma cell line would have been used in the primary screen of Finan et al., DHCR7 
and DHCR24 would not have been identified and confirmed in a secondary screen using 
primary astrocytes since they would have been removed in the first selection. 
However, despite the efforts of finding compounds increasing APOE secretion there is a debate 
weather targeted treatment of APOE4 genotype should lower or increase APOE expression 
since it is not clear if APOE4 results in loss of function or gain of toxic function. Additionally, 
transcriptional changes between APOE3 and APOE4 relating to metabolic processes (286) 
might indicate that compound potency or toxicity between genotypes is not the same such that 
hit findings should be performed or validated in APOE4 genotypes. A contribution to this 
discussion is a study demonstrating that by using human recombinant APOE2/3/4 stimulation 
of hiPSC derived neurons, APOE can function as a signaling molecule to increase APP 
expression (351). Moreover, APOE4 demonstrated higher potency for signaling activation 
compared to APOE3 and APOE2 in their delipidated forms (351). 
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5 Aims of Thesis 
The overall aim was to apply hiPSC derived astrocyte and neuronal models in a pharmaceutical 
screening setting. 
The specific aims were: 
• to develop a fully defined protocol for ltNES derived astrocytes demonstrating 
astrocytic translability on a transcriptomic, proteomic and functional level (adressed in 
paper I) 
• to characterize current astrocytic models available for the pharmaceutical industry 
(adressed in paper I) 
• to apply the astrocytic models in a pharmaceutical assay setting (adressed in paper I) 
• to apply hiPSC derived neruons in a pharmaceutical assay setting (adressed in paper II) 
• to develop a completely defined protocol and remove all animal components to increase 
robustness (adressed in paper I) 
• to study the development of astrocyte biology in vitro to increase the understading and 
level of in vivo translability (adressed in manuscript III) 
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6 Results Summary and Discussion 
6.1 Paper I: 
The establishment of a long-term neuroepithelial-like stem (ltNES) cell (61, 62) having a 
homogenous and stable phenotype over extended culture time provide a valuable cell source 
for subsequent studies. By using ltNES cells as starting material, experimental timelines are 
shorted by several weeks in addition to higher reproducibility and robustness. Translating to 
neuroepithelial stem cells before GW7 the neurogenic ltNES model has predominantly been 
used to characterize spontaneous neuronal differentiation (56, 62, 352). In Paper I we show that 
ltNES can acquire a gliogenic potency by the protein expression of NFIA and SOX9, key 
transcription factors for glia onset. Furthermore, expression of BLBP, S100B, SLC1A3 and 
SLC1A2 together with several transcriptomic markers ALDH1L1, AQP4, TNC, RYR3 ATP1B2, 
ATP1A2, GRM5  strongly indicate that ltNES cells attain an astroglia fate (NES-Astro). We 
then wanted to benchmark the NES-Astro model against other astrocytic models in the 
pharmaceutical industry including astrocytes from various sources; primary adult tissue 
(phaAstro), astrocytoma (CCF) and another commercially available hiPSC derived astrocyte 
(iCellAstro). Notably, an important aspect is that the pharmaceutical industry due to ethical 
considerations, is very restricted in the use of fetal derived models. This means that the most 
logical comparison between NES-Astro and fetal astrocytes, commonly used in the research 
field (20, 269, 322), is not included among the evaluated models. However, to identify neural 
and astrocyte associated characteristics we included ltNES (neural representation) and 
HEK293 cells (non-neural representation). Based on transcriptomic and protein expression we 
could detect large differences between the six models. However, since there is no reliable 
marker or transcriptomic identity fully specifying astrocyte biology we wanted to assess several 
functional properties associated to astrocytes in vivo.  
Removal of excess glutamate in the synaptic cleft is a critical astrocytic function to avoid 
excitotoxicity and keep synaptic homeostasis during neuronal transmission. This is achieved 
by glutamate transport from sodium dependent transporters SLC1A3 and SLC1A2. In this test 
we can demonstrate NES-Astro having an active SLC1A3 dependent glutamate uptake over 
time, not observed for any of the other models. Moreover, astrocytes can display an 
inflammatory response in the event of brain trauma. We simulated this by treatment with pro-
inflammatory cytokines TNF and IL1B evaluating the response by secretion of IL6 and IL8 as 
previously studied (244, 246). We could detect a dose dependent response in the NES-Astro 
model significant from ltNES. Inflammatory response was also observed for the other models. 
Interestingly, the baseline of IL6 and IL8 was high in phaAstro, CCF and iCellAstro while no 
secretion was detected from NES-Astro, indicative of a completely inflammatory inactive state. 
This can plausibly be linked to xeno-free and FBS based culturing condition for NES-Astro 
and the other astrocytic models, respectively, since FBS is known to induce astrocytic 
inflammatory pheontypes (20, 154, 166). Calcium signaling in response to neurotransmitter 
release is another important function of astrocytes for downstream regulation and feedback to 
neurons and neighboring astrocytes. Using a fluorescent Ca2+-dye we could monitor calcium 
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fluctuations in response to ATP and glutamate. NES-Astro and phaAstro could show ATP 
response while only NES-Astro responded to glutamate stimulation. Interestingly, in one 
biological replica, C1, there was no significant difference in the number of ATP and glutamate 
responding cells enabling us to investigate the calcium response patterns. This could show 
asynchronous and synchronous signaling in response to ATP and glutamate, respectively, 
corroborating the findings observed from fetal and adult astrocytes using a refined isolation 
method preserving in vivo phenotypes (154, 208). Additionally, an initial observation was that 
NES-Astro did not display any calcium respond to KCl stimulation. A study by Foo et al. 
demonstrate KCl induced response by FBS-isolated astrocytes in contrast to immunopanned 
astrocytes, which upon FBS treatment respond to KCl (248). 
Cholesterol and lipid homeostasis in the brain is regulated by astrocytes where one of the major 
transporting proteins, APOE, is predominantly produced by astrocytes. Moreover, the APOE4 
isotype, which have reduced binding of cholesterol and lipids compared to APOE2/3, is a 
strong genetic risk factor for developing AD. Basic secretion analysis show that the astrocytic 
models secrete significantly more APOE compared to neural stem cells (ltNES). 
Transcriptomic profile linked to APOE-associated genes display similar expression patterns 
among the astrocytic models except for great difference by the astrocytoma cell line (CCF), 
which have previously been used to study APOE biology (269, 322). Finally, we wanted to 
compare the astrocytic models in a pharmaceutical setting optimized for high-throughput 
screening (HTS). Using pharmacological enhancers of APOE, assessed by a sandwich ELISA, 
we could optimize and demonstrate assay robustness suitable for HTS with Z’ of 0.76. Thereby 
we could run a pilot-screen of APOE annotated compounds across all models. In summary, 
common LXR agonists regulated APOE secretion in CCF as previously shown (269, 322). 
However, overall results displayed that no annotated APOE enhancer included in this 
experiment induced a significant response in all astrocytic models. This indicate that hit-finding 
in HTS for APOE enhancer will be dependent on cellular context. Model bias was also 
demonstrated by Finan et al. which used primary fetal astrocytes in the primary screen (269), 
more commonly used in confirmation/secondary screens (322). The strategy led to the 
identification of new APOE enhancers not stimulating CCF (269), which otherwise would have 
been missed if the CCF was used in the primary screening. Identification of compounds in the 
cholesterol biosynthesis pathway having APOE enhancing effects (269) could be confirmed in 
our study where both NES-Astro and phaAstro responded to stimulation, while no effect was 
observed in the CCF. 
Additionally, since the aim was to develop an astrocytic model applicable for drug screening a 
big emphasis was on model robustness and reproducibility. This included the removal of non-
defined products, handling procedures of media and coating components, optimizing culturing 
timelines and passage time points, in addition to constructing a protocol for standard operating 
procedures providing a day to day instruction for a 6-week period. This enabled the 
establishment of a completely xeno-free culturing system exchanging certain components in 
the media and switching from the traditional coating to human recombinant laminin 521. 
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Protein expression profiles demonstrate the same developmental program of NES-521Astro as 
for NES-Astro.  
All together the NES-Astro model shows biological translability and robustness of high enough 
quality to be applicable in a pharmaceutical setting and demonstrate better model representation 
in several aspects compared to traditional models used today.  
6.2 Paper II 
Besides studying disease phenotypes or mechanisms hiPSC derived models show great 
potential to provide valuable information regarding unwanted side effects from lead 
compounds in a secondary evaluation. We wanted to explore this possibility in a proof of 
concept study for the development of new plasminogen binding inhibitors (PBIs) which are 
used to avoid excess bleeding after traumatic injury or surgeries. First generation PBIs, 
including a commonly used drug TXA, have been associated with an increased incidence of 
seizures (305, 307). The effect has been suggested to depend on the unwanted selectivity of 
TXA towards inhibitory neuronal receptors GABAA and glycine (307-309). Previous 
development of new PBIs which did not displaying activity against inhibitory neuronal 
receptors used a relatively low throughput method. Additionally, this neuronal rat membrane 
binding assay does not provide any information regarding compound mode of action (311). 
Besides validating the application of hiPSC derived neurons for the evaluation of new PBIs we 
wanted to explore the possibility to integrate a technique enabling future high throughput 
screening (HTS) that provides information on mode of action. The label free technology 
measuring dynamic mass redistribution (DMR) by optical sensors, previously used for studying 
G protein-coupled receptor activity (317) is suitable for HTS purposes. As compared to 
astrocyte, the neuronal protocols are more well established proving expressional and functional 
characteristics suited for this evaluation (312, 313). Adaptation of a commercial hiPSC 
neuronal line with the DMR system demonstrated good viability and DMR signal. Next, we 
evaluated if stimulated activity of endogenously expressed GABAA and glycine receptors could 
be detected by the DMR-system, which previously been used for overexpressing or 
immortalized cell lines with high receptor expression (317, 320). Indeed, we could demonstrate 
concentration response curves for GABA and glycine, endogenous ligands for the GABAA and 
glycine receptors, respectively. The signal response could be confirmed to be dependent on 
GABAA and glycine receptor by stimulating with antagonist bicuculline and strychnine, 
respectively. Concentration response curves for antagonists GABAzine and strychnine could 
also be demonstrated. To evaluate assay robustness, we ran the assay at two different time 
points using different vials of hiPSC neurons displaying stringent results.  
Additional evaluation of the assay explored the previous suggested promiscuous properties of 
taurine activating both the GABAA and glycine receptor at high concentrations (353). Applying 
taurine at increasing concentrations under co-treatment with antagonists towards the GABAA 
and glycine receptor demonstrate that taurine below 1mM only activate the glycine receptor 
while concentrations above 1mM also activate the GABAA receptor. To further explore the 
flexibility and granularity of the assay we investigated if we could detect and show indications 
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of the glycine receptor composition by applying picrotoxin, an α-homomeric glycine receptor 
antagonist. The result demonstrated a reduced signal of taurine stimulation at 0.375mM in the 
presence of picrotoxin compared to control indicating that hiPSC neurons have a heterogenous 
expression of α-homomeric and αβ-heteromeric glycine receptor composition.  
After validating the functionality and representability of combining hiPSC neurons with the 
DMR technology we next looked at the claimed effect of commonly used drug TXA. The 
stimulation with TXA showed antagonistic effect on both the GABAA and glycine receptor 
indicating a potential cause for the increase incidence of seizures during TXA administration 
to patients. With the goal to evaluate if the assay could be used in drug developmental programs 
to exclude unwanted chemical properties we evaluated chemical entities from a lead series of 
compounds with PBI properties. We applied one discontinued compound, indicated to have 
effect on the GABAA receptor, and a candidate drug, AZD6564, shown to have no effect on 
inhibitor neuronal receptors (311). In contrast to AZD6564 we could demonstrate that the 
discontinued compound had an antagonistic effect on the GABAA receptor reducing the 
efficacy of GABA down to 70%. 
In summary, the study demonstrates proof of concept that hiPSC neurons together with a HTS 
applicable technique can be used in the stratification of lead series compounds in drug 
development. 
6.3 Manuscript III 
Independent of the application, model representation is critical for its relevance and impact. In 
the light of the results in Paper I, presenting a big difference in model representation of 
astrocyte biology, we ask how the derivation of NES-Astro correlate with in vivo development. 
In what aspects can the NES-Astro model be used to study developmental features of human 
glia biology, indicated to have evolutionary significance to brain development and cognitive 
function, and what is the NES-Astro translability? To rely on results achieved with the NES-
Astro model these are key question to be answered to build confidence in decisions made 
moving forward in drug discovery programs. 
To thoroughly investigate the development of NES-Astro using the FHIA-protocol RNA 
samples were taken at day(d)0, d7, d15, d22, and d28, which the last time point represents the 
same stage as the evaluation in Paper I. To increase confidence in the transcriptomic patterns 
we performed three independent culture, technical replicates, of three independent ltNES cell 
lines, biological replicates, in total n=9. In addition, we used the exact same set up of n=9 at 
the same time points for control conditions where ltNES were cultured under maintenance 
conditions instead with the directed FHIA-protocol. In total this generated 81 RNA samples 
evaluated using RNA sequencing. Basic analysis further confirms the robustness of the FHIA-
protocol presented in Paper I as well as displaying a good transcriptomic coverage 
corresponding to the transcriptome from fetal brain samples (354). Mathematical analysis of 
the transcriptomic patterns clustered genes sharing high fold change compared to control 
condition. Gene list enrichment analysis of these clusters demonstrated clear association to 
 56 
brain and neural cell biology and development. Additionally, genes related to glutamate 
associated biology were significantly changed correlating with the demonstrated glutamate 
function of NES-Astro presented in Paper I. Intriguingly, genes related to circadian rhythm, 
ECM and integrin pathways are significantly regulated during NES-Astro development. These 
are gene classes hypothesis to regulate the stem cell niche of proliferating oRG which is highly 
associated to the expansion of the human neocortex (2, 13, 148). Single cell RNA sequencing 
has enable to categorize cellular diversity based on transcriptome identities. The top 
differentially express transcripts in these diversified cellular profiles can provide indications 
on which cell types make up a certain population of cells. Comparing single cell transcript 
identity profiles with NES-Astro populations during the differentiation display a transition of 
cellular identities also found during embryonic development. Additionally, comparing which 
cell identities are shared across the differentiation time points would indicate how the 
composition of population change over time. What we saw was that intermediate progenitors 
and neurons are only expressed at high levels at few time points while glia associated transcripts 
accumulate over time, indicating an enrichment of the glia population. To validate this 
enrichment of glia transcript identity we looked at the protein expression patterns of known 
markers important in glia biology. In accordance to transcriptomic profiles we could display a 
gradual increase in expression homogeneity of SOX9, NFIA, FABP7, S100B and SLC1A3. 
Recently, there has been an emphasis on the importance of non-coding RNAs, and its relation 
to primate specific cortical complexification (13). From the transcriptomic data we could 
observe a strong down regulation of key regulators in the miRNA biogenesis processes which 
are linked to miRNAs indicated to regulate the neurogenic-to-gliogenic switch (144). To 
further validate the transcriptomic and protein expression profiles, demonstrating the 
occurrence of the neurogenic-to-gliogenic switch taking place during NES-Astro development, 
we performed a small RNAseq at the differentiation time points. A strong increase of the Let-
7 family and downregulation of LIN28A/B previously shown to regulate gliogenic potency 
(144) further validate the switch taking place. Additionally, miRNAs associated to astroglia 
cell fate is upregulated at d28. 
One of the main advantages of using hiPSC is the human origin which is important studying 
human specific traits. Lineage tracing studies indicate that RG and SVZ progenitors are sources 
of astrocytes (12, 33). Since the oSVZ, hosting a proliferative oRG population, is a structure 
associated with human brain development (2, 13, 148) we asked if the NES-Astro model 
displayed human specific developmental features. Based on the transcriptomic patterns we 
could observe an increased expression of oRG identity together with transcripts associated to 
mechanism hypothesized to regulate the stem cell niche of oRG including ECM regulation, 
STAT3 and notch signaling (148). The transition of oRG to acquire an astrocytic fate is not 
known, but some oRG enriched genes are also enriched in astrocyte (148), which we observe 
in the NES-Astro model together with an increase of astrocyte maturation markers (154, 175). 
It is intriguing to speculate that since NES-Astro show an increased transitional association to 
mature astrocytes, an expression profile of GFAP- /S100B+ /SLC1A2+ /SLC1A3+ and the 
functional maturation of glutamate calcium responsiveness the model could represent 
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progenitors of an immature protoplasmic astrocytes (126, 154, 175, 179). That would provide 
the possibility to study one of the major astrocytic subtypes using this hiPSC derived in vitro 
model.  
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7 Conclusions and Future Perspectives 
This thesis demonstrates that hiPSC derived neural models can have a significant role in drug 
developmental programs. Notably, however, the model having the highest representation and 
translability in relation to its feasibility will be favored in attempts to deliver drugs to patients, 
independent on model type. Therefore, the establishment of model translability is key in order 
to draw the right conclusion moving forward in drug development. As demonstrated in the 
pilot-screen of APOE enhancers the current models used in the pharmaceutical industry will 
identify hit compounds with model bias. Even though validation of hits is performed in a 
second model the order in which you use the models, either for a primary screen or in a 
secondary validation stage, will affect hit identification with the risk of excluding compounds 
only active in one model (269). 
As astrocytes are being increasingly recognized to play important roles in human neurological 
diseases (355, 356) there is a need for models with high human translability. Astrocytic model 
representation has for a long time intensively focused on astrocytes associated GFAP 
expression even though a large portion of astrocytes in vivo do not express this protein (126). 
Since many protocols for differentiation (242, 264), isolation (248) and cell cultures (168) are 
FBS-based, known to drive reactivity and GFAP expression (20, 154, 166, 248), the study of 
GFAP negative astrocytes, predominantly protoplasmic astrocytes, will be challenging. 
Improved astrocyte isolation protocols, highly preserving in vivo characteristics (154, 175), and 
more defined culturing conditions (20) still focus on the GFAP+ population. A key factor to 
generate hiPSC derived astrocytes representing the GFAP negative protoplasmic population is 
to understand the developmental origin of astrocyte heterogeneity. Moreover, both the 
GFAP+/- astrocyte populations are diverse in a spatial and functional manner highlighting the 
need for increased stratification of modeling astrocyte biology. Single cell RNA sequencing 
will help identify key transcriptional pathways in astrocyte development, which with even more 
refined RNAseq methods (176), will further help to understand astrocyte heterogeneity.  
Even though astrocyte functional heterogeneity is not fully understood both neurons and 
astrocytes demonstrate great physiological diversity. With increased understanding of cellular 
stratification of the brain we can also more precisely link pathological conditions to specific 
cell types. As this increases the complexity of modeling it also enables more targeted drug 
interventional approach with plausibly lower risk of unwanted side effects. With increasing 
number of subspecific models hiPSC derived neural cells have a great potential role in such 
strategies. Both in disease mechanistic projects or as validation of potential off target effects. 
There is always a limited access to human tissue, and since some of these developmental 
features are linked to human biology animal model representation is not sufficient (148, 154). 
Besides the uncertainties of being an in vitro model system human brain organoids possess a 
great potential to answer some of these questions (175). In addition, since there is a close 
interplay between neurons and astrocytes during their biological development (19) more 
complex models are needed to increase the biological translability of hiPSC derive neural 
models. However, this currently provides a challenge in drug development programs driven by 
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high-throughput screening where monolayers of homogenous cell populations are favored for 
its streamlined process. With technical development of single cell analysis methods including 
transcriptomics and proteomics, this will most likely change where HTS is run in microfluidic 
systems based on single cell stimulation and readout. Alternatively, drug stimulation of 
organoids or organs on a chip, where different cell types are affecting each other, followed by 
single cell analysis will help understand plausible systemic drug effects in vitro. As single cell 
analysis generates enormous amounts of data both infrastructure and data analysis need to be 
developed to provide scientific interpretation and impact. Artificial intelligence will most likely 
be a solution to this problem and might have a central role in future drug discovery. 
  
 60 
8 Acknowledgements 
This research has been supported by the Department of Neuroscience at Karolinska Institutet 
under a grant from Vetenskapsrådet [2013-5731] and AstraZeneca. 
 
I would like to thank my supervisors for the opportunity to be a PhD student. 
 
Furthermore, I would like to thank: 
Anna Falk, for including me in your group and the invaluable guidance through this 
education. For your scientific expertise, support and inspiration. You have been a great 
mentor. 
 
Anna Herland, for your scientific input and structure which brings encouragement and 
optimism. 
 
Ryan Hicks, for your excellent leadership and making me think more clearly. The way you 
put the group first and bring out the best in people is inspiring. Thank you for reminding me 
what is important in life during challenging times. 
 
Gabriella Brolén, for the guidance and bringing me into the stem and primary cell group. 
For believing in me. 
 
Eva Hedlund, for being there. 
 
Gunnar Olsson, for sharing your invaluable experience and making me reflect on the right 
things. 
 
I want to thank all the people making up the science group at KI; Mansoureh Shahsavani, 
Ana Marin Navarro, Matti Lam, Robin Pronk, Elias Uhlin, Malin Kele, Ronny Falk, 
Jahan Salma, Mohsen Moslem, Kelly Day, Harriet Rönnholm. Thank you for always 
making me feel as a part of the group even though I work 500km from you! 
 
To all the members of the primary and stem cell group: Anna Jonebring for the endless 
positive energy you spread, being an inspiration in science and in life, Anette Persson-Kry, 
the guru of stem cells and mother of the group, you make it fell like home, Anna Forslöw, 
for your caring personality Anna Svensson, for unquestionable support Louise Stjernborg, 
for your fantastic optimism and humble attitude despite your invaluable experience, Shailesh 
Gupta, for your valuable support, Cecilia Boreström, for lovely office discussions and your 
great support in good and hard times, Louise Delsing, a true inspiration and great friend, 
Alexander Kvist, for your scientific leadership and positive attitude, Jasmine Farrington, 
for your ever so , Cecilia Graneli, for insightful discussions, and to all of you making the 
primary stem cell group a great place to work, Yasaman Shamshirgaran, Diana Ribeiro, 
Magdalena Mazur, Cecilia Brännemark. Mei Ding. All the people in this group are there 
for each other, providing the possibility to do great science.  
 
Dimitrios Voulgaris, Elisabeth Ax, for great discussions and patience. I hope I could be of 
some support and inspiration in your education. 
 
Piero Ricchiuto, thank you for fantastic scientific discussion and your patience with my 
stupide questions.  
 
Matthew O’Hara, for fantastic discussion, always fun to pick your brain 
 
  61 
Jaqueline Robbins, for fun times in the lab 
 
To people at the AZ Gothenburg site: I would like to thank Alan Sabirsh for the great 
introduction to imaging and image analysis and dedicating time to teach a PhD student. Your 
kindness, scientific support and sharing your scientific expertise have shaped me as a 
scientist. Maryam Clausen, for the endless support both in science and in life, Damla Etal, I 
apologies for dragging you to work early in the morning, but what a great team work! Always 
fun to work with someone as positive as you, Lisbeth Kristensson, for your openness and 
willingness to share your scientific expertise, Marcello Maresca, always fun to discuss new 
genetic approaches and hear your crazy ideas, making me think outside the box, Taheri-
Ghahfarokhi, inspiring hard work and providing insights of what good visualization of 
scientific data can do, Anna Schantz, great collaborations and reflecting talks about the 
important things in life, Himjyot Jaiswal, great friendship and hard work, Katja Madeyski-
Bengtson, for your never-ending support. Always fun and valuable to get your opinion, 
scientifically and on my cross-country technique, Pernilla Eliasson, for being there when 
that bloody FACS machine don’t do as I want, Lauren Dowley, for funny times in the lab 
when other people are still asleep, Madina Karimova, great collaboration and warm 
friendship. I would like to thank Mohammad Bohlooly and Tyrell Norris for your 
leadership, Niek Dekker, John Wiseman, for your scientific leadership. 
 
I want to thank Yolanda Ljungqvist for the early morning company and the tremendous and 
invaluable work keeping the lab running. Without your curiosity to learn and putting others 
first my work would not have been possible. 
 
I want to thank Johan Jirholt for the endless funny conversations at lunch. 
 
To all other persons that I have not mentioned by name, you are all great. 
 
A big thanks to my Mum and Dad for your unconditional love and support! For making me 
believe in myself during the hard times. 
 
To my sisters, Anna and Erica, for your warm love and ever so wise guidance accompanied 
with a fantastic sense of humor! 
 
David and Mattias for your funny irony. 
 
Last but not least, I would like to thank my beloved family. My wonderful daughter, Ella, for 
always making me smile and remind me of what is important in life! My fantastic friend, 
partner, and love of my life, Hanna. You are my everything, I could not have done this 
without you! 
 
 62 
9 References 
1. Lundin A, Falk A. Quick Access to Human 
Astrocytic Software that Drives Neuronal Hardware. 
Stem Cell Reports. 2018;11(4):847-9. 
2. Nowakowski TJ, Pollen AA, Sandoval-Espinosa 
C, Kriegstein AR. Transformation of the Radial Glia 
Scaffold Demarcates Two Stages of Human Cerebral 
Cortex Development. Neuron. 2016;91(6):1219-27. 
3. Lupo G, Bertacchi M, Carucci N, Augusti-Tocco 
G, Biagioni S, Cremisi F. From pluripotency to 
forebrain patterning: an in vitro journey astride 
embryonic stem cells. Cellular and molecular life 
sciences : CMLS. 2014;71(15):2917-30. 
4. Tao Y, Zhang SC. Neural Subtype Specification 
from Human Pluripotent Stem Cells. Cell stem cell. 
2016;19(5):573-86. 
5. Martínez S, Puelles E, Echevarria D. Ontogeny of 
the Vertebrate Nervous System. In: Galizia CG, Lledo 
P-M, editors. Neurosciences - From Molecule to 
Behavior: a university textbook. Berlin, Heidelberg: 
Springer Berlin Heidelberg; 2013. p. 47-61. 
6. Takahashi K, Yamanaka S. Induction of 
pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell. 
2006;126(4):663-76. 
7. Cao SY, Hu Y, Chen C, Yuan F, Xu M, Li Q, et 
al. Enhanced derivation of human pluripotent stem 
cell-derived cortical glutamatergic neurons by a small 
molecule. Scientific Reports. 2017;7(1):3282. 
8. Wang S, Bates J, Li X, Schanz S, Chandler-
Militello D, Levine C, et al. Human iPSC-derived 
oligodendrocyte progenitor cells can myelinate and 
rescue a mouse model of congenital hypomyelination. 
Cell stem cell. 2013;12(2):252-64. 
9. Livesey MR, Magnani D, Cleary EM, Vasistha 
NA, James OT, Selvaraj BT, et al. Maturation and 
electrophysiological properties of human pluripotent 
stem cell-derived oligodendrocytes. Stem cells 
(Dayton, Ohio). 2016;34(4):1040-53. 
10. Molofsky AV, Deneen B. Astrocyte development: 
A Guide for the Perplexed. Glia. 2015;63(8):1320-9. 
11. Goldman SA, Kuypers NJ. How to make an 
oligodendrocyte. Development (Cambridge, 
England). 2015;142(23):3983-95. 
12. Ge WP, Jia JM. Local production of astrocytes in 
the cerebral cortex. Neuroscience. 2016;323:3-9. 
13. Dehay C, Kennedy H, Kosik KS. The outer 
subventricular zone and primate-specific cortical 
complexification. Neuron. 2015;85(4):683-94. 
14. Middeldorp J, Boer K, Sluijs JA, De Filippis L, 
Encha-Razavi F, Vescovi AL, et al. GFAPdelta in 
radial glia and subventricular zone progenitors in the 
developing human cortex. Development (Cambridge, 
England). 2010;137(2):313-21. 
15. Krencik R, Weick JP, Liu Y, Zhang ZJ, Zhang SC. 
Specification of transplantable astroglial subtypes 
from human pluripotent stem cells. Nature 
biotechnology. 2011;29(6):528-34. 
16. Li X, Tao Y, Bradley R, Du Z, Tao Y, Kong L, et 
al. Fast Generation of Functional Subtype Astrocytes 
from Human Pluripotent Stem Cells. Stem Cell 
Reports. 
17. Farmer WT, Abrahamsson T, Chierzi S, Lui C, 
Zaelzer C, Jones EV, et al. Neurons diversify 
astrocytes in the adult brain through sonic hedgehog 
signaling. Science (New York, NY). 
2016;351(6275):849-54. 
18. Magavi S, Friedmann D, Banks G, Stolfi A, Lois 
C. Coincident Generation of Pyramidal Neurons and 
Protoplasmic Astrocytes in Neocortical Columns. The 
Journal of Neuroscience. 2012;32(14):4762. 
19. Morel L, Higashimori H, Tolman M, Yang Y. 
VGluT1+ neuronal glutamatergic signaling regulates 
postnatal developmental maturation of cortical 
protoplasmic astroglia. The Journal of neuroscience : 
the official journal of the Society for Neuroscience. 
2014;34(33):10950-62. 
20. Perriot S, Mathias A, Perriard G, Canales M, 
Jonkmans N, Merienne N, et al. Human Induced 
Pluripotent Stem Cell-Derived Astrocytes Are 
Differentially Activated by Multiple Sclerosis-
Associated Cytokines. Stem Cell Reports. 
2018;11(5):1199-210. 
21. Moore S, Evans LDB, Andersson T, Portelius E, 
Smith J, Dias TB, et al. APP metabolism regulates tau 
proteostasis in human cerebral cortex neurons. Cell 
reports. 2015;11(5):689-96. 
22. Sherman SP, Bang AG. High-throughput screen 
for compounds that modulate neurite growth of 
human induced pluripotent stem cell-derived neurons. 
Disease models & mechanisms. 2018;11(2). 
23. Pei Y, Peng J, Behl M, Sipes NS, Shockley KR, 
Rao MS, et al. Comparative neurotoxicity screening 
in human iPSC-derived neural stem cells, neurons and 
astrocytes. Brain research. 2016;1638(Pt A):57-73. 
24. McNeish J, Gardner JP, Wainger BJ, Woolf CJ, 
Eggan K. From Dish to Bedside: Lessons Learned 
While Translating Findings from a Stem Cell Model 
of Disease to a Clinical Trial. Cell stem cell. 
2015;17(1):8-10. 
25. Lui JH, Hansen DV, Kriegstein AR. Development 
and evolution of the human neocortex. Cell. 
2011;146(1):18-36. 
26. Budday S, Steinmann P, Kuhl E. Physical biology 
of human brain development. Front Cell Neurosci. 
2015;9:257. 
  63 
27. Florio M, Huttner WB. Neural progenitors, 
neurogenesis and the evolution of the neocortex. 
Development (Cambridge, England). 
2014;141(11):2182-94. 
28. Verkhratsky A, Nedergaard M. The homeostatic 
astroglia emerges from evolutionary specialization of 
neural cells. Philosophical transactions of the Royal 
Society of London Series B, Biological sciences. 
2016;371(1700). 
29. Han X, Chen M, Wang F, Windrem M, Wang S, 
Shanz S, et al. Forebrain engraftment by human glial 
progenitor cells enhances synaptic plasticity and 
learning in adult mice. Cell stem cell. 2013;12(3):342-
53. 
30. Windrem MS, Schanz SJ, Morrow C, Munir J, 
Chandler-Militello D, Wang S, et al. A competitive 
advantage by neonatally engrafted human glial 
progenitors yields mice whose brains are chimeric for 
human glia. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2014;34(48):16153-61. 
31. Wurst W, Bally-Cuif L. Neural plate patterning: 
upstream and downstream of the isthmic organizer. 
Nature reviews Neuroscience. 2001;2(2):99-108. 
32. Goridis C, Rohrer H. Specification of 
catecholaminergic and serotonergic neurons. Nature 
reviews Neuroscience. 2002;3(7):531-41. 
33. Garcia-Marques J, Lopez-Mascaraque L. Clonal 
identity determines astrocyte cortical heterogeneity. 
Cereb Cortex. 2013;23(6):1463-72. 
34. Krencik R, Seo K, van Asperen JV, Basu N, 
Cvetkovic C, Barlas S, et al. Systematic Three-
Dimensional Coculture Rapidly Recapitulates 
Interactions between Human Neurons and Astrocytes. 
Stem Cell Reports. 2017;9(6):1745-53. 
35. Oberheim NA, Wang X, Goldman S, Nedergaard 
M. Astrocytic complexity distinguishes the human 
brain. Trends in neurosciences. 2006;29(10):547-53. 
36. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, 
McKhann GM, 2nd, Goldman JE. Phenotypic 
heterogeneity and plasticity of isocortical and 
hippocampal astrocytes in the human brain. The 
Journal of neuroscience : the official journal of the 
Society for Neuroscience. 2014;34(6):2285-98. 
37. Takahashi K, Tanabe K, Ohnuki M, Narita M, 
Ichisaka T, Tomoda K, et al. Induction of pluripotent 
stem cells from adult human fibroblasts by defined 
factors. Cell. 2007;131(5):861-72. 
38. Yu J, Vodyanik MA, Smuga-Otto K, 
Antosiewicz-Bourget J, Frane JL, Tian S, et al. 
Induced pluripotent stem cell lines derived from 
human somatic cells. Science (New York, NY). 
2007;318(5858):1917-20. 
39. Fusaki N, Ban H, Nishiyama A, Saeki K, 
Hasegawa M. Efficient induction of transgene-free 
human pluripotent stem cells using a vector based on 
Sendai virus, an RNA virus that does not integrate into 
the host genome. Proceedings of the Japan Academy 
Series B, Physical and biological sciences. 
2009;85(8):348-62. 
40. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, 
Slukvin II, et al. Human induced pluripotent stem cells 
free of vector and transgene sequences. Science (New 
York, NY). 2009;324(5928):797-801. 
41. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, 
Lau F, et al. Highly efficient reprogramming to 
pluripotency and directed differentiation of human 
cells with synthetic modified mRNA. Cell stem cell. 
2010;7(5):618-30. 
42. Kim D, Kim CH, Moon JI, Chung YG, Chang 
MY, Han BS, et al. Generation of human induced 
pluripotent stem cells by direct delivery of 
reprogramming proteins. Cell stem cell. 
2009;4(6):472-6. 
43. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. 
Pluripotent stem cells induced from mouse somatic 
cells by small-molecule compounds. Science (New 
York, NY). 2013;341(6146):651-4. 
44. Warren L, Wang J. Feeder-free reprogramming of 
human fibroblasts with messenger RNA. Current 
protocols in stem cell biology. 2013;27:Unit 4A.6. 
45. Swistowski A, Peng J, Han Y, Swistowska AM, 
Rao MS, Zeng X. Xeno-free defined conditions for 
culture of human embryonic stem cells, neural stem 
cells and dopaminergic neurons derived from them. 
PloS one. 2009;4(7):e6233. 
46. Rodin S, Antonsson L, Niaudet C, Simonson OE, 
Salmela E, Hansson EM, et al. Clonal culturing of 
human embryonic stem cells on laminin-521/E-
cadherin matrix in defined and xeno-free 
environment. Nature communications. 2014;5:3195. 
47. Baghbaderani BA, Tian X, Neo BH, Burkall A, 
Dimezzo T, Sierra G, et al. cGMP-Manufactured 
Human Induced Pluripotent Stem Cells Are Available 
for Pre-clinical and Clinical Applications. Stem Cell 
Reports. 2015;5(4):647-59. 
48. Ring KL, Tong LM, Balestra ME, Javier R, 
Andrews-Zwilling Y, Li G, et al. Direct 
reprogramming of mouse and human fibroblasts into 
multipotent neural stem cells with a single factor. Cell 
stem cell. 2012;11(1):100-9. 
49. Pfisterer U, Kirkeby A, Torper O, Wood J, 
Nelander J, Dufour A, et al. Direct conversion of 
human fibroblasts to dopaminergic neurons. 
Proceedings of the National Academy of Sciences of 
the United States of America. 2011;108(25):10343-8. 
50. Caiazzo M, Giannelli S, Valente P, Lignani G, 
Carissimo A, Sessa A, et al. Direct conversion of 
fibroblasts into functional astrocytes by defined 
 64 
transcription factors. Stem Cell Reports. 
2015;4(1):25-36. 
51. Bottenstein JE, Sato GH. Growth of a rat 
neuroblastoma cell line in serum-free supplemented 
medium. Proceedings of the National Academy of 
Sciences of the United States of America. 
1979;76(1):514-7. 
52. Brewer GJ, Torricelli JR, Evege EK, Price PJ. 
Optimized survival of hippocampal neurons in B27-
supplemented Neurobasal, a new serum-free medium 
combination. Journal of neuroscience research. 
1993;35(5):567-76. 
53. Vescovi AL, Parati EA, Gritti A, Poulin P, 
Ferrario M, Wanke E, et al. Isolation and cloning of 
multipotential stem cells from the embryonic human 
CNS and establishment of transplantable human 
neural stem cell lines by epigenetic stimulation. 
Experimental neurology. 1999;156(1):71-83. 
54. Carpenter MK, Cui X, Hu ZY, Jackson J, Sherman 
S, Seiger A, et al. In vitro expansion of a multipotent 
population of human neural progenitor cells. 
Experimental neurology. 1999;158(2):265-78. 
55. Zhang SC, Ge B, Duncan ID. Tracing human 
oligodendroglial development in vitro. Journal of 
neuroscience research. 2000;59(3):421-9. 
56. Tailor J, Kittappa R, Leto K, Gates M, Borel M, 
Paulsen O, et al. Stem cells expanded from the human 
embryonic hindbrain stably retain regional 
specification and high neurogenic potency. The 
Journal of neuroscience : the official journal of the 
Society for Neuroscience. 2013;33(30):12407-22. 
57. Sun Y, Pollard S, Conti L, Toselli M, Biella G, 
Parkin G, et al. Long-term tripotent differentiation 
capacity of human neural stem (NS) cells in adherent 
culture. Molecular and cellular neurosciences. 
2008;38(2):245-58. 
58. Conti L, Pollard SM, Gorba T, Reitano E, Toselli 
M, Biella G, et al. Niche-independent symmetrical 
self-renewal of a mammalian tissue stem cell. PLoS 
biology. 2005;3(9):e283. 
59. Zhang SC, Wernig M, Duncan ID, Brustle O, 
Thomson JA. In vitro differentiation of transplantable 
neural precursors from human embryonic stem cells. 
Nature biotechnology. 2001;19(12):1129-33. 
60. Elkabetz Y, Panagiotakos G, Al Shamy G, Socci 
ND, Tabar V, Studer L. Human ES cell-derived neural 
rosettes reveal a functionally distinct early neural stem 
cell stage. Genes & development. 2008;22(2):152-65. 
61. Koch P, Opitz T, Steinbeck JA, Ladewig J, Brustle 
O. A rosette-type, self-renewing human ES cell-
derived neural stem cell with potential for in vitro 
instruction and synaptic integration. Proceedings of 
the National Academy of Sciences of the United 
States of America. 2009;106(9):3225-30. 
62. Falk A, Koch P, Kesavan J, Takashima Y, 
Ladewig J, Alexander M, et al. Capture of 
neuroepithelial-like stem cells from pluripotent stem 
cells provides a versatile system for in vitro 
production of human neurons. PloS one. 
2012;7(1):e29597. 
63. Smith JR, Vallier L, Lupo G, Alexander M, Harris 
WA, Pedersen RA. Inhibition of Activin/Nodal 
signaling promotes specification of human embryonic 
stem cells into neuroectoderm. Developmental 
biology. 2008;313(1):107-17. 
64. Pera MF, Andrade J, Houssami S, Reubinoff B, 
Trounson A, Stanley EG, et al. Regulation of human 
embryonic stem cell differentiation by BMP-2 and its 
antagonist noggin. Journal of cell science. 
2004;117(Pt 7):1269-80. 
65. Gerrard L, Rodgers L, Cui W. Differentiation of 
human embryonic stem cells to neural lineages in 
adherent culture by blocking bone morphogenetic 
protein signaling. Stem cells (Dayton, Ohio). 
2005;23(9):1234-41. 
66. Chambers SM, Fasano CA, Papapetrou EP, 
Tomishima M, Sadelain M, Studer L. Highly efficient 
neural conversion of human ES and iPS cells by dual 
inhibition of SMAD signaling. Nature biotechnology. 
2009;27(3):275-80. 
67. Kim DS, Lee JS, Leem JW, Huh YJ, Kim JY, Kim 
HS, et al. Robust enhancement of neural 
differentiation from human ES and iPS cells 
regardless of their innate difference in differentiation 
propensity. Stem cell reviews. 2010;6(2):270-81. 
68. Shi Y, Kirwan P, Livesey FJ. Directed 
differentiation of human pluripotent stem cells to 
cerebral cortex neurons and neural networks. Nature 
protocols. 2012;7(10):1836-46. 
69. Gonzalez R, Garitaonandia I, Abramihina T, 
Wambua GK, Ostrowska A, Brock M, et al. Deriving 
dopaminergic neurons for clinical use. A practical 
approach. Scientific Reports. 2013;3:1463. 
70. Lu J, Zhong X, Liu H, Hao L, Huang CT-L, 
Sherafat MA, et al. Generation of serotonin neurons 
from human pluripotent stem cells. Nature 
biotechnology. 2016;34(1):89-94. 
71. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman 
DR, Xie Z, et al. Dopamine neurons derived from 
human ES cells efficiently engraft in animal models 
of Parkinson's disease. Nature. 2011;480(7378):547-
51. 
72. Li W, Sun W, Zhang Y, Wei W, Ambasudhan R, 
Xia P, et al. Rapid induction and long-term self-
renewal of primitive neural precursors from human 
embryonic stem cells by small molecule inhibitors. 
Proceedings of the National Academy of Sciences of 
the United States of America. 2011;108(20):8299-
304. 
  65 
73. Reinhardt P, Glatza M, Hemmer K, Tsytsyura Y, 
Thiel CS, Hoing S, et al. Derivation and expansion 
using only small molecules of human neural 
progenitors for neurodegenerative disease modeling. 
PloS one. 2013;8(3):e59252. 
74. Yu KR, Shin JH, Kim JJ, Koog MG, Lee JY, Choi 
SW, et al. Rapid and Efficient Direct Conversion of 
Human Adult Somatic Cells into Neural Stem Cells 
by HMGA2/let-7b. Cell reports. 2015. 
75. Bjorklund A, Lindvall O. Replacing Dopamine 
Neurons in Parkinson's Disease: How did it happen? 
Journal of Parkinson's disease. 2017;7(s1):S21-s31. 
76. Kikuchi T, Morizane A, Doi D, Magotani H, Onoe 
H, Hayashi T, et al. Human iPS cell-derived 
dopaminergic neurons function in a primate 
Parkinson's disease model. Nature. 
2017;548(7669):592-6. 
77. Kirkeby A, Nolbrant S, Tiklova K, Heuer A, Kee 
N, Cardoso T, et al. Predictive Markers Guide 
Differentiation to Improve Graft Outcome in Clinical 
Translation of hESC-Based Therapy for Parkinson's 
Disease. Cell stem cell. 2017;20(1):135-48. 
78. Stern CD, Charite J, Deschamps J, Duboule D, 
Durston AJ, Kmita M, et al. Head-tail patterning of 
the vertebrate embryo: one, two or many unresolved 
problems? The International journal of developmental 
biology. 2006;50(1):3-15. 
79. Puelles L, Harrison M, Paxinos G, Watson C. A 
developmental ontology for the mammalian brain 
based on the prosomeric model. Trends in 
neurosciences. 2013;36(10):570-8. 
80. Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, 
Livesey FJ. A human stem cell model of early 
Alzheimer's disease pathology in Down syndrome. 
Science translational medicine. 2012;4(124):124ra29. 
81. Metzis V, Steinhauser S, Pakanavicius E, Gouti 
M, Stamataki D, Ivanovitch K, et al. Nervous System 
Regionalization Entails Axial Allocation before 
Neural Differentiation. Cell. 2018;175(4):1105-
18.e17. 
82. Vazin T, Ball KA, Lu H, Park H, Ataeijannati Y, 
Head-Gordon T, et al. Efficient derivation of cortical 
glutamatergic neurons from human pluripotent stem 
cells: a model system to study neurotoxicity in 
Alzheimer's disease. Neurobiology of disease. 
2014;62:62-72. 
83. Liu Y, Liu H, Sauvey C, Yao L, Zarnowska ED, 
Zhang SC. Directed differentiation of forebrain 
GABA interneurons from human pluripotent stem 
cells. Nature protocols. 2013;8(9):1670-9. 
84. Liu Y, Weick JP, Liu H, Krencik R, Zhang X, Ma 
L, et al. Medial ganglionic eminence-like cells derived 
from human embryonic stem cells correct learning 
and memory deficits. Nature biotechnology. 
2013;31(5):440-7. 
85. Maroof AM, Keros S, Tyson JA, Ying SW, Ganat 
YM, Merkle FT, et al. Directed differentiation and 
functional maturation of cortical interneurons from 
human embryonic stem cells. Cell stem cell. 
2013;12(5):559-72. 
86. Nicholas CR, Chen J, Tang Y, Southwell DG, 
Chalmers N, Vogt D, et al. Functional maturation of 
hPSC-derived forebrain interneurons requires an 
extended timeline and mimics human neural 
development. Cell stem cell. 2013;12(5):573-86. 
87. Kim TG, Yao R, Monnell T, Cho JH, Vasudevan 
A, Koh A, et al. Efficient specification of interneurons 
from human pluripotent stem cells by dorsoventral 
and rostrocaudal modulation. Stem cells (Dayton, 
Ohio). 2014;32(7):1789-804. 
88. Arber C, Precious SV, Cambray S, Risner-
Janiczek JR, Kelly C, Noakes Z, et al. Activin A 
directs striatal projection neuron differentiation of 
human pluripotent stem cells. Development 
(Cambridge, England). 2015;142(7):1375-86. 
89. Bissonnette CJ, Lyass L, Bhattacharyya BJ, 
Belmadani A, Miller RJ, Kessler JA. The controlled 
generation of functional basal forebrain cholinergic 
neurons from human embryonic stem cells. Stem cells 
(Dayton, Ohio). 2011;29(5):802-11. 
90. Crompton LA, Byrne ML, Taylor H, Kerrigan TL, 
Bru-Mercier G, Badger JL, et al. Stepwise, non-
adherent differentiation of human pluripotent stem 
cells to generate basal forebrain cholinergic neurons 
via hedgehog signaling. Stem cell research. 
2013;11(3):1206-21. 
91. Kirkeby A, Grealish S, Wolf DA, Nelander J, 
Wood J, Lundblad M, et al. Generation of regionally 
specified neural progenitors and functional neurons 
from human embryonic stem cells under defined 
conditions. Cell reports. 2012;1(6):703-14. 
92. Fasano CA, Chambers SM, Lee G, Tomishima 
MJ, Studer L. Efficient derivation of functional floor 
plate tissue from human embryonic stem cells. Cell 
stem cell. 2010;6(4):336-47. 
93. Momcilovic O, Liu Q, Swistowski A, Russo-Tait 
T, Zhao Y, Rao MS, et al. Genome wide profiling of 
dopaminergic neurons derived from human 
embryonic and induced pluripotent stem cells. Stem 
cells and development. 2014;23(4):406-20. 
94. Vazin T, Ashton RS, Conway A, Rode NA, Lee 
SM, Bravo V, et al. The effect of multivalent Sonic 
hedgehog on differentiation of human embryonic 
stem cells into dopaminergic and GABAergic 
neurons. Biomaterials. 2014;35(3):941-8. 
95. Li XJ, Du ZW, Zarnowska ED, Pankratz M, 
Hansen LO, Pearce RA, et al. Specification of 
motoneurons from human embryonic stem cells. 
Nature biotechnology. 2005;23(2):215-21. 
 66 
96. Hu BY, Zhang SC. Differentiation of spinal motor 
neurons from pluripotent human stem cells. Nature 
protocols. 2009;4(9):1295-304. 
97. Du ZW, Chen H, Liu H, Lu J, Qian K, Huang CL, 
et al. Generation and expansion of highly pure motor 
neuron progenitors from human pluripotent stem 
cells. Nature communications. 2015;6:6626. 
98. Qu Q, Li D, Louis KR, Li X, Yang H, Sun Q, et 
al. High-efficiency motor neuron differentiation from 
human pluripotent stem cells and the function of Islet-
1. Nature communications. 2014;5:3449. 
99. Pereira M, Pfisterer U, Rylander D, Torper O, Lau 
S, Lundblad M, et al. Highly efficient generation of 
induced neurons from human fibroblasts that survive 
transplantation into the adult rat brain. Scientific 
Reports. 2014;4:6330-. 
100. Theka I, Caiazzo M, Dvoretskova E, 
Leo D, Ungaro F, Curreli S, et al. Rapid generation of 
functional dopaminergic neurons from human 
induced pluripotent stem cells through a single-step 
procedure using cell lineage transcription factors. 
Stem cells translational medicine. 2013;2(6):473-9. 
101. Yoo AS, Sun AX, Li L, 
Shcheglovitov A, Portmann T, Li Y, et al. 
MicroRNA-mediated conversion of human 
fibroblasts to neurons. Nature. 2011;476(7359):228-
31. 
102. Victor MB, Richner M, 
Hermanstyne TO, Ransdell JL, Sobieski C, Deng PY, 
et al. Generation of human striatal neurons by 
microRNA-dependent direct conversion of 
fibroblasts. Neuron. 2014;84(2):311-23. 
103. Xue Y, Ouyang K, Huang J, Zhou Y, 
Ouyang H, Li H, et al. Direct conversion of fibroblasts 
to neurons by reprogramming PTB-regulated 
microRNA circuits. Cell. 2013;152(1-2):82-96. 
104. Liu X, Huang Q, Li F, Li CY. 
Enhancing the efficiency of direct reprogramming of 
human primary fibroblasts into dopaminergic neuron-
like cells through p53 suppression. Science China Life 
sciences. 2014;57(9):867-75. 
105. Son EY, Ichida JK, Wainger BJ, 
Toma JS, Rafuse VF, Woolf CJ, et al. Conversion of 
mouse and human fibroblasts into functional spinal 
motor neurons. Cell stem cell. 2011;9(3):205-18. 
106. Hester ME, Murtha MJ, Song S, Rao 
M, Miranda CJ, Meyer K, et al. Rapid and efficient 
generation of functional motor neurons from human 
pluripotent stem cells using gene delivered 
transcription factor codes. Molecular therapy : the 
journal of the American Society of Gene Therapy. 
2011;19(10):1905-12. 
107. Lake BB, Ai R, Kaeser GE, Salathia 
NS, Yung YC, Liu R, et al. Neuronal subtypes and 
diversity revealed by single-nucleus RNA sequencing 
of the human brain. Science (New York, NY). 
2016;352(6293):1586-90. 
108. Freeman MR, Rowitch DH. 
Evolving concepts of gliogenesis: a look way back 
and ahead to the next 25 years. Neuron. 
2013;80(3):613-23. 
109. Hochstim C, Deneen B, 
Lukaszewicz A, Zhou Q, Anderson DJ. Identification 
of positionally distinct astrocyte subtypes whose 
identities are specified by a homeodomain code. Cell. 
2008;133(3):510-22. 
110. Tsai HH, Li H, Fuentealba LC, 
Molofsky AV, Taveira-Marques R, Zhuang H, et al. 
Regional astrocyte allocation regulates CNS 
synaptogenesis and repair. Science (New York, NY). 
2012;337(6092):358-62. 
111. Kita Y, Kawakami K, Takahashi Y, 
Murakami F. Development of cerebellar neurons and 
glias revealed by in utero electroporation: Golgi-like 
labeling of cerebellar neurons and glias. PloS one. 
2013;8(7):e70091. 
112. Oberheim NA, Takano T, Han X, He 
W, Lin JH, Wang F, et al. Uniquely hominid features 
of adult human astrocytes. The Journal of 
neuroscience : the official journal of the Society for 
Neuroscience. 2009;29(10):3276-87. 
113. Tabata H. Diverse subtypes of 
astrocytes and their development during 
corticogenesis. Front Neurosci. 2015;9:114. 
114. Şovrea AS, Boşca AB. Astrocytes 
reassessment - an evolving concept part one: 
embryology, biology, morphology and reactivity. 
Journal of molecular psychiatry. 2013;1(1):18-. 
115. Wang DD, Bordey A. The astrocyte 
odyssey. Progress in neurobiology. 2008;86(4):342-
67. 
116. Verkhratsky A, Nedergaard M, Hertz 
L. Why are astrocytes important? Neurochemical 
research. 2015;40(2):389-401. 
117. Robertson JM. Astrocytes and the 
evolution of the human brain. Medical hypotheses. 
2014;82(2):236-9. 
118. Kimelberg HK. The problem of 
astrocyte identity. Neurochemistry international. 
2004;45(2-3):191-202. 
119. Herculano-Houzel S. The 
glia/neuron ratio: how it varies uniformly across brain 
structures and species and what that means for brain 
physiology and evolution. Glia. 2014;62(9):1377-91. 
120. Bayraktar OA, Fuentealba LC, 
Alvarez-Buylla A, Rowitch DH. Astrocyte 
development and heterogeneity. Cold Spring Harb 
Perspect Biol. 2014;7(1):a020362. 
  67 
121. Sosunov AA, Guilfoyle E, Wu X, 
McKhann GM, 2nd, Goldman JE. Phenotypic 
conversions of "protoplasmic" to "reactive" astrocytes 
in Alexander disease. The Journal of neuroscience : 
the official journal of the Society for Neuroscience. 
2013;33(17):7439-50. 
122. Morel L, Chiang MSR, Higashimori 
H, Shoneye T, Iyer LK, Yelick J, et al. Molecular and 
Functional Properties of Regional Astrocytes in the 
Adult Brain. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2017;37(36):8706-17. 
123. Lanjakornsiripan D, Pior B-J, 
Kawaguchi D, Furutachi S, Tahara T, Katsuyama Y, 
et al. Layer-specific morphological and molecular 
differences in neocortical astrocytes and their 
dependence on neuronal layers. Nature 
communications. 2018;9(1):1623. 
124. Marin-Padilla M. Prenatal 
development of fibrous (white matter), protoplasmic 
(gray matter), and layer I astrocytes in the human 
cerebral cortex: a Golgi study. The Journal of 
comparative neurology. 1995;357(4):554-72. 
125. deAzevedo LC, Fallet C, Moura-
Neto V, Daumas-Duport C, Hedin-Pereira C, Lent R. 
Cortical radial glial cells in human fetuses: depth-
correlated transformation into astrocytes. Journal of 
neurobiology. 2003;55(3):288-98. 
126. DeSilva TM, Borenstein NS, Volpe 
JJ, Kinney HC, Rosenberg PA. Expression of EAAT2 
in neurons and protoplasmic astrocytes during human 
cortical development. The Journal of comparative 
neurology. 2012;520(17):3912-32. 
127. Cai J, Chen Y, Cai WH, Hurlock EC, 
Wu H, Kernie SG, et al. A crucial role for Olig2 in 
white matter astrocyte development. Development 
(Cambridge, England). 2007;134(10):1887-99. 
128. Marshall CA, Novitch BG, Goldman 
JE. Olig2 directs astrocyte and oligodendrocyte 
formation in postnatal subventricular zone cells. The 
Journal of neuroscience : the official journal of the 
Society for Neuroscience. 2005;25(32):7289-98. 
129. Ge WP, Miyawaki A, Gage FH, Jan 
YN, Jan LY. Local generation of glia is a major 
astrocyte source in postnatal cortex. Nature. 
2012;484(7394):376-80. 
130. Zhu X, Bergles DE, Nishiyama A. 
NG2 cells generate both oligodendrocytes and gray 
matter astrocytes. Development (Cambridge, 
England). 2008;135(1):145-57. 
131. Guo F, Ma J, McCauley E, 
Bannerman P, Pleasure D. Early postnatal proteolipid 
promoter-expressing progenitors produce 
multilineage cells in vivo. The Journal of 
neuroscience : the official journal of the Society for 
Neuroscience. 2009;29(22):7256-70. 
132. Vue TY, Kim EJ, Parras CM, 
Guillemot F, Johnson JE. Ascl1 controls the number 
and distribution of astrocytes and oligodendrocytes in 
the gray matter and white matter of the spinal cord. 
Development (Cambridge, England). 
2014;141(19):3721-31. 
133. Molofsky AV, Kelley KW, Tsai HH, 
Redmond SA, Chang SM, Madireddy L, et al. 
Astrocyte-encoded positional cues maintain 
sensorimotor circuit integrity. Nature. 
2014;509(7499):189-94. 
134. Ulitsky I, Bartel DP. lincRNAs: 
genomics, evolution, and mechanisms. Cell. 
2013;154(1):26-46. 
135. Kapusta A, Feschotte C. Volatile 
evolution of long noncoding RNA repertoires: 
mechanisms and biological implications. Trends in 
genetics : TIG. 2014;30(10):439-52. 
136. Awan HM, Shah A, Rashid F, Shan 
G. Primate-specific Long Non-coding RNAs and 
MicroRNAs. Genomics, proteomics & 
bioinformatics. 2017;15(3):187-95. 
137. Quan Z, Zheng D, Qing H. 
Regulatory Roles of Long Non-Coding RNAs in the 
Central Nervous System and Associated 
Neurodegenerative Diseases. Front Cell Neurosci. 
2017;11:175. 
138. Derrien T, Johnson R, Bussotti G, 
Tanzer A, Djebali S, Tilgner H, et al. The GENCODE 
v7 catalog of human long noncoding RNAs: analysis 
of their gene structure, evolution, and expression. 
Genome research. 2012;22(9):1775-89. 
139. Sheik Mohamed J, Gaughwin PM, 
Lim B, Robson P, Lipovich L. Conserved long 
noncoding RNAs transcriptionally regulated by Oct4 
and Nanog modulate pluripotency in mouse 
embryonic stem cells. RNA (New York, NY). 
2010;16(2):324-37. 
140. Ng SY, Johnson R, Stanton LW. 
Human long non-coding RNAs promote pluripotency 
and neuronal differentiation by association with 
chromatin modifiers and transcription factors. Embo 
j. 2012;31(3):522-33. 
141. Mercer TR, Qureshi IA, Gokhan S, 
Dinger ME, Li G, Mattick JS, et al. Long noncoding 
RNAs in neuronal-glial fate specification and 
oligodendrocyte lineage maturation. BMC Neurosci. 
2010;11:14. 
142. Modarresi F, Faghihi MA, Lopez-
Toledano MA, Fatemi RP, Magistri M, Brothers SP, 
et al. Inhibition of natural antisense transcripts in vivo 
results in gene-specific transcriptional upregulation. 
Nature biotechnology. 2012;30(5):453-9. 
143. Rajman M, Schratt G. MicroRNAs 
in neural development: from master regulators to fine-
 68 
tuners. Development (Cambridge, England). 
2017;144(13):2310-22. 
144. Patterson M, Gaeta X, Loo K, 
Edwards M, Smale S, Cinkornpumin J, et al. let-7 
miRNAs can act through notch to regulate human 
gliogenesis. Stem Cell Reports. 2014;3(5):758-73. 
145. Morel L, Regan M, Higashimori H, 
Ng SK, Esau C, Vidensky S, et al. Neuronal exosomal 
miRNA-dependent translational regulation of 
astroglial glutamate transporter GLT1. The Journal of 
biological chemistry. 2013;288(10):7105-16. 
146. Boulay AC, Saubamea B, Adam N, 
Chasseigneaux S, Mazare N, Gilbert A, et al. 
Translation in astrocyte distal processes sets 
molecular heterogeneity at the gliovascular interface. 
Cell discovery. 2017;3:17005. 
147. Rani N, Nowakowski TJ, Zhou H, 
Godshalk SE, Lisi V, Kriegstein AR, et al. A Primate 
lncRNA Mediates Notch Signaling during Neuronal 
Development by Sequestering miRNA. Neuron. 
2016;90(6):1174-88. 
148. Pollen AA, Nowakowski TJ, Chen J, 
Retallack H, Sandoval-Espinosa C, Nicholas CR, et 
al. Molecular identity of human outer radial glia 
during cortical development. Cell. 2015;163(1):55-
67. 
149. Zhou M, Schools GP, Kimelberg 
HK. GFAP mRNA positive glia acutely isolated from 
rat hippocampus predominantly show complex 
current patterns. Brain research Molecular brain 
research. 2000;76(1):121-31. 
150. Rusakov DA. Disentangling 
calcium-driven astrocyte physiology. Nature reviews 
Neuroscience. 2015;16(4):226-33. 
151. Bushong EA, Martone ME, Jones 
YZ, Ellisman MH. Protoplasmic astrocytes in CA1 
stratum radiatum occupy separate anatomical 
domains. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2002;22(1):183-92. 
152. Yang Y, Higashimori H, Morel L. 
Developmental maturation of astrocytes and 
pathogenesis of neurodevelopmental disorders. 
Journal of neurodevelopmental disorders. 
2013;5(1):22. 
153. Simard M, Arcuino G, Takano T, Liu 
QS, Nedergaard M. Signaling at the gliovascular 
interface. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2003;23(27):9254-62. 
154. Zhang Y, Sloan SA, Clarke LE, 
Caneda C, Plaza CA, Blumenthal PD, et al. 
Purification and Characterization of Progenitor and 
Mature Human Astrocytes Reveals Transcriptional 
and Functional Differences with Mouse. Neuron. 
2016;89(1):37-53. 
155. Magistri M, Khoury N, Mazza EM, 
Velmeshev D, Lee JK, Bicciato S, et al. A 
comparative transcriptomic analysis of astrocytes 
differentiation from human neural progenitor cells. 
The European journal of neuroscience. 
2016;44(10):2858-70. 
156. Heller JP, Rusakov DA. 
Morphological plasticity of astroglia: Understanding 
synaptic microenvironment. Glia. 2015;63(12):2133-
51. 
157. Hon CC, Ramilowski JA, 
Harshbarger J, Bertin N, Rackham OJ, Gough J, et al. 
An atlas of human long non-coding RNAs with 
accurate 5' ends. Nature. 2017;543(7644):199-204. 
158. Hawrylycz M, Miller JA, Menon V, 
Feng D, Dolbeare T, Guillozet-Bongaarts AL, et al. 
Canonical genetic signatures of the adult human brain. 
Nature neuroscience. 2015;18(12):1832-44. 
159. Oldham MC, Konopka G, Iwamoto 
K, Langfelder P, Kato T, Horvath S, et al. Functional 
organization of the transcriptome in human brain. 
Nature neuroscience. 2008;11(11):1271-82. 
160. Teh DBL, Prasad A, Jiang W, Ariffin 
MZ, Khanna S, Belorkar A, et al. Transcriptome 
Analysis Reveals Neuroprotective aspects of Human 
Reactive Astrocytes induced by Interleukin 1beta. 
Scientific Reports. 2017;7(1):13988. 
161. Casselli T, Qureshi H, Peterson E, 
Perley D, Blake E, Jokinen B, et al. MicroRNA and 
mRNA Transcriptome Profiling in Primary Human 
Astrocytes Infected with Borrelia burgdorferi. PloS 
one. 2017;12(1):e0170961-e. 
162. Crowe EP, Tuzer F, Gregory BD, 
Donahue G, Gosai SJ, Cohen J, et al. Changes in the 
Transcriptome of Human Astrocytes Accompanying 
Oxidative Stress-Induced Senescence. Frontiers in 
aging neuroscience. 2016;8:208. 
163. Darmanis S, Sloan SA, Zhang Y, 
Enge M, Caneda C, Shuer LM, et al. A survey of 
human brain transcriptome diversity at the single cell 
level. Proceedings of the National Academy of 
Sciences of the United States of America. 
2015;112(23):7285-90. 
164. Spaethling JM, Na YJ, Lee J, 
Ulyanova AV, Baltuch GH, Bell TJ, et al. Primary 
Cell Culture of Live Neurosurgically Resected Aged 
Adult Human Brain Cells and Single Cell 
Transcriptomics. Cell reports. 2017;18(3):791-803. 
165. Liu SJ, Nowakowski TJ, Pollen AA, 
Lui JH, Horlbeck MA, Attenello FJ, et al. Single-cell 
analysis of long non-coding RNAs in the developing 
human neocortex. Genome biology. 2016;17:67. 
  69 
166. Zamanian JL, Xu L, Foo LC, Nouri 
N, Zhou L, Giffard RG, et al. Genomic analysis of 
reactive astrogliosis. The Journal of neuroscience : the 
official journal of the Society for Neuroscience. 
2012;32(18):6391-410. 
167. de Rie D, Abugessaisa I, Alam T, 
Arner E, Arner P, Ashoor H, et al. An integrated 
expression atlas of miRNAs and their promoters in 
human and mouse. Nature biotechnology. 
2017;35(9):872-8. 
168. Malik N, Wang X, Shah S, 
Efthymiou AG, Yan B, Heman-Ackah S, et al. 
Comparison of the gene expression profiles of human 
fetal cortical astrocytes with pluripotent stem cell 
derived neural stem cells identifies human astrocyte 
markers and signaling pathways and transcription 
factors active in human astrocytes. PloS one. 
2014;9(5):e96139. 
169. Yao Z, Mich JK, Ku S, Menon V, 
Krostag AR, Martinez RA, et al. A Single-Cell 
Roadmap of Lineage Bifurcation in Human ESC 
Models of Embryonic Brain Development. Cell stem 
cell. 2017;20(1):120-34. 
170. Fietz SA, Lachmann R, Brandl H, 
Kircher M, Samusik N, Schroder R, et al. 
Transcriptomes of germinal zones of human and 
mouse fetal neocortex suggest a role of extracellular 
matrix in progenitor self-renewal. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2012;109(29):11836-41. 
171. Johnson MB, Wang PP, Atabay KD, 
Murphy EA, Doan RN, Hecht JL, et al. Single-cell 
analysis reveals transcriptional heterogeneity of 
neural progenitors in human cortex. Nature 
neuroscience. 2015;18(5):637-46. 
172. Pollen AA, Nowakowski TJ, Shuga 
J, Wang X, Leyrat AA, Lui JH, et al. Low-coverage 
single-cell mRNA sequencing reveals cellular 
heterogeneity and activated signaling pathways in 
developing cerebral cortex. Nature biotechnology. 
2014;32(10):1053-8. 
173. Thomsen ER, Mich JK, Yao Z, 
Hodge RD, Doyle AM, Jang S, et al. Fixed single-cell 
transcriptomic characterization of human radial glial 
diversity. Nature methods. 2016;13(1):87-93. 
174. Florio M, Albert M, Taverna E, 
Namba T, Brandl H, Lewitus E, et al. Human-specific 
gene ARHGAP11B promotes basal progenitor 
amplification and neocortex expansion. Science (New 
York, NY). 2015;347(6229):1465-70. 
175. Sloan SA, Darmanis S, Huber N, 
Khan TA, Birey F, Caneda C, et al. Human Astrocyte 
Maturation Captured in 3D Cerebral Cortical 
Spheroids Derived from Pluripotent Stem Cells. 
Neuron. 2017;95(4):779-90.e6. 
176. La Manno G, Soldatov R, Zeisel A, 
Braun E, Hochgerner H, Petukhov V, et al. RNA 
velocity of single cells. Nature. 2018;560(7719):494-
8. 
177. Rao VT, Ludwin SK, Fuh SC, 
Sawaya R, Moore CS, Ho MK, et al. MicroRNA 
Expression Patterns in Human Astrocytes in Relation 
to Anatomical Location and Age. Journal of 
neuropathology and experimental neurology. 
2016;75(2):156-66. 
178. Middeldorp J, Hol EM. GFAP in 
health and disease. Progress in neurobiology. 
2011;93(3):421-43. 
179. Steiner J, Bernstein H-G, Bielau H, 
Berndt A, Brisch R, Mawrin C, et al. Evidence for a 
wide extra-astrocytic distribution of S100B in human 
brain. BMC Neuroscience. 2007;8:2-. 
180. Roelofs RF, Fischer DF, Houtman 
SH, Sluijs JA, Van Haren W, Van Leeuwen FW, et al. 
Adult human subventricular, subgranular, and subpial 
zones contain astrocytes with a specialized 
intermediate filament cytoskeleton. Glia. 
2005;52(4):289-300. 
181. van den Berge SA, Middeldorp J, 
Zhang CE, Curtis MA, Leonard BW, Mastroeni D, et 
al. Longterm quiescent cells in the aged human 
subventricular neurogenic system specifically express 
GFAP-delta. Aging cell. 2010;9(3):313-26. 
182. Kang P, Lee HK, Glasgow SM, 
Finley M, Donti T, Gaber ZB, et al. Sox9 and NFIA 
coordinate a transcriptional regulatory cascade during 
the initiation of gliogenesis. Neuron. 2012;74(1):79-
94. 
183. Canals I, Ginisty A, Quist E, 
Timmerman R, Fritze J, Miskinyte G, et al. Rapid and 
efficient induction of functional astrocytes from 
human pluripotent stem cells. Nature methods. 
2018;15(9):693-6. 
184. Sun W, Cornwell A, Li J, Peng S, 
Osorio MJ, Aalling N, et al. SOX9 Is an Astrocyte-
Specific Nuclear Marker in the Adult Brain Outside 
the Neurogenic Regions. The Journal of neuroscience 
: the official journal of the Society for Neuroscience. 
2017;37(17):4493-507. 
185. Yang Y, Vidensky S, Jin L, Jie C, 
Lorenzini I, Frankl M, et al. Molecular comparison of 
GLT1+ and ALDH1L1+ astrocytes in vivo in 
astroglial reporter mice. Glia. 2011;59(2):200-7. 
186. Nagy JI, Patel D, Ochalski PA, 
Stelmack GL. Connexin30 in rodent, cat and human 
brain: selective expression in gray matter astrocytes, 
co-localization with connexin43 at gap junctions and 
late developmental appearance. Neuroscience. 
1999;88(2):447-68. 
 70 
187. Griemsmann S, Hoft SP, Bedner P, 
Zhang J, von Staden E, Beinhauer A, et al. 
Characterization of Panglial Gap Junction Networks 
in the Thalamus, Neocortex, and Hippocampus 
Reveals a Unique Population of Glial Cells. Cereb 
Cortex. 2015;25(10):3420-33. 
188. Nwaobi SE, Cuddapah VA, 
Patterson KC, Randolph AC, Olsen ML. The role of 
glial-specific Kir4.1 in normal and pathological states 
of the CNS. Acta neuropathologica. 2016;132(1):1-
21. 
189. Adam SA, Schnell O, Poschl J, 
Eigenbrod S, Kretzschmar HA, Tonn JC, et al. 
ALDH1A1 is a marker of astrocytic differentiation 
during brain development and correlates with better 
survival in glioblastoma patients. Brain pathology 
(Zurich, Switzerland). 2012;22(6):788-97. 
190. Norenberg MD, Martinez-
Hernandez A. Fine structural localization of 
glutamine synthetase in astrocytes of rat brain. Brain 
research. 1979;161(2):303-10. 
191. Kamphuis W, Mamber C, Moeton 
M, Kooijman L, Sluijs JA, Jansen AHP, et al. GFAP 
Isoforms in Adult Mouse Brain with a Focus on 
Neurogenic Astrocytes and Reactive Astrogliosis in 
Mouse Models of Alzheimer Disease. PloS one. 
2012;7(8):e42823. 
192. Schnell C, Shahmoradi A, Wichert 
SP, Mayerl S, Hagos Y, Heuer H, et al. The 
multispecific thyroid hormone transporter OATP1C1 
mediates cell-specific sulforhodamine 101-labeling of 
hippocampal astrocytes. Brain structure & function. 
2015;220(1):193-203. 
193. Nimmerjahn A, Kirchhoff F, Kerr 
JN, Helmchen F. Sulforhodamine 101 as a specific 
marker of astroglia in the neocortex in vivo. Nature 
methods. 2004;1(1):31-7. 
194. Hill RA, Grutzendler J. In vivo 
imaging of oligodendrocytes with sulforhodamine 
101. Nature methods. 2014;11(11):1081-2. 
195. Roberts LM, Woodford K, Zhou M, 
Black DS, Haggerty JE, Tate EH, et al. Expression of 
the thyroid hormone transporters monocarboxylate 
transporter-8 (SLC16A2) and organic ion transporter-
14 (SLCO1C1) at the blood-brain barrier. 
Endocrinology. 2008;149(12):6251-61. 
196. Morte B, Bernal J. Thyroid hormone 
action: astrocyte-neuron communication. Frontiers in 
endocrinology. 2014;5:82-. 
197. Fan X, Dong J, Zhong S, Wei Y, Wu 
Q, Yan L, et al. Spatial transcriptomic survey of 
human embryonic cerebral cortex by single-cell 
RNA-seq analysis. Cell research. 2018;28(7):730-45. 
198. Hasel P, Dando O, Jiwaji Z, Baxter 
P, Todd AC, Heron S, et al. Neurons and neuronal 
activity control gene expression in astrocytes to 
regulate their development and metabolism. Nature 
communications. 2017;8:15132. 
199. Schousboe A, Bak LK, 
Waagepetersen HS. Astrocytic Control of 
Biosynthesis and Turnover of the Neurotransmitters 
Glutamate and GABA. Frontiers in endocrinology. 
2013;4:102. 
200. Scimemi A. Structure, function, and 
plasticity of GABA transporters. Frontiers in cellular 
neuroscience. 2014;8:161-. 
201. Araque A, Carmignoto G, Haydon 
PG, Oliet SH, Robitaille R, Volterra A. 
Gliotransmitters travel in time and space. Neuron. 
2014;81(4):728-39. 
202. Bazargani N, Attwell D. Astrocyte 
calcium signaling: the third wave. Nature 
neuroscience. 2016;19(2):182-9. 
203. Agulhon C, Sun MY, Murphy T, 
Myers T, Lauderdale K, Fiacco TA. Calcium 
Signaling and Gliotransmission in Normal vs. 
Reactive Astrocytes. Frontiers in pharmacology. 
2012;3:139. 
204. Cheung G, Sibille J, Zapata J, 
Rouach N. Activity-Dependent Plasticity of 
Astroglial Potassium and Glutamate Clearance. 
Neural plasticity. 2015;2015:109106. 
205. Kreft M, Bak LK, Waagepetersen 
HS, Schousboe A. Aspects of astrocyte energy 
metabolism, amino acid neurotransmitter 
homoeostasis and metabolic compartmentation. ASN 
neuro. 2012;4(3):e00086. 
206. Falkowska A, Gutowska I, 
Goschorska M, Nowacki P, Chlubek D, Baranowska-
Bosiacka I. Energy Metabolism of the Brain, 
Including the Cooperation between Astrocytes and 
Neurons, Especially in the Context of Glycogen 
Metabolism. International journal of molecular 
sciences. 2015;16(11):25959-81. 
207. Sofroniew MV. Astrogliosis. Cold 
Spring Harbor Perspectives in Biology. 
2015;7(2):a020420. 
208. Liddelow SA, Guttenplan KA, 
Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. 
Neurotoxic reactive astrocytes are induced by 
activated microglia. Nature. 2017;541(7638):481-7. 
209. Pekny M, Pekna M. Astrocyte 
reactivity and reactive astrogliosis: costs and benefits. 
Physiological reviews. 2014;94(4):1077-98. 
210. Burda JE, Sofroniew MV. Reactive 
gliosis and the multicellular response to CNS damage 
and disease. Neuron. 2014;81(2):229-48. 
  71 
211. Papadopoulos MC, Verkman AS. 
Aquaporin water channels in the nervous system. 
Nature reviews Neuroscience. 2013;14(4):265-77. 
212. Steinman MQ, Gao V, Alberini CM. 
The Role of Lactate-Mediated Metabolic Coupling 
between Astrocytes and Neurons in Long-Term 
Memory Formation. Frontiers in integrative 
neuroscience. 2016;10:10-. 
213. Ota Y, Zanetti AT, Hallock RM. The 
role of astrocytes in the regulation of synaptic 
plasticity and memory formation. Neural plasticity. 
2013;2013:185463. 
214. Allen CF, Shaw PJ, Ferraiuolo L. 
Can Astrocytes Be a Target for Precision Medicine? 
Advances in experimental medicine and biology. 
2017;1007:111-28. 
215. Xin W, Bonci A. Functional 
Astrocyte Heterogeneity and Implications for Their 
Role in Shaping Neurotransmission. Frontiers in 
cellular neuroscience. 2018;12:141-. 
216. Eroglu C, Barres BA. Regulation of 
synaptic connectivity by glia. Nature. 
2010;468(7321):223-31. 
217. Alvarez JI, Katayama T, Prat A. 
Glial influence on the blood brain barrier. Glia. 
2013;61(12):1939-58. 
218. Clements JD, Lester RA, Tong G, 
Jahr CE, Westbrook GL. The time course of glutamate 
in the synaptic cleft. Science (New York, NY). 
1992;258(5087):1498-501. 
219. Kessler JP. Control of cleft glutamate 
concentration and glutamate spill-out by perisynaptic 
glia: uptake and diffusion barriers. PloS one. 
2013;8(8):e70791. 
220. Holmseth S, Dehnes Y, Huang YH, 
Follin-Arbelet VV, Grutle NJ, Mylonakou MN, et al. 
The Density of EAAC1 (EAAT3) Glutamate 
Transporters Expressed by Neurons in the 
Mammalian CNS. The Journal of Neuroscience. 
2012;32(17):6000-13. 
221. Hanson E, Armbruster M, Cantu D, 
Andresen L, Taylor A, Danbolt NC, et al. Astrocytic 
glutamate uptake is slow and does not limit neuronal 
NMDA receptor activation in the neonatal neocortex. 
Glia. 2015;63(10):1784-96. 
222. Lewerenz J, Maher P. Chronic 
Glutamate Toxicity in Neurodegenerative Diseases-
What is the Evidence? Frontiers in neuroscience. 
2015;9:469-. 
223. McKenna MC. Glutamate pays its 
own way in astrocytes. Frontiers in endocrinology. 
2013;4:191. 
224. Westergaard N, Drejer J, Schousboe 
A, Sonnewald U. Evaluation of the importance of 
transamination versus deamination in astrocytic 
metabolism of [U-13C]glutamate. Glia. 
1996;17(2):160-8. 
225. Lovatt D, Sonnewald U, 
Waagepetersen HS, Schousboe A, He W, Lin JH, et 
al. The transcriptome and metabolic gene signature of 
protoplasmic astrocytes in the adult murine cortex. 
The Journal of neuroscience : the official journal of 
the Society for Neuroscience. 2007;27(45):12255-66. 
226. McKenna MC, Sonnewald U, Huang 
X, Stevenson J, Zielke HR. Exogenous glutamate 
concentration regulates the metabolic fate of 
glutamate in astrocytes. Journal of neurochemistry. 
1996;66(1):386-93. 
227. Bak LK, Schousboe A, 
Waagepetersen HS. The glutamate/GABA-glutamine 
cycle: aspects of transport, neurotransmitter 
homeostasis and ammonia transfer. Journal of 
neurochemistry. 2006;98(3):641-53. 
228. Walz W, Lang MK. 
Immunocytochemical evidence for a distinct GFAP-
negative subpopulation of astrocytes in the adult rat 
hippocampus. Neuroscience letters. 1998;257(3):127-
30. 
229. Anlauf E, Derouiche A. Glutamine 
synthetase as an astrocytic marker: its cell type and 
vesicle localization. Frontiers in endocrinology. 
2013;4:144. 
230. Serio A, Bilican B, Barmada SJ, 
Ando DM, Zhao C, Siller R, et al. Astrocyte pathology 
and the absence of non-cell autonomy in an induced 
pluripotent stem cell model of TDP-43 proteinopathy. 
Proceedings of the National Academy of Sciences of 
the United States of America. 2013;110(12):4697-
702. 
231. Gupta K, Patani R, Baxter P, Serio A, 
Story D, Tsujita T, et al. Human embryonic stem cell 
derived astrocytes mediate non-cell-autonomous 
neuroprotection through endogenous and drug-
induced mechanisms. Cell death and differentiation. 
2012;19(5):779-87. 
232. Chen C, Jiang P, Xue H, Peterson 
SE, Tran HT, McCann AE, et al. Role of astroglia in 
Down's syndrome revealed by patient-derived human-
induced pluripotent stem cells. Nature 
communications. 2014;5:4430. 
233. Shaltouki A, Peng J, Liu Q, Rao MS, 
Zeng X. Efficient generation of astrocytes from 
human pluripotent stem cells in defined conditions. 
Stem cells (Dayton, Ohio). 2013;31(5):941-52. 
234. Palm T, Bolognin S, Meiser J, 
Nickels S, Träger C, Meilenbrock R-L, et al. Rapid 
and robust generation of long-term self-renewing 
human neural stem cells with the ability to generate 
mature astroglia. Scientific Reports. 2015;5:16321. 
 72 
235. Grewer C, Gameiro A, Rauen T. 
SLC1 glutamate transporters. Pflugers Archiv : 
European journal of physiology. 2014;466(1):3-24. 
236. Wanner IB, Anderson MA, Song B, 
Levine J, Fernandez A, Gray-Thompson Z, et al. Glial 
scar borders are formed by newly proliferated, 
elongated astrocytes that interact to corral 
inflammatory and fibrotic cells via STAT3-dependent 
mechanisms after spinal cord injury. The Journal of 
neuroscience : the official journal of the Society for 
Neuroscience. 2013;33(31):12870-86. 
237. Sirko S, Behrendt G, Johansson PA, 
Tripathi P, Costa M, Bek S, et al. Reactive glia in the 
injured brain acquire stem cell properties in response 
to sonic hedgehog. [corrected]. Cell stem cell. 
2013;12(4):426-39. 
238. Alberdi E, Wyssenbach A, Alberdi 
M, Sanchez-Gomez MV, Cavaliere F, Rodriguez JJ, 
et al. Ca(2+) -dependent endoplasmic reticulum stress 
correlates with astrogliosis in oligomeric amyloid 
beta-treated astrocytes and in a model of Alzheimer's 
disease. Aging cell. 2013;12(2):292-302. 
239. Bouvier DS, Jones EV, Quesseveur 
G, Davoli MA, T AF, Quirion R, et al. High 
Resolution Dissection of Reactive Glial Nets in 
Alzheimer's Disease. Scientific Reports. 
2016;6:24544. 
240. Vartak-Sharma N, Ghorpade A. 
Astrocyte elevated gene-1 regulates astrocyte 
responses to neural injury: implications for reactive 
astrogliosis and neurodegeneration. Journal of 
neuroinflammation. 2012;9:195. 
241. Choi SS, Lee HJ, Lim I, Satoh J, Kim 
SU. Human astrocytes: secretome profiles of 
cytokines and chemokines. PloS one. 
2014;9(4):e92325. 
242. Roybon L, Lamas NJ, Garcia-Diaz 
A, Yang EJ, Sattler R, Jackson-Lewis V, et al. Human 
stem cell-derived spinal cord astrocytes with defined 
mature or reactive phenotypes. Cell reports. 
2013;4(5):1035-48. 
243. Holmqvist S, Brouwer M, Djelloul 
M, Diaz AG, Devine MJ, Hammarberg A, et al. 
Generation of human pluripotent stem cell reporter 
lines for the isolation of and reporting on astrocytes 
generated from ventral midbrain and ventral spinal 
cord neural progenitors. Stem cell research. 
2015;15(1):203-20. 
244. Santos R, Vadodaria KC, Jaeger BN, 
Mei A, Lefcochilos-Fogelquist S, Mendes APD, et al. 
Differentiation of Inflammation-Responsive 
Astrocytes from Glial Progenitors Generated from 
Human Induced Pluripotent Stem Cells. Stem Cell 
Reports.8(6):1757-69. 
245. Oksanen M, Petersen AJ, Naumenko 
N, Puttonen K, Lehtonen S, Gubert Olive M, et al. 
PSEN1 Mutant iPSC-Derived Model Reveals Severe 
Astrocyte Pathology in Alzheimer's Disease. Stem 
Cell Reports. 2017;9(6):1885-97. 
246. Tcw J, Wang M, Pimenova AA, 
Bowles KR, Hartley BJ, Lacin E, et al. An Efficient 
Platform for Astrocyte Differentiation from Human 
Induced Pluripotent Stem Cells. Stem Cell Reports. 
2017;9(2):600-14. 
247. Tarassishin L, Suh HS, Lee SC. LPS 
and IL-1 differentially activate mouse and human 
astrocytes: role of CD14. Glia. 2014;62(6):999-1013. 
248. Foo LC, Allen NJ, Bushong EA, 
Ventura PB, Chung WS, Zhou L, et al. Development 
of a method for the purification and culture of rodent 
astrocytes. Neuron. 2011;71(5):799-811. 
249. Shigetomi E, Patel S, Khakh BS. 
Probing the Complexities of Astrocyte Calcium 
Signaling. Trends in cell biology. 2016;26(4):300-12. 
250. Verkhratsky A, Nedergaard M. 
Physiology of Astroglia. Physiological reviews. 
2018;98(1):239-389. 
251. Leybaert L, Sanderson MJ. 
Intercellular Ca(2+) waves: mechanisms and function. 
Physiological reviews. 2012;92(3):1359-92. 
252. Panatier A, Vallee J, Haber M, Murai 
KK, Lacaille JC, Robitaille R. Astrocytes are 
endogenous regulators of basal transmission at central 
synapses. Cell. 2011;146(5):785-98. 
253. Wang X, Lou N, Xu Q, Tian GF, 
Peng WG, Han X, et al. Astrocytic Ca2+ signaling 
evoked by sensory stimulation in vivo. Nature 
neuroscience. 2006;9(6):816-23. 
254. Sun W, McConnell E, Pare JF, Xu Q, 
Chen M, Peng W, et al. Glutamate-dependent 
neuroglial calcium signaling differs between young 
and adult brain. Science (New York, NY). 
2013;339(6116):197-200. 
255. Hamilton N, Vayro S, Kirchhoff F, 
Verkhratsky A, Robbins J, Gorecki DC, et al. 
Mechanisms of ATP- and glutamate-mediated 
calcium signaling in white matter astrocytes. Glia. 
2008;56(7):734-49. 
256. Pannasch U, Rouach N. Emerging 
role for astroglial networks in information processing: 
from synapse to behavior. Trends in neurosciences. 
2013;36(7):405-17. 
257. Suadicani SO, De Pina-Benabou 
MH, Urban-Maldonado M, Spray DC, Scemes E. 
Acute downregulation of Cx43 alters P2Y receptor 
expression levels in mouse spinal cord astrocytes. 
Glia. 2003;42(2):160-71. 
258. Lallouette J, De Pittà M, Ben-Jacob 
E, Berry H. Sparse short-distance connections 
enhance calcium wave propagation in a 3D model of 
  73 
astrocyte networks. Frontiers in Computational 
Neuroscience. 2014;8(45). 
259. Wang F, Smith NA, Xu Q, Fujita T, 
Baba A, Matsuda T, et al. Astrocytes modulate neural 
network activity by Ca(2)+-dependent uptake of 
extracellular K+. Science signaling. 
2012;5(218):ra26. 
260. Bay V, Butt AM. Relationship 
between glial potassium regulation and axon 
excitability: a role for glial Kir4.1 channels. Glia. 
2012;60(4):651-60. 
261. Jiang P, Chen C, Wang R, 
Chechneva OV, Chung SH, Rao MS, et al. hESC-
derived Olig2+ progenitors generate a subtype of 
astroglia with protective effects against ischaemic 
brain injury. Nature communications. 2013;4:2196. 
262. Krencik R, Hokanson KC, Narayan 
AR, Dvornik J, Rooney GE, Rauen KA, et al. 
Dysregulation of astrocyte extracellular signaling in 
Costello syndrome. Science translational medicine. 
2015;7(286):286ra66. 
263. Bardy C, van den Hurk M, Eames T, 
Marchand C, Hernandez RV, Kellogg M, et al. 
Neuronal medium that supports basic synaptic 
functions and activity of human neurons in vitro. 
Proceedings of the National Academy of Sciences of 
the United States of America. 2015;112(20):E2725-
34. 
264. Kondo T, Asai M, Tsukita K, Kutoku 
Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer's 
disease with iPSCs reveals stress phenotypes 
associated with intracellular Abeta and differential 
drug responsiveness. Cell stem cell. 2013;12(4):487-
96. 
265. Jones VC, Atkinson-Dell R, 
Verkhratsky A, Mohamet L. Aberrant iPSC-derived 
human astrocytes in Alzheimer's disease. Cell death & 
disease. 2017;8(3):e2696. 
266. Juopperi TA, Kim WR, Chiang CH, 
Yu H, Margolis RL, Ross CA, et al. Astrocytes 
generated from patient induced pluripotent stem cells 
recapitulate features of Huntington's disease patient 
cells. Molecular brain. 2012;5:17. 
267. Kondo T, Funayama M, Miyake M, 
Tsukita K, Era T, Osaka H, et al. Modeling Alexander 
disease with patient iPSCs reveals cellular and 
molecular pathology of astrocytes. Acta 
neuropathologica communications. 2016;4(1):69. 
268. Windrem MS, Osipovitch M, Liu Z, 
Bates J, Chandler-Militello D, Zou L, et al. Human 
iPSC Glial Mouse Chimeras Reveal Glial 
Contributions to Schizophrenia. Cell stem cell. 
2017;21(2):195-208.e6. 
269. Finan GM, Realubit R, Chung S, 
Lutjohann D, Wang N, Cirrito JR, et al. Bioactive 
Compound Screen for Pharmacological Enhancers of 
Apolipoprotein E in Primary Human Astrocytes. Cell 
chemical biology. 2016;23(12):1526-38. 
270. Johansson CB, Svensson M, 
Wallstedt L, Janson AM, Frisen J. Neural stem cells 
in the adult human brain. Experimental cell research. 
1999;253(2):733-6. 
271. Haidet-Phillips AM, Hester ME, 
Miranda CJ, Meyer K, Braun L, Frakes A, et al. 
Astrocytes from familial and sporadic ALS patients 
are toxic to motor neurons. Nature biotechnology. 
2011;29(9):824-8. 
272. Chew LJ, DeBoy CA, Senatorov 
VV, Jr. Finding degrees of separation: experimental 
approaches for astroglial and oligodendroglial cell 
isolation and genetic targeting. Journal of 
neuroscience methods. 2014;236:125-47. 
273. Windrem MS, Nunes MC, 
Rashbaum WK, Schwartz TH, Goodman RA, 
McKhann G, 2nd, et al. Fetal and adult human 
oligodendrocyte progenitor cell isolates myelinate the 
congenitally dysmyelinated brain. Nature medicine. 
2004;10(1):93-7. 
274. Windrem MS, Roy NS, Wang J, 
Nunes M, Benraiss A, Goodman R, et al. Progenitor 
cells derived from the adult human subcortical white 
matter disperse and differentiate as oligodendrocytes 
within demyelinated lesions of the rat brain. Journal 
of neuroscience research. 2002;69(6):966-75. 
275. Jana M, Jana A, Pal U, Pahan K. A 
simplified method for isolating highly purified 
neurons, oligodendrocytes, astrocytes, and microglia 
from the same human fetal brain tissue. 
Neurochemical research. 2007;32(12):2015-22. 
276. Palmer TD, Schwartz PH, Taupin P, 
Kaspar B, Stein SA, Gage FH. Cell culture. Progenitor 
cells from human brain after death. Nature. 
2001;411(6833):42-3. 
277. Kanski R, van Strien ME, van Tijn P, 
Hol EM. A star is born: new insights into the 
mechanism of astrogenesis. Cell Mol Life Sci. 
2014;71(3):433-47. 
278. Stipursky J, Spohr TC, Sousa VO, 
Gomes FC. Neuron-astroglial interactions in cell-fate 
commitment and maturation in the central nervous 
system. Neurochemical research. 2012;37(11):2402-
18. 
279. Lafaille FG, Pessach IM, Zhang SY, 
Ciancanelli MJ, Herman M, Abhyankar A, et al. 
Impaired intrinsic immunity to HSV-1 in human 
iPSC-derived TLR3-deficient CNS cells. Nature. 
2012;491(7426):769-73. 
280. Zhang PW, Haidet-Phillips AM, 
Pham JT, Lee Y, Huo Y, Tienari PJ, et al. Generation 
of GFAP::GFP astrocyte reporter lines from human 
 74 
adult fibroblast-derived iPS cells using zinc-finger 
nuclease technology. Glia. 2016;64(1):63-75. 
281. Li Y, Balasubramanian U, Cohen D, 
Zhang PW, Mosmiller E, Sattler R, et al. A 
comprehensive library of familial human amyotrophic 
lateral sclerosis induced pluripotent stem cells. PloS 
one. 2015;10(3):e0118266. 
282. Sareen D, Gowing G, Sahabian A, 
Staggenborg K, Paradis R, Avalos P, et al. Human 
induced pluripotent stem cells are a novel source of 
neural progenitor cells (iNPCs) that migrate and 
integrate in the rodent spinal cord. The Journal of 
comparative neurology. 2014;522(12):2707-28. 
283. Edri R, Yaffe Y, Ziller MJ, Mutukula 
N, Volkman R, David E, et al. Analysing human 
neural stem cell ontogeny by consecutive isolation of 
Notch active neural progenitors. Nature 
communications. 2015;6:6500. 
284. Majumder A, Dhara SK, Swetenburg 
R, Mithani M, Cao K, Medrzycki M, et al. Inhibition 
of DNA methyltransferases and histone deacetylases 
induces astrocytic differentiation of neural 
progenitors. Stem cell research. 2013;11(1):574-86. 
285. Emdad L, D'Souza SL, Kothari HP, 
Qadeer ZA, Germano IM. Efficient differentiation of 
human embryonic and induced pluripotent stem cells 
into functional astrocytes. Stem cells and 
development. 2012;21(3):404-10. 
286. Lin YT, Seo J, Gao F, Feldman HM, 
Wen HL, Penney J, et al. APOE4 Causes Widespread 
Molecular and Cellular Alterations Associated with 
Alzheimer's Disease Phenotypes in Human iPSC-
Derived Brain Cell Types. Neuron. 2018;98(6):1141-
54.e7. 
287. Cheng C, Fass DM, Folz-Donahue 
K, MacDonald ME, Haggarty SJ. Highly Expandable 
Human iPS Cell-Derived Neural Progenitor Cells 
(NPC) and Neurons for Central Nervous System 
Disease Modeling and High-Throughput Screening. 
Current protocols in human genetics. 2017;92:21.8.1-
.8. 
288. Pasca AM, Sloan SA, Clarke LE, 
Tian Y, Makinson CD, Huber N, et al. Functional 
cortical neurons and astrocytes from human 
pluripotent stem cells in 3D culture. Nature methods. 
2015;12(7):671-8. 
289. Lee CY, Dallerac G, Ezan P, 
Anderova M, Rouach N. Glucose Tightly Controls 
Morphological and Functional Properties of 
Astrocytes. Frontiers in aging neuroscience. 
2016;8:82. 
290. Shen Y, Tian Y, Shi X, Yang J, 
Ouyang L, Gao J, et al. Exposure to high glutamate 
concentration activates aerobic glycolysis but inhibits 
ATP-linked respiration in cultured cortical astrocytes. 
Cell biochemistry and function. 2014;32(6):530-7. 
291. Rosafio K, Pellerin L. Oxygen 
tension controls the expression of the 
monocarboxylate transporter MCT4 in cultured 
mouse cortical astrocytes via a hypoxia-inducible 
factor-1alpha-mediated transcriptional regulation. 
Glia. 2014;62(3):477-90. 
292. Yasui T, Uezono N, Nakashima H, 
Noguchi H, Matsuda T, Noda-Andoh T, et al. 
Hypoxia Epigenetically Confers Astrocytic 
Differentiation Potential on Human Pluripotent Cell-
Derived Neural Precursor Cells. Stem Cell Reports. 
2017;8(6):1743-56. 
293. Di Lullo E, Kriegstein AR. The use 
of brain organoids to investigate neural development 
and disease. Nature reviews Neuroscience. 
2017;18(10):573-84. 
294. Dezonne RS, Sartore RC, 
Nascimento JM, Saia-Cereda VM, Romao LF, Alves-
Leon SV, et al. Derivation of Functional Human 
Astrocytes from Cerebral Organoids. Scientific 
Reports. 2017;7:45091. 
295. Efthymiou A, Shaltouki A, Steiner 
JP, Jha B, Heman-Ackah SM, Swistowski A, et al. 
Functional screening assays with neurons generated 
from pluripotent stem cell-derived neural stem cells. 
Journal of biomolecular screening. 2014;19(1):32-43. 
296. Yuan SH, Martin J, Elia J, Flippin J, 
Paramban RI, Hefferan MP, et al. Cell-surface marker 
signatures for the isolation of neural stem cells, glia 
and neurons derived from human pluripotent stem 
cells. PloS one. 2011;6(3):e17540. 
297. Avior Y, Sagi I, Benvenisty N. 
Pluripotent stem cells in disease modelling and drug 
discovery. Nature reviews Molecular cell biology. 
2016;17(3):170-82. 
298. Liu GH, Qu J, Suzuki K, Nivet E, Li 
M, Montserrat N, et al. Progressive degeneration of 
human neural stem cells caused by pathogenic 
LRRK2. Nature. 2012;491(7425):603-7. 
299. An MC, Zhang N, Scott G, Montoro 
D, Wittkop T, Mooney S, et al. Genetic correction of 
Huntington's disease phenotypes in induced 
pluripotent stem cells. Cell stem cell. 2012;11(2):253-
63. 
300. Cook D, Brown D, Alexander R, 
March R, Morgan P, Satterthwaite G, et al. Lessons 
learned from the fate of AstraZeneca&#39;s drug 
pipeline: a five-dimensional framework. Nature 
Reviews Drug Discovery. 2014;13:419. 
301. Pankevich DE, Altevogt BM, 
Dunlop J, Gage FH, Hyman SE. Improving and 
accelerating drug development for nervous system 
disorders. Neuron. 2014;84(3):546-53. 
  75 
302. Cesarman-Maus G, Hajjar KA. 
Molecular mechanisms of fibrinolysis. British journal 
of haematology. 2005;129(3):307-21. 
303. Henry DA, Carless PA, Moxey AJ, 
O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-
fibrinolytic use for minimising perioperative 
allogeneic blood transfusion. The Cochrane database 
of systematic reviews. 2011(1):Cd001886. 
304. Roberts I, Shakur H, Afolabi A, 
Brohi K, Coats T, Dewan Y, et al. The importance of 
early treatment with tranexamic acid in bleeding 
trauma patients: an exploratory analysis of the 
CRASH-2 randomised controlled trial. Lancet 
(London, England). 2011;377(9771):1096-101, 
101.e1-2. 
305. Sharma V, Katznelson R, Jerath A, 
Garrido‐Olivares L, Carroll J, Rao V, et al. The 
association between tranexamic acid and convulsive 
seizures after cardiac surgery: a multivariate analysis 
in 11 529 patients. Anaesthesia. 2014;69(2):124-30. 
306. Hochschwender SM, Laursen RA. 
The lysine binding sites of human plasminogen. 
Evidence for a critical tryptophan in the binding site 
of kringle 4. Journal of Biological Chemistry. 
1981;256(21):11172-6. 
307. Lecker I, Wang DS, Whissell PD, 
Avramescu S, Mazer CD, Orser BA. Tranexamic 
acid-associated seizures: Causes and treatment. 
Annals of neurology. 2016;79(1):18-26. 
308. Furtmuller R, Schlag MG, Berger M, 
Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, 
a widely used antifibrinolytic agent, causes 
convulsions by a gamma-aminobutyric acid(A) 
receptor antagonistic effect. The Journal of 
pharmacology and experimental therapeutics. 
2002;301(1):168-73. 
309. Kratzer S, Irl H, Mattusch C, Burge 
M, Kurz J, Kochs E, et al. Tranexamic acid impairs 
gamma-aminobutyric acid receptor type A-mediated 
synaptic transmission in the murine amygdala: a 
potential mechanism for drug-induced seizures? 
Anesthesiology. 2014;120(3):639-49. 
310. Boström J, Grant JA, Fjellström O, 
Thelin A, Gustafsson D. Potent Fibrinolysis Inhibitor 
Discovered by Shape and Electrostatic 
Complementarity to the Drug Tranexamic Acid. 
Journal of Medicinal Chemistry. 2013;56(8):3273-80. 
311. Cheng L, Pettersen D, Ohlsson B, 
Schell P, Karle M, Evertsson E, et al. Discovery of the 
Fibrinolysis Inhibitor AZD6564, Acting via 
Interference of a Protein–Protein Interaction. ACS 
Medicinal Chemistry Letters. 2014;5(5):538-43. 
312. Haythornthwaite A, Stoelzle S, 
Hasler A, Kiss A, Mosbacher J, George M, et al. 
Characterizing human ion channels in induced 
pluripotent stem cell-derived neurons. Journal of 
biomolecular screening. 2012;17(9):1264-72. 
313. Dage JL, Colvin EM, Fouillet A, 
Langron E, Roell WC, Li J, et al. Pharmacological 
characterisation of ligand- and voltage-gated ion 
channels expressed in human iPSC-derived forebrain 
neurons. Psychopharmacology. 2014;231(6):1105-
24. 
314. Amin H, Maccione A, Marinaro F, 
Zordan S, Nieus T, Berdondini L. Electrical 
Responses and Spontaneous Activity of Human iPS-
Derived Neuronal Networks Characterized for 3-
month Culture with 4096-Electrode Arrays. Frontiers 
in Neuroscience. 2016;10:121. 
315. James OT, Livesey MR, Qiu J, 
Dando O, Bilican B, Haghi G, et al. Ionotropic GABA 
and glycine receptor subunit composition in human 
pluripotent stem cell-derived excitatory cortical 
neurones. The Journal of physiology. 
2014;592(19):4353-63. 
316. Franz D, Olsen HL, Klink O, Gimsa 
J. Automated and manual patch clamp data of human 
induced pluripotent stem cell-derived dopaminergic 
neurons. Scientific data. 2017;4:170056. 
317. Schroder R, Janssen N, Schmidt J, 
Kebig A, Merten N, Hennen S, et al. Deconvolution 
of complex G protein-coupled receptor signaling in 
live cells using dynamic mass redistribution 
measurements. Nature biotechnology. 
2010;28(9):943-9. 
318. Schroder R, Schmidt J, Blattermann 
S, Peters L, Janssen N, Grundmann M, et al. Applying 
label-free dynamic mass redistribution technology to 
frame signaling of G protein-coupled receptors 
noninvasively in living cells. Nature protocols. 
2011;6(11):1748-60. 
319. Verdonk E, Johnson K, McGuinness 
R, Leung G, Chen YW, Tang HR, et al. Cellular 
dielectric spectroscopy: a label-free comprehensive 
platform for functional evaluation of endogenous 
receptors. Assay and drug development technologies. 
2006;4(5):609-19. 
320. Klein AB, Nittegaard-Nielsen M, 
Christensen JT, Al-Khawaja A, Wellendorph P. 
Demonstration of the dynamic mass redistribution 
label-free technology as a useful cell-based 
pharmacological assay for endogenously expressed 
GABAA receptors. MedChemComm. 2016;7(3):426-
32. 
321. Almad A, Maragakis NJ. A stocked 
toolbox for understanding the role of astrocytes in 
disease. Nature reviews Neurology. 2018;14(6):351-
62. 
322. Fan J, Zareyan S, Zhao W, Shimizu 
Y, Pfeifer TA, Tak JH, et al. Identification of a 
 76 
Chrysanthemic Ester as an Apolipoprotein E Inducer 
in Astrocytes. PloS one. 2016;11(9):e0162384. 
323. Marchetto MC, Muotri AR, Mu Y, 
Smith AM, Cezar GG, Gage FH. Non-cell-
autonomous effect of human SOD1 G37R astrocytes 
on motor neurons derived from human embryonic 
stem cells. Cell stem cell. 2008;3(6):649-57. 
324. Thorne N, Malik N, Shah S, Zhao J, 
Class B, Aguisanda F, et al. High-Throughput 
Phenotypic Screening of Human Astrocytes to 
Identify Compounds That Protect Against Oxidative 
Stress. Stem cells translational medicine. 
2016;5(5):613-27. 
325. Badr CE, Wurdinger T, Tannous BA. 
Functional drug screening assay reveals potential 
glioma therapeutics. Assay and drug development 
technologies. 2011;9(3):281-9. 
326. Stricker SH, Feber A, Engstrom PG, 
Caren H, Kurian KM, Takashima Y, et al. Widespread 
resetting of DNA methylation in glioblastoma-
initiating cells suppresses malignant cellular behavior 
in a lineage-dependent manner. Genes & 
development. 2013;27(6):654-69. 
327. Funato K, Major T, Lewis PW, Allis 
CD, Tabar V. Use of human embryonic stem cells to 
model pediatric gliomas with H3.3K27M histone 
mutation. Science (New York, NY). 
2014;346(6216):1529-33. 
328. Sancho-Martinez I, Nivet E, Xia Y, 
Hishida T, Aguirre A, Ocampo A, et al. Establishment 
of human iPSC-based models for the study and 
targeting of glioma initiating cells. Nature 
communications. 2016;7:10743. 
329. Auderset L, Cullen CL, Young KM. 
Low Density Lipoprotein-Receptor Related Protein 1 
Is Differentially Expressed by Neuronal and Glial 
Populations in the Developing and Mature Mouse 
Central Nervous System. PloS one. 
2016;11(6):e0155878. 
330. Fan QW, Iosbe I, Asou H, 
Yanagisawa K, Michikawa M. Expression and 
regulation of apolipoprotein E receptors in the cells of 
the central nervous system in culture: A review. 
Journal of the American Aging Association. 
2001;24(1):1-10. 
331. Grehan S, Tse E, Taylor JM. Two 
distal downstream enhancers direct expression of the 
human apolipoprotein E gene to astrocytes in the 
brain. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2001;21(3):812-22. 
332. Nordestgaard LT, Tybjaerg-Hansen 
A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-
function mutation in ABCA1 and risk of Alzheimer's 
disease and cerebrovascular disease. Alzheimer's & 
dementia : the journal of the Alzheimer's Association. 
2015;11(12):1430-8. 
333. Liu CC, Liu CC, Kanekiyo T, Xu H, 
Bu G. Apolipoprotein E and Alzheimer disease: risk, 
mechanisms and therapy. Nature reviews Neurology. 
2013;9(2):106-18. 
334. Blennow K, de Leon MJ, Zetterberg 
H. Alzheimer's disease. Lancet (London, England). 
2006;368(9533):387-403. 
335. Hatters DM, Peters-Libeu CA, 
Weisgraber KH. Apolipoprotein E structure: insights 
into function. Trends in biochemical sciences. 
2006;31(8):445-54. 
336. Mahley RW, Huang Y. Small-
molecule structure correctors target abnormal protein 
structure and function: structure corrector rescue of 
apolipoprotein E4-associated neuropathology. J Med 
Chem. 2012;55(21):8997-9008. 
337. Castellano JM, Kim J, Stewart FR, 
Jiang H, DeMattos RB, Patterson BW, et al. Human 
apoE isoforms differentially regulate brain amyloid-
beta peptide clearance. Science translational 
medicine. 2011;3(89):89ra57. 
338. Tokuda T, Calero M, Matsubara E, 
Vidal R, Kumar A, Permanne B, et al. Lipidation of 
apolipoprotein E influences its isoform-specific 
interaction with Alzheimer's amyloid beta peptides. 
The Biochemical journal. 2000;348 Pt 2:359-65. 
339. Nielsen HM, Veerhuis R, Holmqvist 
B, Janciauskiene S. Binding and uptake of A beta1-42 
by primary human astrocytes in vitro. Glia. 
2009;57(9):978-88. 
340. Jiang Q, Lee CY, Mandrekar S, 
Wilkinson B, Cramer P, Zelcer N, et al. ApoE 
promotes the proteolytic degradation of Abeta. 
Neuron. 2008;58(5):681-93. 
341. Bell RD, Sagare AP, Friedman AE, 
Bedi GS, Holtzman DM, Deane R, et al. Transport 
pathways for clearance of human Alzheimer's 
amyloid beta-peptide and apolipoproteins E and J in 
the mouse central nervous system. Journal of cerebral 
blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and 
Metabolism. 2007;27(5):909-18. 
342. Donkin JJ, Stukas S, Hirsch-
Reinshagen V, Namjoshi D, Wilkinson A, May S, et 
al. ATP-binding cassette transporter A1 mediates the 
beneficial effects of the liver X receptor agonist 
GW3965 on object recognition memory and amyloid 
burden in amyloid precursor protein/presenilin 1 
mice. The Journal of biological chemistry. 
2010;285(44):34144-54. 
343. Zhao J, Fu Y, Liu CC, Shinohara M, 
Nielsen HM, Dong Q, et al. Retinoic acid isomers 
facilitate apolipoprotein E production and lipidation in 
  77 
astrocytes through the retinoid X receptor/retinoic 
acid receptor pathway. The Journal of biological 
chemistry. 2014;289(16):11282-92. 
344. Mangialasche F, Solomon A, 
Winblad B, Mecocci P, Kivipelto M. Alzheimer's 
disease: clinical trials and drug development. The 
Lancet Neurology. 2010;9(7):702-16. 
345. Sasaguri H, Nilsson P, Hashimoto S, 
Nagata K, Saito T, De Strooper B, et al. APP mouse 
models for Alzheimer's disease preclinical studies. 
The EMBO journal. 2017;36(17):2473-87. 
346. Liao MC, Muratore CR, Gierahn 
TM, Sullivan SE, Srikanth P, De Jager PL, et al. 
Single-Cell Detection of Secreted Abeta and 
sAPPalpha from Human IPSC-Derived Neurons and 
Astrocytes. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 
2016;36(5):1730-46. 
347. Hong C, Tontonoz P. Liver X 
receptors in lipid metabolism: opportunities for drug 
discovery. Nature reviews Drug discovery. 
2014;13(6):433-44. 
348. Fan J, Zhao RQ, Parro C, Zhao W, 
Chou HY, Robert J, et al. Small molecule inducers of 
ABCA1 and apoE that act through indirect activation 
of the LXR pathway. Journal of lipid research. 
2018;59(5):830-42. 
349. Greeve I, Hermans-Borgmeyer I, 
Brellinger C, Kasper D, Gomez-Isla T, Behl C, et al. 
The human DIMINUTO/DWARF1 homolog seladin-
1 confers resistance to Alzheimer's disease-associated 
neurodegeneration and oxidative stress. The Journal 
of neuroscience : the official journal of the Society for 
Neuroscience. 2000;20(19):7345-52. 
350. Wang Y, Rogers PM, Stayrook KR, 
Su C, Varga G, Shen Q, et al. The selective 
Alzheimer's disease indicator-1 gene (Seladin-
1/DHCR24) is a liver X receptor target gene. 
Molecular pharmacology. 2008;74(6):1716-21. 
351. Huang YA, Zhou B, Wernig M, 
Sudhof TC. ApoE2, ApoE3, and ApoE4 
Differentially Stimulate APP Transcription and Abeta 
Secretion. Cell. 2017;168(3):427-41.e21. 
352. Zhang D, Pekkanen-Mattila M, 
Shahsavani M, Falk A, Teixeira AI, Herland A. A 3D 
Alzheimer's disease culture model and the induction 
of P21-activated kinase mediated sensing in iPSC 
derived neurons. Biomaterials. 2014;35(5):1420-8. 
353. Bhattarai JP, Park SJ, Chun SW, Cho 
DH, Han SK. Activation of synaptic and extrasynaptic 
glycine receptors by taurine in preoptic hypothalamic 
neurons. Neuroscience letters. 2015;608:51-6. 
354. Kashi K, Henderson L, Bonetti A, 
Carninci P. Discovery and functional analysis of 
lncRNAs: Methodologies to investigate an 
uncharacterized transcriptome. Biochimica et 
biophysica acta. 2016;1859(1):3-15. 
355. Pekny M, Pekna M, Messing A, 
Steinhauser C, Lee JM, Parpura V, et al. Astrocytes: a 
central element in neurological diseases. Acta 
neuropathologica. 2016;131(3):323-45. 
356. Ben Haim L, Carrillo-de Sauvage 
MA, Ceyzeriat K, Escartin C. Elusive roles for 
reactive astrocytes in neurodegenerative diseases. 
Front Cell Neurosci. 2015;9:278. 
 
